I'M MARY GLENSHAW,
DESIGNATESSED FEDERAL OFFICIAL
EXECUTIVE SECRETARY OF OFFICE OF
AIDS RESEARCH ADVISORY COUNCIL.
WELCOME, THANK YOU FOR JOIN
ARING US TODAY.
AS A BRIEF REMINDER OUR COUNCIL
IS GOVERNED BY PROVISIONS OF THE
FEDERAL ADVISORY COMMITTEE ACT
AS AMENDED WHICH SETS FORTH
STANDARDS FOR THE FORMATION AND
USE OF ADVISORY COMMITTEES.
AS SUCH MY ROLE IS TO BE PREPARE
AGENDAS MEETINGS, ATTEND AND
APPROVE ALL COUNCIL AND
SUBCOMMITTEE MEETINGS.
I WILL ADJOURN ANY MEETING WHEN
DETERMINED TO BE IN PUBLIC
INTEREST AND CHAIR MEETINGS WHEN
DIRECTED BY THE NIH OR THE OAR
DIRECTOR.
PLEASE ALSO WELCOME MS. BURK WHO
WILL FULFILL THESE DUTIES IN THE
EVENT I'M ABSENT.
AS IN PREVIOUS MEETINGS GENERAL
GUIDELINES FOR TODAY KINDLY STAY
T MUTED UNLESS SPEAKING.
KEEP YOUR CAMERA ON MOST OF THE
MEETING.
FEEL FREE TO HIDE MOMENTARILY
AND RETURN AS NEEDED.
WHEN YOU LIKE TO PARTICIPATE IN
DISCUSSION WE ASK THAT YOU
PHYSICALLY RAISE YOUR HAND OR
USE THE ZOOM RAISE HAND FEATURE.
FROM TOLBERT AND I WILL NOTE
THOSE WHO WANT TO SPEAK AND CALL
IN TURN SO WE CAN AVOID SPEAKING
OVER EACH OTHER.
PLEASE BE AWARE THAT YOU WILL
NEED TO LOWER YOUR ZOOM HAND
FEATURE ONCE YOU MADE YOUR
REMARKS.
FEEL FREE TO USE THE CHAT,
KINDLY KEEP MESSAGES TO
LOGISTICS ISSUES AND IF YOU HAVE
ANY ISSUES OR CONCERNS, PLEASE
SEND ME OR MELISSA A TEXT.
OUR PHONE NUMBERS ARE IN THE
EMAIL.
SO NOW REMINDER ABOUT OUR
POLICIES REGARDING CONFLICT OF
INTEREST.
COUNCIL MEMBERS MAY NOT
PARTICIPATE IN REVIEWER
DISCUSSION OF SPECIFIC PROGRAM
OR PROJECT FOR WHICH THEY HAVE A
REAL OR APPARENT CONFLICT OF
INTEREST.
IF A PROGRAM OR PROJECT IS
DISCUSSED THAT PREVENTS A
CONFLICT TO YOU, YOU MUST EXCUSE
YOURSELF FROM NEATING.
TO DO THIS SIGNAL ME AND WE WILL
REMOVE YOU TO A SEPARATE MEETING
SPACE IN ZOOM AND THEN RETURN
YOU AFTER THAT PORTION IS OVER.
AFTER THE MEETING, KINDLY
ELECTRONICALLY SIGN THE CONFLICT
OF INTEREST FORM WE WILL MAIL TO
YOU LATER TODAY.
AND SEND IT BACK TO ME TO VERIFY
THAT NOTHING POSTED A CONFLICT
FOR YOU.
ARE THERE ANY QUESTIONS
REGARDING POTENTIAL CONFLICT OF
INTEREST WITH REGARD TO TODAY'S
AGENDA?
ALL RIGHT.
HEARING NONE, TODAY'S MEETING IS
OPEN TO GENERAL PUBLIC AND
CURRENTLY BEING RECORDED AN
VIDEOCAST LIVE.
NOW TO DR. TOLBERT.
>> GOOD AFTERNOON, EVERYONE.
THE 60TH MEETING OF OFFICE OF
AIDS RESEARCH ADVISORY COUNCIL
IS NOW IN SESSION.
I WOULD LIKE TO WELCOME THE
COUNCIL MEMBERS AND INVITED
SPEAKERS NIH COLLEAGUES AND
GUESTS LISTENING IN.
WE WILL START TODAY WITH THE
ROLE CALL OF ALL PERSONS
ATTENDING.
COLLEAGUES WHEN I CALL YOUR NAME
PLEASE STATE YOUR POSITION AND
INSTITUTIONAL AFFILIATION.
WE WILL START WITH OUR OARAC
VOTING MEMBERS, DR. (INAUDIBLE).
>> PRESENT.
I AM PROFESSOR AND CHAIR OF THE
DEPARTMENT OF COMMUNITY HEALTH
AND PREVENTIVE MEDICINE
MOREHOUSE SCHOOL OF MEDICINE.
>> DR. MARGARET L BRENDOU.
>> GOOD AFTERNOON, I'M PROFESSOR
OF MANAGEMENT SCIENCE AND EDGE
NEARING AT STANFORD UNIVERSITY
AND PROFESSOR HEALTH POLICY.
>> I'M PROFESSOR INTERNAL
MEDICINE MICROBIOLOGY
IMMUNOLOGY, UNIVERSITY OF
MICHIGAN ALSO DIRECTOR OF MSTP
ASSOCIATE DEAN OF PHI SINCE
SCIENTIST EDUCATION AND
TRAINING.
>> DR. HEIDI.
>> I'M HERE, I'M PROFESSOR OF
MEDICINE INFECTIOUS DISEASE
UNIVERSITY OF WASHINGTON
>> THANK YOU.
DR. MEHTA.
>> SHRUTI MEHTA.
DEPARTMENT OF EPIDEMIOLOGY.
>> IS DR. MILLER WITH US TODAY?
THE NOT YET.
DR. JOHN SLEASMAN.
>> I'M JOHN SLEASMAN, PROFESSOR
ALLERGY IMMUNOLOGY DUKE
UNIVERSITY SCOLD OF MED.
>> THANK YOU.
DR. IVY TURNBULL.
DR. TURNBULL IS NOT WITH US.
>> HE IS.
>> I'M SORRY.
>> HE IS HERE.
MAYBE AN AUDIO ISSUE.
>> MY CAMERA DOESN'T WORK.
IT'S THE HOST STOPPED VIDEO.
BUT I'M DEPUTY EXECUTIVE
DIRECTOR AIDS ALLIANCE FOR WOMEN
INFANTS CHILDREN AND FAMILIES IN
WASHINGTON D.C.
>> THANK YOU.
YOU ARE AUDIO WAS MUFFLED BUT I
THINK WE WERE ABLE TO HEAR YOUR
INTRO.
SO NEXT I WILL MOVE TO THE OARAC
EX-OFFICIOS.
DR. VICTORIA DAVY
>> ASSOCIATE DIRECTOR FOR
RESEARCH AND DEVELOPMENT OF THE
DEPARTMENT OF VETERANS AFFAIRS.
AND OF COURSE THE VA EX-OFFICIO.
THANK YOU.
>> THANK YOU.
DR. DIFFENBACH WHO WILL JOIN
LATER.
DR.
>> DR. ROHAN HAZRA DIRECTOR
DIVISION OF EXTRAMURAL RESEARCH
NICHD.
>> REAR ADMIRAL JOHN HERMAN.
>> DIRECTOR OF NATIONAL CENTER
FOR HIV VIRAL HEPATITIS, STD AT
CDC.
>> WE WILL MOVE TO ADVISORY
COUNCIL REPRESENTATIVES.
DR. FRANCIS OZMAN.
>> FRANCIS OSMAN, PROFESSOR
EMERITUS NEUROSURGERY.
THE CO-DIRECTOR OF THE BRAIN
TUMOR RESEARCH PROGRAM AT DUKE
UNIVERSITY.
>> THANK YOU.
DR. BOB Y YARCHOAN.
>> I'M REPRESENTING THE NATIONAL
CANCER ADVISORY BOARD.
>> THANK YOU, DR. OSMAN.
IS DR. BOB YARCHOAN WITH US
TODAY?
>> MAYBE JOINING LATER.
>> THANK YOU, DR. MONICA DUNDEE.
>> MY NAME IS MONICA DUNDEE,
PROFESSOR OF MEDICINE INFECTIOUS
DISEASE AT UCSF AND I'M
REPRESENTING THE NIAID ADVISORY
COUNCIL, ARAC TODAY.
ON OARAC.
>> DR. MARGUERITA LIGHTFOOT.
>> HI EVERYONE.
MARGUERITA LIGHTFOOT ASSOCIATE
DEAN FOR RESEARCH AT THE OHSU
PSU SCHOOL OF PUBLIC HEALTH
REPRESENTING NIMH COUNCIL.
>> THANK YOU.
DR. REDONNA CHANDLER.
>> GOOD MORNING.
MY NAME IS REDONNA CHANDLER,
DIRECTOR OF THE RESEARCH PROGRAM
AT NIDA.
>> THANK YOU.
SO NOW TO OUR OAR LEADERSHIP
SPEAKERS DR. MAUREEN GOODENOW.
>> HERE.
>> I'M SORRY.
THANK YOU DR. GLENSHAW.
>> I'M HERE AS WELL.
>> DR. LEO BERTI.
>> HE WILL BE JOINING LATER:
>> AND MS. CORETTA BURK.
>> I'M HERE.
THANK YOU.
>> THANK YOU.
SO LASTLY OUR INVITED SPEAKERS
AND GUESTS LISTED IN ORDER OF
APPEARANCE SOME SPEAKERS MAY
JOIN THE MEETING LATER BUT WE
WILL GO AHEAD AND AT LEAST
ACKNOWLEDGE THEM ON THE ROLL
CALL.
SO FIRST WE HAVE DR. SUSAN
GREGURICK.
WHO WILL JOIN LATER.
>> I BELIEVE THEY ARE ALL
JOINING LATER.
>> GREAT.
ROLL CALL.
MS. KAY HAYES, DR. LAURA
CHEEVER.
REAR ADMIRAL JONATHAN MERMIN.
MR. JIN PARK.
DR. HENRY MASUR.
SO WE ALSO NOTE REGRETS FROM DR.
JOENA SACSHA COLONEL JULIE ACHE
AND DOCTORED RICARDO RIVERA.
SO IS WILL ANYONE THAT I DID NOT
CALL?
>> DR. ROBERT YARCHOAN WAS
SUPPOSED TO BE ON.
NOT SURE IF LAST MINUTE HE
HASN'T TOLD ME HE'S NOT COMING
ON, HEAD OF HIV CANCER RESEARCH
OF THE NCI.
MAUREEN.
WAS ANY CHANGE IN HIS JOINING
US?
>> NO, I UNDERSTAND THAT HE WILL
BE JOINING US.
>> OKAY SO HE SHOULD BE ON THE
-- SO WE CAN ACKNOWLEDGE HIM
LATER WHEN HE JOINS.
BUT THANK YOU FOR THAT.
SO OUR FIRST ORDER OF BUSINESS
IS TO APPROVE MINUTE THE FED 20,
22 OARAC MEETING YOU SHOULD HAVE
RECEIVED THESE MINUTES
ELECTRONICALLY IN THE BRIEFING
BOOK.
ANY ADDITIONS OR CORRECTIONS TO
THE MINUTES?
IF NOT IS THERE A MOTION TO
ACCEPT THE MINUTES AS THEY
STAND.
(INDISCERNIBLE)
>> IS THERE A SECOND TO THE
MOTION TO ACCEPT THE MINUTES?
>> I WILL SECOND THAT.
>> THANK YOU.
THE MOTION IS PASSED AND MINUTES
ARE APPROVED.
SO THANK YOU, EVERYONE LET ME
PROVIDE A BRIEF OVERVIEW OF
TODAY'S AGENDA FROM THE OAR
DIRECTOR.
A PRESENTATION FROM DIRECTOR OF
OFFICE OF DATA SCIENCE
STRATEGIES.
AND UPDATE ON PRESENTATION FROM
HHS INCLUDING THE CDC AND HRSA.
UPDATES FROM THE OARAC HIV
CLINICAL GUIDELINES WORKING
GROUPS.
AN UPDATES -- THE AGENDA ALSO
INCLUDES TIME FOR REGISTERED
PUBLIC COMMENTS, ANYONE
LISTENING IN TODAY WHO WISHES TO
MAKE A PUBLIC COMMENT SHOULD
EMAIL DR. GLENSHAW AT OARAC
INFO@NIH.GOV, OARACINFO AT
NIH.GOV WITH YOUR NAME
AFFILIATION QUESTION OR COMMENT.
PLEASE VISIT THE OAR WEBSITE OR
THE FEDERAL REGISTER NOTICE FOR
MORE DETAILS.
SO COLLEAGUES AS REMINDER PER
OUR CHARTER AND LEGISLATION THE
OARAC ADVISES THE OAR DIRECTOR O
ON BROAD MATTERS RELATING TO HIV
RESEARCH POLICIES PRIORITIES AN
STRATEGIC PLANNING INCLUDING
REVIEW OF THE NIH HIV AIDS
PROGRAM.
SO WE LOOK FORWARD TO PROVIDING
OUR INPUT.
WE WILL NOW HEAR FROM DR.
GOODENOW, DIRECTOR OF THE OFFICE
OF AIDS RESEARCH, DR. GOODENOW
PASS OVER TO YOU.
>> THANK YOU BRAN BLANTON.
GOOD DAY, EVERYONE.
LET ME JUST GET MY -- OKAY.
WELCOME TO ALL, THIS IS THE 60TH
MEETING OF THE OARAC.
AND TIME TO REFLECT ON ALL THE
WORK WE HAVE BEEN DOING
TOGETHER.
FROM IT IS OAR IS EXTREMELY
GRATEFUL TO OUR ADVISORY BOARD
FOR PROVIDING GUIDANCE TO HELP
DEFINE POLICIES AND RESEARCH
STRATEGIES TO THE NIH AGENDA.
WE ARE PARTICULARLY INDEBTED TO
CURRENT PAST OARAC MEMBERS WHO
GENEROUSLY PROVIDED TIME AND
EXPERTISE TO SUPPORT THE NIH OAR
MISSION AS LEGISLATED IN 1988.
AS YOU KNOW JUNE IS PRIDE MONTH
AND IN FOUR DAYS WE WILL BE
OBSERVING NATIONAL HIV TESTING
DAY.
NIH OAR HAS BEEN ACTIVELY
WORKING WITH OUR PARTNERS TO
PROMOTE AND AMPLIFY ACTIVITIES
RELATED TO THESE IMPORTANT
EVENTS.
I'M GOING TO START WITH A FEW
BRIEF UPDATES.
YOU HAVE ALREADY MET DR. IVY
TURN BULL LAST OCTOBER AS AD HOC
OARAC MEMBER AND I'M PLEASED TO
ANNOUNCE THAT AS OF TODAY'S
MEETING SHE JOINS OARAC AS
VOTING MEMBER.
AS DEPUTY EXECUTIVE DIRECTOR OF
THE AIDS ALLIANCE FOR WOMEN
INFANTS CHILDREN YOUTH AND
FAMILIES, DR. TURN BULL
ADVOCATES FOR PUBLIC POLICIES
BENEFIT THESE CONSTITUENTS AND
CONSTITUENCIES AND MORE
INFORMATION IS INCLUDED IN BIO
WHICH APPEARS IN REGION
MATERIALS.
WELCOME, IVY.
THANK YOU FOR YOUR
PARTICIPATION, WE LOOK FORWARD
TO YOUR CONTRIBUTIONS.
NIH OAR RECENTLY RESTRUCTURED
COMMUNICATIONS AND SCIENCE
POLICY INTO A NEW POLICY
LEGISLATION COMMUNICATIONS AND
ENGAGEMENT PLACE TEAM.
WHICH IS LED NOW BY OARC POLICY
ADVISORY DR. (INAUDIBLE).
DR. LYNN JOINED NIH OAR IN MAY
FROM PREVIOUS POSITION AT NICHD.
WHERE SHE WAS THE LEAD HEALTH
SCIENCE POLICY ANALYST FOR THE
SCIENCE POLICY AND PLANNING
BRANCH OFFICE OF SCIENCE POLICY
PROGRAM ANALYSIS.
EACH OF THE TEAMS, THE FIVE
TEAMS SHOWN ON THE SLIDE WORK
ACROSS THE OAR, THE OFFICE TO
FULFILL THE OAR MISSION.
THE TEAM LEADS FORM THE OAR
DIRECTORS MANAGEMENT ADVISORY
TEAM.
A TERRIFIC GROUP OF PARTNERS WHO
ARE ESSENTIAL TO OAR TO ACHIEVE
ITS MISSION.
I WOULD LIKE TO TAKE THIS
OPPORTUNITY TO THANK THEM ALL, I
APPRECIATE THE WORK YOU AND YOUR
TEAMS DO FOR NIH OAR.
SO THE REST OF MY REPORT, IT
WILL BE INCLUDE -- IT WILL
INCLUDE AN UPDATE ON THE NIH
RESEARCH BUDGET, DESCRIPTION OF
INTERAGENCY COLLABORATIONS
BETWEEN THE NIH OAR AND OUR
PARTNERS ACROSS THE FEDERAL
GOVERNMENT.
UPDATES ON ACTIVITIES PROMOTING
KEY OAR SCIENTIFIC WORK FORCE
PRIORITIES.
SO LET'S START WITH AN OVERVIEW
OF THE NIH HIV RESEARCH BUDGET.
FROM HISTORICAL PERSPECTIVE
AFTER SIGNIFICANT BUDGET
INCREASES, FOR THE HIV PROGRAM
INTO THE EARLY 2000s, NIH HIV
FUNDING WAS FLAT DURING FISCAL
YEARS 2014 TO 2018.
WHICH REPRESENTED BY THE FIRST
FIVE BARS ON THE GRAPH ON THE
SLIDE.
FROM 2019 TO 2021 THERE WERE NEW
FUNDS TOTALLY ABOUT $87 MILLION
WHICH RAISED THE ANNUAL BUDGET
TO JUST OVER 2 BILLION IN FY 21.
IF FY 2022 FAR MOST THE RIGHT
BAR ON THE FAR MOST RIGHT OF THE
SLIDE, THE CONGRESSIONAL
ALLOCATION TO THE OAR INCLUDED
AN INCREASE OF MORE THAN $100
MILLION FOR NIH HIV AIDS
RESEARCH WHICH IS 3.4% OVER THE
FY 2021 LEVEL AND ACTIVE LEVEL.
THIS IS THE LARGEST INCREASE FOR
HIV RESEARCH SINCE FY 2014
REPRESENTS 13.4% OF THE
ESTIMATED $775 MILLION REQUESTED
IN THE FY 2022 PROFESSIONAL
JUDGMENT BUDGET.
THE INCREASED FUNDS SUPPORT
FOCUSED INVESTMENTS IN AREAS
ALIGNED WITH THE GOALS OF THE
NIH STRATEGIC PLAN FOR HIV AND
HIV RELATED RESEARCH.
THE OBJECTIVES OF THE NATIONAL
HIV AIDS STRATEGY INCLUDING THE
ENDING THE HIV EPIDEMIC
INITIATIVE AND THE AREAS
EMPHASIZED IN THE FY 2022
PROFESSIONAL JUDGMENT BUDGETS.
AS A REMINDER EACH YEAR THE NIH
OAR PREPARES A PROPROFESSIONAL
BUDGET OR PJ, AS REQUIRED BY NIH
REVITALIZATION ACT OF 1993.
THE LEGISLATION AND I QUOTE,
MANDATES A COMPREHENSIVE PLAN
THROUGH CONDUCT AND SUPPORT OF
ALL AIDS ACTIVITIES WITH NIH AND
REQUIRES IN A FULL FUNDING
BUDGET FOR CARRYING OUT THE PLAN
REWE SUBMITTED TO THE PRESIDENT.
DEVELOPMENT PROVIDES THE OFFICE
OF AN ANNUAL OPPORTUNITY TO
PRESENT AN ASPIRATIONAL BUDGET
THAT HIGHLIGHTS AREAS THAT
BENEFIT FROM ADDITIONAL
INVESTMENT.
THESE HIGHLIGHTED AREAS IDENTIFY
EACH YEAR THROUGH ENGAGEMENTS
WITH NIH ICOs, THE INSTITUTE
CENTERS AND OFFICES.
FEDERAL PARTNERS, AND HIV
COMMUNITY LEADERS.
E RELEASED THIS MONOTO CONGRESS
AND PRESIDENT, THE FY 20223
ESTIMATES $639 MILLION IN
ADDITIONAL FUNDS, A 20% INCREASE
IN HIV RESEARCH INVESTMENT OVER
FY 2022.
THE ESTIMATED FUNDING WOULD
EXPAND THE NIH INVESTMENTS TO
CATALYZE KEY AREAS KEY RESEARCH
AREAS SUCH AS IN NO SPECIFIC
ORDER EXPAND BASIC RESEARCH IN
BIOMEDICAL BEHAVIORAL SOCIAL
SCIENCES, ADDRESS HIV
CO-OCCURRING CONDITIONS, DEVELOP
TRAININGS FORMATIVE TECHNOLOGIES
METHODOLOGIES AND IMPLEMENTATION
APPROACHES, AND ENHANCE
DIVERSITY AND STRENGTHEN
CAPACITY OF THE HIV RESEARCH
WORK FORCE.
THE PJ WAS PROVIDED TO COUNCIL
MEMBERS IN ADVANCE OF TODAY'S
MEETING AND IS AVAILABLE TO
PUBLIC ON OAR WEBSITE.
AS WELL THERE IS NEW BLOG POST
THAT INCLUDES INFORMATION ON THE
FY 22 PJ AND FY 2022 BUDGET
INCREASE.
SO MOVING ON WHILE COORDINATING
HIV RESEARCH ACROSS THE NIH, THE
NIH OAR ALSO PARTNERS ACROSS THE
FEDERAL GOVERNMENT AS OUTLINED
IN THE OAR LEGISLATION.
NIH IS ONE OF THE 11 OPERATING
DIVISIONS IN DEPARTMENT OF
HEALTH AND HUMAN SERVICES.
THE OAR IS LOCATED WITHIN THE
NIH OFFICE OF DIRECTOR AND IS
THE SECOND OLDEST OF THE 14 NIH
COORDINATING PLANNING AND
STRATEGIC INITIATIVE OFFICES.
THE DIRECTOR FROM ONE OF THE
OFFICES, DATA SCIENCE STRATEGY
IS PRESENTING LATER TODAY TO THE
OARAC.
TWO ADDITIONAL OFFICES TRIBAL
HEALTH RESEARCH AND OFFICE OF
RESEARCH FOR WOMEN'S HEALTH ARE
REFERENCESSED IN MY PRESENTATION
TODAY.
-- REFERENCED IN MY PRESENTATION
TODAY.
COMMUNICATION AND COLLABORATION
WITH OTHER FEDERAL AGENCIES ARE
CRUCIAL TO ESTABLISH EFFECTIVE
STRATEGIES FOR HIV PREVENTION
TREATMENT AND CARE ACROSS THE
NATIONAL AND GLOBAL COMMUNITIES.
THESE COLLABORATIONS PLAY A KEY
ROLE TO MAXIMIZE THE RETURN ON
PUBLIC INVESTMENT AND FACILITATE
A WHOLE GOVERN AGENDA TO END THE
HIV PANDEMIC.
GLOBALLY AND IN THE UNITED
STATES.
ONE WAY ACROSS AGENCY
COMMUNICATION OCCURS IS THROUGH
OARAC.
AS YOU HEARD TODAY ADDITION TO
VOTING MEMBERS, OARAC INCLUDES
EX-OFFICIO MEMBERS REPRESENTING
HEALTH AND HUMAN SERVICES, CDC,
VETERANS ADMINISTRATION AND
DEPARTMENT OF DEFENSE.
WITH OTHER EX-OFFICIO MEMBERS
REPRESENTING THE NIH OFFICE OF
DIRECTOR, AND THE INSTITUTE AND
CENTERS WITH THE LARGEST
PROPORTION OF NIH HIV FUNDING.
FROM LINKAGES ACROSS FEDERAL
AGENCIES ARE FACILITATED BY
INTERACTIVE NETWORK OF ADVISORY
BOARDS AND PARTNERSHIPS THAT
PROVIDE CRITICAL INFORMATION AND
EXPERT ADVICE TO OAR THAT CAN
INFORM THE NIH HIV RESEARCH
ENTERPRISE.
WE MENTIONED OARAC IN ADDITION
THERE IS ILLUSTRATED ON THE
SLIDE IN BLUE SYMBOL LOWER
MIDDLE PART OF THE SLIDE, THE
NAC, NIH HIV AIDS EXECUTIVE
COMMITTEE COMPRISED OF
REPRESENTATIVES FROM ACROSS THE
NIH AND IS THE OAR ADVISORY
COORDINATING COMMITTEE FOR ALL
NIH HIV RESEARCH EFFORTS.
IN ADDITION THERE IS THE CHA,
HHS CDC HRSA ADVISORY COMMITTEE
ON HIV, VIRAL HEPATITIS AND STD
PREVENTION AND TREATMENT.
AND YOU WILL BE HEARING MORE
ABOUT THIS FROM CDC AND HRSA
TODAY.
AND AS WELL THERE IS THE
PRESIDENTIAL ADVISORY COUNCIL ON
HIV AIDS.
THAT ADVISES THE WHITE HOUSE
THROUGH THE HHS ASSISTANT
SECRETARY OF HEALTH AND HHS
SECRETARY.
CHOCK SIMILAR TO OARAC ALSO
INCLUDE EX-OFFICIO AND FEDERAL
STAFF AS WELL AS COMMUNITY
ACADEMIC AND PRIVATE SECTOR
PARTNERS.
JUST TO POINT OUT THAT THE
ADVISORY GROUPS INCLUDED IN THIS
SLIDE ARE NOT EXHAUSTIVE.
FOR EXAMPLE PEPFAR IN THE UPPER
RIGHT SIDE OF THE SLIDE HAS A
SCIENTIFIC ADVISORY BOARD THAT
ALSO INCLUDES SUBJECT MATTER
EXPERTS CIVIL SOCIETY FEDERAL
PARTNERS HHS AGENCIES.
THE IMPORTANT POINT IS SHARED
MEMBERSHIP BY FEDERAL AGENCIES
ON DIFFERENT ADVISORY BOARDS
PROMOTES FLUID COMMUNICATION AND
UNDERSTANDING OF THE PERSPECTIVE
OF EACH AGENCY'S ROLE IN SHAPING
HIV AIDS POLICIES ACROSS THE
GOVERNMENT.
THE GUIDANCE OAR RECEIVES
DIRECTLY FROM ITS OWN COUNCIL
OARAC AND INDIRECTLY FROM OTHER
ADVISORY COUNCILS CONTRIBUTES TO
THE DEVELOPMENT OF THE NIH HIV
RESEARCH AGENDA AND THE BUDGET
REQUEST PRESENTED TO CONGRESS
AND TO THE WHITE HOUSE.
SO NOW IN THE FOLLOWING SLIDES I
WILL DESCRIBE SPECIFIC
ENGAGEMENTS BETWEEN VARIOUS
FEDERAL PARTNERS INVOLVED IN
NATIONAL AND INTERNATIONAL
EFFORTS TO END THE HIV EPIDEMIC.
FROIN ADDITION THE OARAC AGENDA
TODAY INCLUDES SEVERAL OF OUR
NIH OAR FEDERAL PARTNERS AS I
MENTIONED, WE WILL DISCUSS
RELATIONSHIPS AND SYNERGIES THAT
MAKE MULTI-FACETED FEDERAL HIV
RESPONSE UNIQUE, EFFECTIVE AND
WELL ANNOUNCED.
SO INCLUDED IN SOME OF THE
IMPORTANT INTERAGENCY
ACTIVITIES, LAST YEAR THE OAR
COORDINATED THE NIH INPUT TO
UPDATE NATIONAL HIV AIDS
STRATEGY THIS YEAR OAR CONVENED
PARTNERS FROM 19 NIH INSTITUTE
CENTERS AND OFFICES AND SHARED
THE NAIC IN HOUSE WORKING GROUP
TO CATALOG IMPLEMENTATION
ACTIONS THAT SPAN BASIC CLINICAL
SOCIAL BEHAVIORAL AND
IMPLEMENTATION RESEARCH.
THESE ACTIVITIES ADDRESSED
FOCUSED AREAS OF HIV WORK FORCE
EXPANSION AND DIVERSIFICATION
AND STIGMA AND DISPARITIES
REDUCTION AMONG ALL IN HOUSE
PRIORITY POPULATIONS.
NIH OAR WILL CONTINUE TO
COORDINATE MONITOR AND REPORT ON
NIH WIDE HOUSE ACTIVITIES WITHIN
HIV LEADERSHIP AND OTHER
PARTNERS.
THE OAR IS CURRENTLY PROVIDING
STAFF SUPPORT TO OFFICE OF THE
WHITE HOUSE OFFICE OF NATIONAL
HIV AIDS POLICY, IS WORKING WITH
NIAID NIMH IN COLLABORATION WITH
THE CDC, HRSA AND SAMHSA ON
AGENCY ONAC WORKING GROUP TO
DEVELOP QUALITY OF LIFE
INDICATORS, FOR THE NATIONAL HIV
AIDS STRATEGY.
LAST MONTH NIH ATTENDED AN
OPERATIONAL LEADERSHIP TEAM
RETREAT HOSTED BY THE ONAC
DIRECTOR HAROLD PHILLIPS.
DISCUSSIONS ON STATUS NEUTRAL
AND APPROACH IMPLICATIONS FOR
THE HIV EPIDEMIC AND THE
NATIONAL HIVE AIDS STRATEGY, AS
WELL AS PLANNING START OF PHASE
2 IN 2026.
THE FIRST THREE YEARS OF THE NIH
EHE FUNDING ARE SUMMARIZED ON
RIGHT SIDE OF THE SLIDE.
WHILE THE DIRECT EH FUNDING HAS
BEEN FOCUSED TO THE CFAR
PROGRAMS, NIH ALSO LEVERAGES
BASED HIV FUNDING TO SUPPORT AND
EXPAND EFFORTS TO MEET EHE
OBJECTIVES, BUT ALSO ADVANCE THE
NIH HIV RESEARCH MISSION.
LAST MONTH KAY HAYES WAS
APPOINTED DEPUTY ASSISTANT
SECRETARY FOR INFECTIOUS
DISEASES AND THE DIRECTOR OF THE
OFFICE OF INFECTIOUS DISEASE AND
HIV AIDS POLICY.
WITH THE SHORTER OIDP ACRONYM.
WE LOOK FORWARD TO HEARING MORE
FROM HER LATER IN TODAY'S
PROGRAM, IN HER ROLE AS DEPUTY
ASSISTANT SECRETARY KAY SERVES
AS EXECUTIVE DIRECTOR OF THE
PRESIDENTIAL ADVISORY COUNCIL ON
HIV AIDS.
OAR INTERACTIONS HAVE INCLUDED
IN MARCH PARTICIPATED IN THE
73RD MEETING AS THE NIH EXUPPISH
OWE MEMBER.
-- EX-OFFICIO MEMBER.
AT THE RECENT PLANNING SESSION
OAR DEPUTY DIREC DIRECTOR AND TE
DADES DIRECTOR BRIEFED ABOUT
PLANNED HIV PREVENTION CARE REAM
AND CURE RESEARCH.
IN MAY I REPRESENTED THE NIH OAR
AT MOLECULAR HIV CLUSTER
DETECTION AND RESPONSE WORK
GROUP.
SUGGESTIONS FOR HIV CLUSTER
DETECTION POLICIES AND PRACTICES
WERE SUBMITTED TO THE PACHA
STIGMA AND DISTE DISPARITIES
SUBCOMMITTEE FOR CONSIDERATION
ADVISING THE PRESIDENT VIA HHS
AND OFFICE OF NATIONAL HIV AIDS
POLICY.
THE NIH OAR IS CDC HRSA ADVISORY
COMMITTEE IS MENTIONED, AND WE
WILL HEAR MORE ABOUT THIS FROM
RARE ADMIRAL JOHN MERMIN AND
FROM DR. (INAUDIBLE).
EARLIER THIS MONTH AMBASSADOR AT
LARGE DR. JOHN (INAUDIBLE)
OFFICIALLY ASSUMED HIS NEW ROLE
AS U.S. GLOBAL AIDS COORDINATOR
AND SPECIAL REPETITIVE FOR --
REPRESENTATIVE FOR GLOBAL HEALTH
DIPLOMACY STATE DEPARTMENT.
HE'S THE FIFTH PERSON TO HOLD
THIS POSITION, SINCE U.S.
PRESIDENT EMERGENCY PLAN FOR
AIDS RELIEF PEPFAR DOESOR WAS
CREATED IN 2003 UNDER THE
PRESIDENT BUSH.
NIH OAR WILL CONTINUE TO WORK
WITH PEPFAR LEADERSHIP TO
ACCELERATE PROGRESS ON THE
GLOBAL HIV RESPONSE.
AND LATER TODAY WE WILL REVEAL
MORE ABOUT PEPFAR FROM JIN PARK,
DIRECTOR OF THE OFFICE WITHIN
THE HHS OFFICE OF GLOBAL
AFFAIRS.
THE NIH HIV RESEARCH PORTFOLIO
IS TRULY GLOBAL.
INTERNATIONAL HIV RESEARCH
REPRESENTS APPROXIMATELY 20% OF
THE TOTAL ANNUAL NIH HIV
RESEARCH FUNDING.
IN FY 2021, THAT MEANT OVER $600
MILLION WAS INVESTED IN MORE
THAN 1100 HIV RESEARCH PROJECTS
OR RESEARCH GRANTS IN 95
COUNTRIES OUTSIDE THE UNITED
STATES.
THIS INTERNATIONAL RESEARCH
PORTFOLIO FOCUSES ON HIV
PRIORITY AREAS RELEVANT FOR BOTH
HOST NATION AND THE UNITED
STATES.
INCLUDING MULTI-NATIONAL HIV
CLINICAL TRIAL NETWORKS,
INITIATIVES FOCUSED ON
IMPLEMENTATION SCIENCE, AND
TRAINING AND CAPACITY BUILDING
EFFORTS.
BIDIRECTIONAL LESSONS LEARNED
FROM THE EFFORTS WILL PROVIDE
VALID MODELS OF REAL LIFE
IMPLEMENTATION TO SUPPORT
DOMESTICALLY.
SIMILAR TO HOW NIH OAR LEVERAGES
DOMESTIC FUNDS, NIH PEPFAR
EXPANDS INTERNATIONAL
COLLABORATION TO LEVERAGE AND
BUILD UPON NETWORKS AND
INFRASTRUCTURE, CLINICAL
PRACTICE GUIDELINES FOR HIV AIDS
PREPARED BY THE OARAC WORKING
GROUPS, ENHANCE HEALTH WORK
FORCE AND IMPLEMENT ADVANCE
DIAGNOSISSIC AND CLINICAL
MONITORING TECHNOLOGIES.
DIAGNOSTIC AND CLINICAL
MONITORING TECHNOLOGIES.
AS I TURN TO UPDATES ON KEY NIH
OAR SCIENTIFIC WORK FORCE
PRIORITIES, LISTENING SESSIONS
HAVE CONTINUED DURING THE TRAVEL
RESTRICTIONS DUE TO THE COVID
PANDEMIC.
VIRTUAL ENGAGEMENTS HAVE BEEN
EFFECTIVE IN THE ABSENCE OF IN
PERSON MEETINGS.
AND A REPORT SUMMARIZING
FINDINGS FROM THE VIRTUAL
LISTENING SESSIONS THROUGH JULY
OF LAST YEAR IS NOW AVAILABLE ON
OAR WEBSITE.
RECENTLY IN MAY THE NIH OAR
PARTICIPATED IN TWO VIRTUAL
LISTENING SESSIONS, IN TEXAS.
THE SESSIONS WERE HOSTED BY THE
TEXAS DEVELOPMENTAL CENTER FOR
AIDS RESEARCH, THE DC FAR AND
THE HOUSTON HEALTH DEPARTMENT.
AND INCLUDED RESEARCHERS
CLINICIANS, ADVOCATES AND
COMMUNITY MEMBERS.
WE HEARD LOCAL CONCERNS ABOUT
SPECIFIC ISSUES INCLUDING HIGH
INCIDENCE OF SUBSTANCE USE
BEYOND OPIOID AND PEOPLE WITH
HIV.
DIFFICULTIES ACCESSING LONG
ACTING HIV MEDICATION, NEED TO
ADDRESS HIGHLY PREVALENT LOCAL
CO-MORBIDITIES SUCH AS OBESITY,
LACK CLINICAL GUIDANCE ABOUT HIV
MEDICATION AND NEED TO CONTINUE
ADDRESSING INTERSECTIONAL
STIGMA.
ALSO IN MAY THE NIH OAR WAS
INVITED TO HOST A LISTENING
SESSION AT NATIONAL -- ANNUAL
MEETING OF NATIONAL COUNCIL OF
URBAN INDIAN HEALTH.
THE NATIONAL -- NIH TRIBAL
HEALTH RESEARCH OFFICE DIRECTOR
DR. DAVID WILSON SERVED AS
MODERATOR.
THIS WAS THE FIRST OAR LISTENING
SESSION FOCUSED SPECIFICALLY ON
NATIVE AMERICAN POPULATIONS.
IN THIS COMMUNITY SETTING WE
LEARNED THE CRITICAL VALUE OF
PROVIDING HIV CLINICAL
INTERVENTION WITHIN A CULTURAL
CONTEXT THAT INCORPORATES
SPIRITUAL PRACTICES, AND FAMILY
DYNAMICS INTO HIV TREATMENT.
IN APRIL THE HIV NIH AIDS FOCUS
GROUP TO USED ON EARLY CAREER
INVESTIGATORS CONVENED A
WORKSHOP WITH GRADUATE STUDENTS,
EARLY CAREER INVESTIGATORS AND
SEASONED MANAGERS.
APPROXIMATELY 150 PARTICIPANTS
ATTENDED.
AMONG OTHER GOALS OF THE
WORKSHOP INTENDED TO STIMULATE
SCIENTIFIC EXCHANGE NETWORKING
AND COLLABORATION AMONG THE NEXT
GENERATION OF INVESTIGATORS.
AND INCREASE FAMILIARITY ABOUT
THE NIH REVIEW AND FUNDING
PROCESSES.
THE WORKSHOP INCLUDED A MOCK
REVIEW SESSION AND WAS AN
OPPORTUNITY TO DEMYSTIFY THE
SCIENTIFIC REVIEW PROCESS FOR
INVESTIGATORS.
NEXT STEPS INCLUDE DEVELOPMENT
OF FOLLOW-ON WORKSHOP FOR HIV
EARLY CAREER INVESTIGATORS
INFORMED BY PARTICIPANT
FEEDBACK, ENHANCE AND UPDATED
WEB CONTENT FOR RESOURCES FOR
HIV EARLY CAREER INVESTIGATORS.
INCREASE NETWORKING
OPPORTUNITIES PARTICULARLY IN
PERSON MEETINGS MAY INCREASE AND
DEVELOPMENT OF SUSTAINABILITY
PLAN FOR DIVERSE HIV RESEARCH
WORK FORCE.
THE NIH JUST ANNOUNCED THE
APPOINTMENT OF MR. KEVIN
WILLIAMS AS NEW DIRECTOR OF THE
NIH OFFICE OF EQUITY DIVERSITY
AND INCLUSION.
AS YOU MAY KNOW NIH LAUNCHED A
GRANT PROGRAM AIMED AT CLOSING
THE GAP IN FUNDING RATES BETWEEN
BLACK AND WHITE INVESTIGATORS
AND WE WILL HEAR MORE ABOUT THIS
PROGRAM LATER THIS AFTERNOON.
THE OAR WORK FORCE ACTIVITIES
WITH THE EARLY CAREER
INVESTIGATORS ARE ALIGNED WITH
THE GOALS OF THE NIH UNITE
MISSION.
WITH THE FIRST NIH WIDE
STRATEGIC PLAN FOR DIVERSITY
EQUITY INCLUSION AND
ACCESSIBILITY.
THIS PLAN IS BEING FINALIZED AND
INCLUDES STRATEGIES TO
STRENGTHEN THE CAREERS OF WOMEN
IN THE HIV RESEARCH WORK FORCE
AS WELL.
WITHIN THIS CONTEXT THE NIH OAR
REPRESENTATION IN NIH STUDIES
INCLUDING WORK FORCE RESEARCH
GAPS AND OPPORTUNITIES AT THE
WOMEN'S RESEARCH INITIATIVE ON
HIV AIDS HOSTED BY THE WELL
PROJECT LAST MONTHS.
THE WOMEN RESEARCH INITIATIVE
BRINGS TOGETHER LEADERS IN HIV
TO IDENTIFY KEY OPPORTUNITIES TO
ACCELERATE THE UNDERSTANDING OF
HIV DISEASE IN WOMEN.
NIH OAR PARTICIPATED IN THE
ADVISORY CABINET OF THE NIH
MATERNAL MORBIDITY AND MORTALITY
TASK FORCE.
TO DISCUSS THE IMPROVE
INITIATIVE.
THIS ACTIVITY IS LED BY DR.
DIANA BY YANKEE, DIRECTOR OF
EUNICE -- BIANCI, NATIONAL
INSTITUTE OF CHILD HEALTH AND
HUMAN DEVELOPMENT.
DR. JANINE CLAYTON, NIH
ASSOCIATE DIRECTOR FOR RESEARCH
ON WOMEN HELP AND DIRECTOR OF
THE NIH OFFICE OF RESEARCH ON
WOMEN'S HEALTH.
AND DR. COURTNEY ACLIN ACTING
NIH ASSOCIATE DEPUTY DIRECTOR.
IN 2022 CONGRESS APPROVED THE
PRESIDENT REQUEST FOR $30
MILLION TO ENHANCE THIS PROGRAM.
SO THE TASK FORCE CABINET AND
HAVE BEEN DEVELOPING INNOVATIVE
INITIATIVE OPPORTUNITIES TO
ACCELERATE PROGRESS FOR THE
HEALTH OF PREGNANT WOMEN --
PREGNANT PEOPLE WITH HIV.
ROHAN, I THINK YOU ARE ON THE
CALL.
I DON'T KNOW IF THERE IS
ANYTHING ADDITIONAL TO ADD TO
THIS DISCUSSION SECTION, THAT
WOULD BE GREAT.
HIV AND AGING CONTINUES AS A
HIGH PRIORITY ACTIVITY FOR THE
NIH HIV RESEARCH PORTFOLIO.
THE OAR WAS INVITED TO PRESENT
AT RECENT FEDERAL AIDS POLICY
PARTNERSHIP MEETING ON THE NIH
HIV AGING RESEARCH LANDSCAPE.
THAT IS A NATIONAL ADVOCACY
COALITION OF MORE THAN 120 LOCAL
REGIONAL AND NATIONAL
ORGANIZATIONS FOCUSED ON FUNDING
LEGISLATION AND POLICY TO END
THE HIV EPIDEMIC.
ONE ITEM DISCUSSED WAS NIH OAR
FUNDING OF SEVERAL SUPPLEMENTS
THROUGH NOTICE OF SPECIAL
INTEREST, THAT IS INDICATED ON
THE SLIDE ISSUED EARLIER THIS
YEAR IN ONGOING COLLABORATION
FOR NATIONAL INSTITUTE ON AGING,
THE NOCI EXPANDS CURRENT NIH
AGING RESEARCH MORE GENERAL NIH
HIV RESEARCH TO INCLUDE HIV
OBJECTIVES AND EXPLORE HEALTH
OUTCOMES OF PEOPLE WITH HIV
THROUGHOUT THE LIFE SPAN.
I MET WITH THE NATIONAL
INSTITUTE FOR AGING DIRECTOR DR.
RICHARD HODES TO REVIEW NIH AND
AGING UPCOMING RESEARCH
PRIORITIES AND EXPAND THE
ACTIVITIES MOVING FORWARDS.
-- MOVING FORWARD.
SINCE THE LAST OARAC SEVERAL NIH
WORKSHOPS DISCUSSED THE PROGRESS
AND FUTURE DIRECTIONS OF HIV AND
AGING RESEARCH INCLUDING THE
PATHOGENESIS OF AGE RELATED HIV
NEURODEGENERATION WORKSHOP AND
THE NIH INTRAMURAL NEURAL HIV
RESEARCH WORKSHOP FOR 2022.
AT THE UPCOMING AIDS 2022
CONFERENCE NEXT MONTH OAR
TOGETHER WITH MEMBER OF NIH
INSTITUTES AND CENTERS, WILL
LEAD ACTIVELY PARTICIPATE IN
WORKSHOPS SYMPOSIA PRESENTATIONS
AND OTHER ACTIVITIES.
SPECIFICALLY NIH OAR WILL LEAD
SESSIONS ON GLOBAL DOMESTIC
BIDIRECTIONAL LESSONS LEARNED.
THE NIH OAR NIMH LAUNCH OF
SPECIAL ISSUE IN THE AMERICAN
JOURNAL OF PUBLIC HEALTH
FOCUSING ON HIV RELATED
INTERSECTIONAL STIGMA AND
DISCRIMINATION TO IMPROVE
OUTCOMES AND INFORM PUBLIC
HEALTH.
AND A SATELLITE SESSION ON
IMPLEMENTATION SCIENCE AS
RELATED TO THE EHE INITIATIVE.
THERE ARE ALSO NUMBER OF OTHER
NIH SESSIONS THAT COUPLE TO NOTE
AS WORKSHOP ADVANCING HIV HEALTH
COMMUNICATION SCIENCE SPONSORED
BY THE NATIONAL INSTITUTE OF
MENTAL HEALTH DIVISION OF AIDS
RESEARCH, A SESSION ON THE USE
OF BEHAVIORAL ECONOMICS AND
CONDITIONAL INCENTIVES IN NIH
TREATMENT AND PREVENTION.
SPONSORED BY FOGARTY
INTERNATIONAL CENTER AND NIMH.
AND A SESSION FOCUSED ON RECENT
EVIDENCE OPTIMAL METHODS TO
EVALUATE NEURAL DEVELOPMENTAL
OUTCOMES IN HIV.
SO HOPE THAT MANY OF YOU WILL BE
PARTICIPATING.
PERHAPS WE WILL GET TO
(INAUDIBLE).
SHORTLY AFTER I FINISH MY
REMARKS WE WILL HEAR FROM DR.
SUSAN GREGURICK WHO IS DIRECTOR
OF THE NIH OFFICE OF DATA
SCIENCE STRATEGY ODSS.
THIS OFFICE PROVIDES LEADERSHIP
AND COORDINATION AT BROAD RANGE
OF NIH WIDE DATA SCIENCE
ACTIVITIES TO REALIZE THE AGENCY
VISION FOR MODERNIZED INTEGRATED
BIOMEDICAL DATA ECOSYSTEM.
ACHIEVING THIS WILL MAXIMIZE
VALUE OF DATA GENERATED THROUGH
NIH FUNDED RESEARCH AND EXPAND
ACCESS TO DATA SETS THAT MAY
INFORM HIV RESEARCH.
DR. GREGURICK WILL DISCUSS DATA
SHARING PRACTICES, DATA
TRIANGULATION, ACCESSIBILITY AND
TRANSPARENCY, THESE ARE TOPICS
FOR CURRENT AND FUTURE
COLLABORATIONS THAT WILL YIELD
BENEFITS WITHIN THE NIH
COMMUNITY AND BEYOND WITH THE
EXTRAMURAL RESEARCH COMMUNITY.
SO I THINK THIS THE REST OF THE
DAY, BLANTON HAS OUTLINED THIS
FOR YOU, IT IS IN YOUR PROGRAM
SO I FOR SAKE OF TIME MOVE
FORWARD.
JUST TO REMIND YOU THAT NEXT
OARAC.
IS THURSDAY, THE 27TH.
AND WE MEMBERSHIP ABOUT
CONFERENCES FOR HYBRID VERSUS
ALL VIRTUAL MEETING.
SO PLEASE MAKE SURE THAT YOU USE
SURVEY, SHOULD TAKE ABOUT A
MINUTE.
THERE ARE MANY WAYS TO STAY
CONNECTED WITH OAR IN OUR
ACTIVITIES, PLEASE VISIT OUR
WEBSITE, JOIN OUR LIST AND
FOLLOW US ON SOCIAL MEDIA.
THANK YOU FOR YOUR ATTENTION AND
I THINK THERE'S TIME FOR US TO
HAVE SOME CONVERSATION.
BLANTON, BLACK TO YOU.
-- BACK TO YOU.
>> THANK YOU, DR. GOODENOW FOR A
VERY EXCELLENT REPORT.
SO COLLEAGUES I WANT TO OPEN UP
NOW FOR DISCUSSION AND REMIND
YOU TO PLEASE RAISE YOUR HANDS.
AND WE WILL ACKNOWLEDGE YOU.
>> I HAD A QUICK QUESTION ABOUT
THE LISTENING SESSION.
HOW (INAUDIBLE)?
>> AM I -- GOOD QUESTION.
LISTENING SESSIONS ARE SET UP
PLEASE REALLY MIXTURE OF LOTS OF
TIMES PEOPLE INVITE US TO COME
AND HAVE LISTENING SESSIONS WITH
THEM.
SOMETIMES DURING OTHER TYPES OF
INTERACTIONS IT WILL BECOME
CLEAR THIS IS A GOOD
OPPORTUNITY.
SOMETIMES WE USE LISTENING
SESSIONS AS SIDE BAR ACTIVITIES
OR ACTIVITIES ON THE MARGINS OF
MEETINGS THAT WE MIGHT BE
ATTENDING.
WE WILL PROBABLY DO SOME TYPE OF
LISTENING SESSION OR SITE VISIT
IN MONTREAL.
UPCOMING MEETING IN OCTOBER OF
THE USCHA HELD IN PUERTO RICO
AND WE WILL BE ADDING ON SOME
SITE VISITS AND LISTENING
SESSIONS IN PUERTO RICO
PARTICULARLY BECAUSE THE NIH OAR
INVESTED A LARGE AMOUNT OF
MONEY, CONSTRUCTION MONEY IN
2017 AFTER HURRICANE MARIE
DESTROYED THE NON -HUMAN PRIMATE
CENTER IN PUERTO RICO.
SO THEY HAVE BEEN REBUILDING,
THEY ARE EXCITED ABOUT US BEING
THERE.
TO LOOK AND SEE WHAT THEY HAVE
BEEN DOING.
SO IT IS A VARIETY OF WAYS AND
WE ARE OPEN TO ANYONE WANTING A
CONVERSATION ABOUT IT.
THE LISTENING SESSIONS
THEMSELVES WHEN THEY ARE HELD
ONE OF THE THINGS WE HAVE BEEN
ABLE TO CAPITALIZE ON AND TO
MAINTAIN IS THE IDEA OF HAVING
RELATIVELY SMALL GROUPS AND
LISTENING SESSIONS ARE USUALLY
ADVERTISING AND OPEN TO PEOPLE
IN THE AREA, THEY DECIDE WHO IS
GOING TO BE INCLUDED IF IT IS A
COMMUNITY GROUP THEY DECIDE WHO
IS GOING TO BE INCLUDED.
BUT THEY ACTUALLY WE ARE SORT OF
CONCERNED ABOUT LOSING A LOT OF
INTIMACY AND CONVERSATIONAL
ASPECTS OF THESE ENGAGEMENTS
THAT OCCUR IN PERSON, THEY ARE
VERY EFFECTIVE IN THE VIRTUAL
SPACE PARTLY BECAUSE ABLE TO
KEEP THE SIZE OF EACH ENCOUNTER
USUALLY NO BIGGER THAN YOU CAN
GET PICTURES ON THE SCREEN AT
THE SAME TIME.
SO IT IS -- WE HAVE BEEN
MODIFYING ADAPTING EVERYONE'S
EXPERIENCE.
DOES THAT HELP?
>> THANK YOU.
>> DR. ALI-OSMAN.
>> GREAT PRESENTATION.
WONDERING EXTENT TO WHICH OFFICE
-- NIH OFFICE OF AIDS RESEARCH
COORDINATES RELATED ACTIVITY
ACROSS THE INSTITUTES, AND TO
LEVERAGE EACH OTHER, SO ON.
A LITTLE BIT ENLIGHTENMENT ON
THAT.
>> THAT IS A REALLY GOOD
QUESTION BECAUSE IT IS AN
IMPORTANT ASPECT OF THE OAR
ACTIVITIES AND NOT ONLY
ACTIVITIES THAT HAVE DEVELOPED
BUT ACTIVITIES THAT ARE MANDATED
IN THE LEGISLATION.
WHEN OFFICE OF AIDS RESEARCH WAS
SET UP, WHICH WAS VERY EARLY IN
THE DAYS OF THE PANDEMIC, I
THINK THERE WAS NIH FUNDING TO
NIH RESEARCH EVEN BEFORE THERE
WAS AN OFFICIAL CONGRESSIONALLY
DESIGNATED OFFICE.
BUT IN ALL THIS IS GOING ON IN
EARLY '80s, AND BY THE TIME
THE ACTUAL LEGISLATION MID
1980s, IT WAS VERY CLEAR TO
THE LEADERSHIP AND THE
PRINCIPLES AT THAT TIME THE WAY
FOR THIS TO FUNCTION WAS TO BE
AT LEVEL SO THEY -- SO THE
ACTIVITIES COULD BE COORDINATED
AND WOULDN'T DEPEND ANY ONE
INSTITUTE OR CENTER.
THEN OVER TIME THE OFFICE MODEL
HAS REALLY EXPANDED TO OTHER
SUBJECT MATTER AREAS THAT WE
JUST TALKED ABOUT, TRIBAL HEALTH
RESEARCH WOMEN HEALTH RESEARCH
SEXUAL AND GENDER MINORITY
RESEARCH, SO THERE IS NOW A
CADRE OF OFFICES INVOLVED IN
COORDINATING ACROSS THE NIH
DIFFERENT ASPECTS OF THE NIH
RESEARCH PORTFOLIO THAT CAN BE
ASSIGNED NOT WITHIN THE SCOPE OF
THE WORK OF ANY ONE INSTITUTE OR
CENTER.
SO THE WAY WE DO THAT IS USING
-- WE HAVE SIMILAR METHODOLOGIES
WE APPLY IN PARTICULAR SOME THAT
I MENTION TODAY, WE HAVE THE
OARAC, WE ALSO HAVE INTERNAL
COORDINATING COMMISSION --
COMMITTEE, EXECUTIVE COMMITTEE
WHICH HAS REPRESENTATIVES OF
EACH OF THE INSTITUTES CENTERS
AND OFFICES THAT ARE
PARTICIPATING IN THE AGENDA.
IN THE HIV AGENDA.
FUNDING FOR IT.
SO THAT EVERYONE HAS AN
OPPORTUNITY TO INPUT AND THEN IT
IS OUR JOB TO TRIANGULATE ALL
THE INFORMATION THAT WE GET FROM
OUR INTERNAL FOLKS, FEDERAL
COLLEAGUES AND PARTNERS FROM THE
EXTRAMURAL COMMUNITY, FROM THE
COMMUNITY AND ADVOCATES.
AND COME UP WITH A WAY TO KEEP
THE AGENDA MOVING FORWARD AND
KEEP IT NIMBLE AND AGILE IN THE
WAY THAT IT REALLY NEEDS TO BE
FOR FIELD MOVING VERY FAST, IF
YOU THINK ABOUT IT.
WE HAVE COME A LONG WAY IN 40
YEARS.
THERE'S REALLY CHANGE IS ALMOST
-- IS A GIVEN IN THE WAY THAT WE
FUNCTION, WE WERE STILL DOING
EVERYTHING THE WAY IT WAS DONE
40 YEARS AGO ALL THE UNDERSTOOD
FUNDING WAS GOING TO THE SAME
TOPICS IT WENT TO YEARS AGO,
THAT I DON'T THINK WOULD BE
VIEWED BEING SUCCESSFUL PROGRAM.
SO THE BALANCING COMES IN AND
WHERE WE USE ADVICE AND IS HOW
DO YOU BALANCE THE NEEDS WITH
THE RESOURCES.
AND KEEP RESOURCES FLUID TO BE
ABLE TO ACCOMMODATE NEW NEEDS,
WHEN THERE IS NEW MONEY THAT
EASIER THAN WHEN WHETHER IS NOT
BEFORE MY PREDECESSORS AND WE
HAVE CONTINUED SOME OF THESE
PRACTICES, DIFFERENT WAYS THAT
IT IS POSSIBLE TO KEEP MONEY
MOVING THROUGH THE PORTFOLIO TO
ACCOMMODATE A LOT OF NEW AREAS
THAT REALLY NEED ATTENTION NOW.
>> THANK YOU.
MAUREEN, I WOULD LIKE TO ASK A
FOLLOW-UP QUESTION TO THAT, BUT
FIRST I WANT TO CONGRATULATE YOU
ON INCREASING IN THE
CONGRESSIONAL BUDGET AND ALSO
RESEARCH PRIORITY AREAS THAT ARE
HIGHLIGHTED.
MY FOLLOW-UP, I MAY HAVE MISSED
THIS, I NOTICE THAT SOME ICs
WERE MISSING IN YOUR SLIDE IN
TERMS OF INTRAAGENCY
COLLABORATION AND PARTNERSHIPS.
I WAS -- IF I'M CORRECT ON THAT,
I MAY HAVE MISSED -- MAY HAVE
NOT SEEN THAT CORRECTLY BUT IF
THAT IS TRUE, THAT SOME ICs
ARE NOT LISTED AND INVOLVE CAN
YOU ENLIGHTEN US ON THE
MECHANISMS AND STRATEGIES TO
GARNER THOSE PARTNERSHIPS?
>> SO FIRST THE ONES THAT I
MENTION TODAY ARE JUST A SMALL
NUMBER OF EXAMPLES THAT OCCURRED
IN THE LAST THREE MONTHS BECAUSE
WE -- THERE IS UNFORTUNATELY WE
TOOK SOME SLIDES OUT BUT I'M
SORRY WE DO NOW BECAUSE IT WAS
BASED ON TIMES, I THINK I CAME
IN JUST ON TIME SO WE HAD TO GET
TWO SLIDES OUT OF THERE.
THERE IS OUT OF THE 27
INSTITUTES AND CENTERS, I THINK
THAT THE NUMBER OF INSTITUTES
AND CENTERS WHO HAVE HIV
PROGRAMS AND RECEIVED PART OF
THE HIV ALLOCATION IS SOMETHING
LIKE 20.
OF THE INSTITUTES AND CENTERS.
AND OUT OF THE OFFICES, THE 14
OFFICES THERE IS 8 THAT ARE
REALLY DOING PROGRAMMATIC WORK
AND VIRTUALLY ALL OF THEM ARE
INVOLVED IN THE NIH PROGRAM SO
IT IS INCREDIBLY INTERACTIVE.
WIDESPREAD.
AND THEN THE DEPTH OF THE
INVESTMENT, THE DEPTH AND
INSTITUTE CENTER OFFICE LEVEL,
TO WHICH THEY ARE INVOLVED, IS
VARIABLE TOO, DEPENDING.
AND AGAIN, THERE'S INSTITUTES
THAT RECEIVE TRADITIONALLY MORE
MONEY AND IN SOME CASES IT IS A
LARGE PROPORTION OF THEIR
BUDGET.
FOR EXAMPLE NIAID RECEIVES ABOUT
TALKING VERY ROUGH NUMBERS,
SOMETHING LIKE 60% OF HIV
ALLOCATION.
THAT'S OVER -- THAT IS SOMEWHERE
LIKE 33, 35% OF BUDGET SO VERY
BIG COMMITMENT WITHIN THEIR IC
OBVIOUSLY HIV.
THE FOGARTY INSTITUTE HAS
SMALLER BUDGET, ABOUT 25
MILLION, BUT THEY ALSO HAVE A
LARGE PROPORTION, 30% OR MORE,
THEIR BUDGET IS ALSO HIV.
FROM THE HIV PORTFOLIO.
I THINK THE IMPORTANT PIECE IS
HOW THE -- HOW THESE FLUCTUATE
OVER TIME AND THE OVERALL
ENTERPRISE AND RESEARCH GOALS,
NEED NEW INPUT AND NEW AREAS
THAT WE ARE ABLE TO EXPAND FOR
EXAMPLE IN ASIA NOW, IN NURSING
RESEARCH, IN BIOTECHNOLOGY,
AREAS THAT ARE REALLY BECOMING
MORE AND MORE IMPORTANT FOR THE
PORTFOLIO TO BE ABLE TO ACHIEVE
THE GOALS OF THE NEXT NOT ONLY
THROUGH THE CURRENT STRATEGIC
PLAN BUT GOING FORWARDS.
AS WELL.
>> THANK YOU.
ARE THERE OTHER QUESTIONS OR
COMMENTS?
IF NONE I THINK WE CAN MOVE
AHEAD WITH THE SCHEDULE, THANK
YOU AGAIN, DR. GOODENOW FOR THE
REPORT.
AND I BELIEVE OUR FIRST SPEAKER
IS AVAILABLE WITH US, AND AS DR.
GOODENOW MENTIONED WE WILL HEAR
NEXT FROM DR. SUSAN GREGURICK.
SO I WILL MOVE AHEAD AN
INTRODUCE DR. GREGURICK.
DR. GREGURICK WAS APPOINTED
ASSOCIATE DIRECTOR FOR DATA
SCIENCE AND DIRECTOR OF OF OF
OFFICE OF DATA SCIENCE STRATEGY
AT THE NIH IN 2019.
UNDER DR. GREGURICK'S
LEADERSHIP, THE ODSSS LEADS
IMPLEMENTATION OF THE NIH
STRATEGIC PLAN FOR DATA SCIENCE
THROUGH SCIENTIFIC TECHNICAL AND
OPERATIONAL COLLABORATION WITH
THE INSTITUTES CENTERS AND
OFFICES THAT COMPRISE NIH.
DR. GREGURICK RECEIVED A 2020
LEADERSHIP BIOLOGY CONTROL
SCIENCES AWARD -- BIOLOGICAL
SCIENCES AWARD, CONGRATULATIONS
FOR HER WORK IN THIS ROLE.
SO WITH THAT, WE ARE DI LIGHTED
TO HAVE YOU JOIN US TODAY, DR.
GREGURICK, PASS IT OVER TO YOU.
>> THANK YOU SO MUCH.
IT IS A PLEASURE TO BE HERE
TODAY.
I'M LOOKING FORWARD TO OUR
DISCUSSIONS AND I HOPE THAT WHAT
I SHOW YOU WHICH IS ESSENTIALLY
GOING TO BE A LITTLE BIT OF
REVERE AND REVIEW ALL THE THINGS
THAT WE HAVE DONE OVER THE PAST
ONE TO TWO YEARS SUPPORTED BY
THE OFFICE OF DATA SCIENCE
STRATEGY AND OUR WORK IN OUR
OFFICE.
SO THE NEXT SLIDE.
IT IS A LITTLE HIGHLIGHT OF
NORTH STAR FOR DATA SCIENCE NIH,
THE STRATEGIC PLAN FOR DATA
SCIENCE, THESE ARE THE GOALS OF
THE STREAM PLAN TO SUPPORT
INFRASTRUCTURE AND ARCHITECTURE
FOR DATA SIEGES, LEVERAGING
TOOLS AND TECHNOLOGY AND
SERVICES ENHANCING BIOMEDICAL
DATA SCIENCE RESEARCH WORK
FORCE.
ENABLING RESEARCHERS TO SHARE
DATA TO ACCESS DATA AND TO
CREATE INTEROPERABILITY BETWEEN
DATA AND RESOURCES, ENSURING AT
THE SAME TIME THE SECURITY AND
CONFIDENTIALITY OF PATIENT AND
PARTICIPANT DATA AND ALSO
IMPROVING OUR ABILITY TO CAPTURE
CURE RATE VALIDATE AND STORE
ANALYZE NOT JUST CLINICAL DATA
BUT ALL DATA AND FINALLY PROMOTE
DEVELOPMENT AND REFINEMENT OF
DATA STANDARDS INCLUDING DATA
VOCABULARY, DATA MODEL AND
ONTOLOGIES.
SO NEXT SLIDE.
A BROAD VISION.
OUR OFFICE SITS WITHIN THE
OFFICE OF DPKPSI.
OUR GOAL IS TO PROVIDE
LEADERSHIP COORDINATION ON
STRATEGIC PLAN ACROSS NIH TO
IMPLEMENT AND DEVELOP OUR VISION
PROOUR MODERNIZE INTEGRATED
BIOMEDICAL DATA ECOSYSTEM AND AT
THE SAME TIME ENHANCING THE
TALENTED STRONG DETERSIONS WORK
FORCE AND BUILD STRATEGIC
PARTNERSHIP NOT JUST WITH NIH
BUT OTHER FEDERAL AGENCIES
NON-PROFITS AND INTERNATIONAL
PARTNERSHIPS.
NEXT SLIDE IS ANOTHER WAY TO
LOOK AT THE STRATEGIC PLAN BUT
NOW IN TERMS OF -- INSTEAD OF
LOFTY GOALS BUT IN TERMS OF
APPLICATION OF WHAT WE ARE GOING
TO DO, I CAN'T TALK ABOUT ALL
THE THINGS WE DOING SO I
SELECTED A FEW HIGHLIGHTS THAT I
THOUGHT WOULD BE OF INTEREST TO
THIS GROUP.
IT TAKES A VILLAGE TO DO THE
WORK WE WILL TALK ABOUT.
WE WORK WITH ALMOST 200 NIH
STAFF FROM 23 INSTITUTES CENTERS
AND OFFICES AND ALL THESE
CONTRIBUTE IN VARIOUS WAYS
SOMETIMES LEADING AND SOMETIMES
PARTICIPATING IN THE ACTIVITIES
THAT WE TALK ABOUT.
BUT TO START NEXT SLIDE, I NEED
TO TALK ABOUT AND GROUND US IN
NIH FINAL POLICY FOR DATA
MANAGEMENT AND DATA SHARING.
I'M SURE YOU FAMILIAR WITH DATA
POLICY, IT GOES INTO EFFECT LESS
THAN A YEAR FROM NOW, JANUARY
25, 2023.
REQUIRING NIH APPLICANTS TO
PROSPECT TVLY PLAN FOR HOW DATA
WILL BE SHARED AND STORED
SUBMISSION OF DATA MANAGEMENT
AND SHARING PLAN AT THE TIME OF
APPLICATION.
YOU ARE GOING TO OUTLINE HOW
SCIENTIFIC DATA AND ANY METADATA
OR STANDARDS WILL BE MANAGED AND
SHARE AND TAKEN INTO ACCOUNT POO
TENIAL RESTRICTIONS OR
LIMITATIONS TO SHARE OF DATA.
THE PLAN WILL BE PART OF YOUR
BUDGET JUSTIFICATION AND YOUR
APPLICATION.
WE WILL BE SUBMITING A PDF WITH
GRANT APPLICATION, WE RECOMMEND
YOUR PLAN BE NO MORE THAN TWO
BEIGES IN LENGTH AND WILL BE --
PAGES IN LEG AND EXPLORE THE USE
OF STRUCTURED FORMS --
STRUCTURED PDF FORMS TO COLLECT
THE INFORMATION IN THE FUTURE
BUT AT THIS PARTICULAR TIME I
DON'T BELIEVE STRUCTURE FORMSES
ARE POSSIBLE.
THIS POLICY APPLIES TO ALL
FUNDED RESEARCH, CONDUCTED AT
NIH THAT DOES GENERATE
SCIENTIFIC DATA INCLUDES
EXTRAMURAL GRANTS, CONTRACTS,
AND INTRAMURAL RESEARCH PROJECTS
AS WELL.
IT DOES NOT INCLUDE ACTIVITIES
THAT DO NOT GENERATE DATA WHICH
INCLUDES TRAINING INFRASTRUCTURE
DEVELOPMENT OR NON-RESEARCH
ACTIVITIES.
NOT ONLY FEW SLIDES FROM DR.
LAWYER NEXT SLIDE JUST QUICKLY
HIGHLIGHT WHAT ARE SOME OF THE
KEY PARAMETERS.
OFFICE OF NIH SUPPORTED
RESEARCH, GENERATING SCIENTIFIC
DATA, THIS IS RECORDED FACTUAL
MATERIALS, THAT WILL BE OF
SUFFICIENT QUALITY AND ABLE
REPLICATE RESEARCH FINDING.
NOTE BOOKS OR CASE REPORTS.
WHEN SHOULD YOU SHARE YOUR DATA,
CERTAINLY AS SOON AS REASONABLE
BUT NO LATER THAN PUBLICATION OR
END OF YOUR AWARD.
NEXT SLIDE IS HIGHLIGHT WHAT
SOME ELEMENTS COULD BE FOR YOUR
DATA MANAGEMENT SHARING PLAN
INCLUDING THE DATA TYPES THAT
YOU INTEND TO PRESERVE AND
SHARE.
THE RELATED TOOLS AND SOFTWARE
CODE NEEDED TO GENERATE AND
IMPLEMENT THE DATA AND ANY
NECESSARY STANDARDS, INCLUDING
MOST IMPORTANT METADATA, THE
PRESERVATION PLAN HOW DATA WILL
BE ACCESSED AND TIMELINESS OF
THAT DATA, AS WELL AS ANY
REDISTRIBUTION CONSIDERATIONS
PARTICULARLY FACTORS THAT IMPACT
ACCESS AND OF COURSE OVERALL
POOL MANAGE DATA IN THE LAB.
APPLICANTS WILL BE SUBMITTING
THIS AS PDF WITH GRANT
APPLICATION COMPLIANCE WITH DATA
MANAGEMENT SHARING PLAN IS
APPROVED BY FUNDING INSTITUTE OR
CENTER THAT MANAGES THE AWARD.
THE NEXT SLIDE, THERE IS A LOT
OF INFORMATION MORE INFORMATION
BEING EVERY DAY TO OFFICE OF
EXTRAMURAL RESEARCH SHARING THAT
NIH.GOV WEBSITE I ENCOURAGE YOU
TO REVIEW THIS WEBSITE, PRETTY
MUCH ON REGULAR BASIS, THERE IS
GOING TO BE A NUMBER OF WEBINARS
COMING OUT, I KNOW FOR SURE A
WEBINAR AUGUST 11, THAT WILL
HELP COMMUNITY UNDERSTAND
PREPARE FOR THIS POLICY.
THESE WEBINARS LAB REPORTED, IF
YOU CAN'T MAKE IT ON AUGUST 11
THERE LAB REPORTED VIEWING OF
THAT WEBINAR.
YOU WILL SEE MORE INFORMATION
RELEASED ON NIH DATA SHARING
WEBSITE INCLUDING AN OVERVIEW OF
THE POLICY, SOME POINTS ON
CONSIDERATION FOR BUDGETING FOR
DATA MANAGEMENT AND SHARING
COSTS, THERE WILL BE GUIDE
NOTICES ON THE IMPLEMENTATION
AND IN PARTICULAR PROTECTING
PRIVACY WHEN SHARING HUMAN
RELATED PARTICIPANT DATA, AND
SOME RESPONSIBLE DATA MANAGEMENT
AND SHARING CONCEPTS WHEN
CONSIDERING AMERICAN INDIAN
ALASKA NATIVE PARTICIPANT DATA.
SO I HOPE YOU WILL CONTINUE TO
MONITOR THIS WEBSITE, THESE ARE
VERY IMPACTFUL AND CULTURE
CHANGING ACTIVITIES IN DATA
MANAGEMENT DATA SHARING.
THE NEXT SLIDE WILL HIGHLIGHT
WHAT WE MY OFFICE IN PARTICULAR
AND ACROSS NIH CAN DO O TO
SUPPORT DATA MANAGEMENT AND DATA
SHARING.
THAT IS THE POLICY IN LITTLE
MORE ON IMPLEMENTATION.
SO I THINK WE ALL RECOGNIZE THAT
THERE IS NOT GOING TO BE ONE
SIZE FITS ALL SOLUTION TO
SHARING DATA.
RESEARCHERS ACROSS BIOMEDICAL
ENTERPRISE HAVE DIFFERENT
EXPECTATIONS AND DIFFERENT
EXPERIENCES AND THEIR NEEDS FOR
DATA SHARING.
NIH INVESTIGATORS CAN SHARE DATA
AS PART OF THEIR SUPPLEMENTAL
MATERIAL ASSOCIATED WITH THE
PUBLICATIONS AND THIS IS SHARED
VIA PUBMED CENTRAL, ON THE FAR
LEFT-HAND SIDE OF THE SLIDE.
PUBMED CENTRAL DATA ASSOCIATED
WITH PUBLICATIONS IS SHARED
THROUGH OUR STRIDES PARTNERSHIP
WITH THE AWS OPEN DATA
SPONSORSHIP PROGRAMMING, YOU CAN
FIND THAT DATA THERE AND USE IT.
INVESTIGATORS CAN ALSO SHARE
DATA AND OTHER MATERIALS FROM
THE RESEARCH IN A NUMBER OF
GENERAL REPOSITORIES SHOWN IN
CENTER OF THE SLIDE, TALK IN A
MOMENT ABOUT OUR WORK TO ENHANCE
DATA SHARING THROUGH GENERALIST
REPOSITORIES.
FINALLY, RESEARCHERS CAN PARTNER
WITH US AND OUR STRIDES PROGRAM,
THAT IS A PARTNERSHIP AWS GOOGLE
MICROSOFT ENSURE, DATA CAN BE
STORED AND MADE ACCESSIBLE ON
THE STRIDES PLATFORM.
I WILL TELL YOU A LITTLE LATER
HOW MUCH DATA NIH IS STORING AND
SHARING ON OUR THREE CLOUD
SERVICE PROVIDERS, IT IS
STAGGERING.
THIS IS A WELL SUITED PLATFORM.
WHEN YOU HAVE VERY, VERY LARGE
DATA SETS.
THE NEXT SLIDE.
TALKS ABOUT MAKING DATA MORE
FAIR FINDABLE ACCESSIBLE AND
INTEROPERABLE AND REUSABLE AND
AI READY.
ENHANCING DATA TO BE FAIR IS
OFTEN A BIT OF CHALLENGE,
REQUIRES ENGAGEMENT AND FEEDBACK
FROM APPLICATION.
GOING BEYOND FAIR DATA, MAKING
DATA AI READY, REQUIRES
REPRESENTATION OF INFORMATION
METADATA.
UNDERSTANDING PERSISTENCE OF
NOISE, UNDERSTANDING UNCERTAINTY
OF LABELS AND AM OF DATA SO DATA
TOXICITY AND IMPACT OF
COMPUTATIONAL MODEL PERFORMANCE.
WE HAVE RUN A NUMBER OF
SUPPLEMENTAL PROGRAMS TO BRING
NIH RESEARCHERS TOGETHER WITH
RESEARCHERS AND ARTIFICIAL
INTELLIGENCE MACHINE LEARNING,
AND DATA SCIENCE TO MAKE NIH
SUPPORTED DATA FAIR READY SO YOU
CAN SEE STATISTICS ON THE RIGHT
HAND SIDE IN TERMS OF NUMBER OF
AWARDS MADE, THIS PAST YEAR, WE
WILL BE AWARDING MORE PROGRAMS
IN FY 22, THIS SUMMER.
AND I JUST WANT TO HIGHLIGHT ON
THE NEXT SLIDE, A SNAP SHOT HOW
RESEARCHERS ARE MAKING DATA MORE
AI READY SO YOU CAN SEE WHERE
THE COMMUNITY IS.
I WOULD LIKE TO CALL A
PARTICULAR RESEARCHERS DR. MARIA
VASQUEZ, WORKING FOR ELECTRONIC
HEALTH DATA FROM HOSPITALS THAT
ARE SOCIALLY ECONOMICALLY
DIVERSE POPULATIONS TO USE DATA
IN MACHINE LEARNING ALGORITHMS
AND HER GOAL IS TO BETTER
PREDICT AND UNDERSTAND WHO IS AT
RISK FOR DEVELOPING SEPSIS THAT
WOULD BE CAUSED BY MULTI-DRUG
RESISTANCE MICROBES.
THAT'S HER INTEREST IS DRUG
RESISTANCE MICROBES.
ELECTRONIC HEALTHCARE DATA IS
TRICKY TO WORK WITH BUT IN
PARTICULAR FOR UNDER-REPRESENTED
POPULATIONS IT IS NOTORIOUSLY
CHALLENGING BECAUSE DATA IS
SPARSE, THERE IS FAIRLY
INCONSISTENT METADATA, WITH
ELECTRONIC HEALTHCARE RECORDS,
IN FACT THERE IS A LOT OF
LITERATURE SITING TO THE FACT
THAT THE DESCRIPTORS INCLUDING
RACE AND ETHNICITY ARE OFTEN
MISREPRESENTED IN THE EHR DATA
FOR UNDER-REPRESENTED
POPULATIONS SO WORK IS
IMPACTFUL.
THE NEXT SLIDE.
MAKING DATA AI READY BUT IT
NEEDS TO GO SOMEWHERE.
WE HAVE BEEN ENHANCING A NUMBER
OF YEARS, NIH SUPPORTED
REPOSITORIES TO ALIGN WITH THE
OSTP DESIRE CHARACTERISTICS FOR
REPOSITORY THAT INCLUDE
TRANSPARENCY OF FUNCTION
RESPONSIBILITY OF DATA
STEWARDSHIP, USER FOCUSED AND
COMMUNITY FOCUSED DRIVEN
CAPABILITIES, SUSTAINABILITY,
ALIGNMENT AND ATTENTION TO
TECHNOLOGIES, AND TRUST.
SO TODAY WE HAVE SUPPORTED 17
AWARDS AND YOU CAN SEE THEM ON
THE LEFT-HAND SIDE, I HOPE SOME
OF THESE ARE FAMILIAR WITH YOU
AND MANY OF THESE DATA
REPOSITORIES ARE BECOMING MUCH
MORE ALIGNED WITH THE OSTTP
CHARACTERISTICS ARE EXCELLENT
PLACES TO CONSIDER SHARING DATA.
NEXT SLIDE.
WE ALSO HAVE NUMBER OF PROGRAMS
THAT SUPPORT DATA REPOSITORY AND
KNOWLEDGE BASES.
DATA REPOSITORY AND KNOWLEDGE
BASES ARE THEMSELVES RESOURCES
AND TYPICALLY THEY HAVE BEEN
SUPPORTED BY RO1 TYPE GRANTS OR
OTHER TYPE OF GRANTS.
SO THIS PROGRAM SUPPORTS THE
DATA REPOSITORIES AND KNOWLEDGE
BASE AS BIOMEDICAL DATA
RESOURCES WITH THEIR OWN FUNDING
MECHANISM AND A SPECIAL EMPHASIS
PANEL THAT IS OVERSEEN BY THE
CENTER FOR SCIENTIFIC REVIEW.
THIS PROGRAM REQUIRES THAT NIH
DATA REPOSITORY AND KNOWLEDGE
BASE APPLICANTS SUPPORT A
PARTICULAR NIH IC MISSION AND
SUPPORT DATA MANAGEMENT AND
SHARING WITH DEMONSTRATED
SCIENTIFIC IMPACT WITHIN THE
COMMUNITY.
APPLICANTS NEED TO ADDRESS THE
QUALITY OF THE DATA SERVICES AS
WELL AS METHODS TO INCREASE
EFFICIENCY OF OPERATION.
SUCH AS FOR EXAMPLE, AUTOMATED
CAPABILITY FOR CURATION, QUALITY
ASSURANCE AND QUALITY CONTROL OR
ALSO CONSIDER LEVERAGING STRIDES
IN OUR CLOUD INFRASTRUCTURE.
APPLICANTS NEED TO ENGAGE WITH
SCIENTIFIC COMMUNITY AND WITH
THE SCIENCE JOURNALS THAT ALIGN
WITH FOCUS.
WE DO WANT COMMUNITY JOURNAL
ENGAGEMENT WITH THESE
APPLICATIONS.
AS WELL AS ESTABLISHING THE
TRANSPARENCY OF GOVERNANCE.
WE ARE ENCOURAGING GOOD DATA
MANAGEMENT PRACTICES AND DATA
LIFE CYCLE PRACTICES.
AS WELL AS NEW THIS YEAR
DEVELOPING METRICS THAT CAN BE
SHARED OPENLY FOR USE AND
UTILITY OF DATA REPOSITORIES.
YOU CAN SEE JUST A FEW EXAMPLES
OF NUMBER OF APPLICATIONS THAT
WERE FUNDED THIS PAST YEAR.
AND I THINK PERHAPS MAYBE SOME
OF YOU MIGHT BE FAMILIAR WITH IC
TV.
THESE ARE FAIRLY WELL DEVELOPED
REPOSITORY AND KNOWLEDGE BASES.
THIS PROGRAM WILL CONTINUE FOR
THE NEXT THREE YEARS AND PERHAPS
SHIFT A LITTLE BIT TO ALSO
INCLUDE NOT JUST WELL
ESTABLISHED DATA REPOSITORIES
AND KNOWLEDGE BASE BUT NEWLY
EMERGING DATA KNOWLEDGE BASES
AND REPOSITORIES.
NEXT SLIDE IN ADDITION TO ALL OF
THOSE GREAT DOMAIN SPECIFIC
REPOSITORY, WE DO ENCOURAGE YOU
TO EXPLORE DOMAIN SPECIFIC
REPOSITORIES AS A FIRST STANCE
FOR SHARING DATA.
THERE ARE NUMBER OF GENERAL
REPOSITORIES THAT OFFER
ADDITIONAL CAPABILITIES TO SHARE
DATA AND SCIENTIFIC DIGITAL
PRODUCTS THAT ARE A RESULT OF
THEIR RESEARCH.
WE JUST RECENTLY LAUNCHED THE
PROGRAM THIS YEAR, THE
GENERALIST REPOSITORY ECOSYSTEM
INITIATIVE TO SUPPORT A
COLLABORATION BETWEEN THE SIX
GENERALIST REPOSITORIES YOU SEE
LISTED ON THE BOTTOM OF THE
SLIDE AND AND I WILL NOTE WE ARE
WORKING WITH 7TH GENERALIST
REPOSITORY TO ADD TO OUR
PORTFOLIO.
WHAT ARE OUR GOALS?
WE WANTS TO MAKE EASIER FOR
RESEARCHERS TO SHARE DATA FUNDED
BY NIH AND COMPLY WITH OUR DATA
MANAGEMENT AND SHARING POLICY.
WE ALSO WANT TO MAKE IT EASIER
FOR RESEARCHERS TO FINDS NIH
SUPPORTED DATA ACROSS THESE
REPOSITORIES.
OF COURSE WE WANT TO ENHANCE
RIGOR AND REPRODUCIBILITY AND
DEVELOP SHARE SET OF CORE
METRICS ACROSS REPOSITORY.
THIS IS FOR US A REALLY
IMPORTANT KEY CONCEPT IS
AGREEING ON CORE METRICS THAT
ENHANCE THE USER AND USABILITY
OF THESE REPOSITORIES.
AS WELL AS CORE METADATA.
WE DO WANT TO ENHANCE
DISCOVERABILITY AND AGREE UPON
SET OF CORE METADATA THAT
DESCRIBES OUR DATA ACROSS SIX
REPOSITORIES, SO THEN WE CAN
ACTUALLY HELP RESEARCHERS FIND
THE DATA.
THEN WE WANTS TO ENCOURAGE A
SECONDARY REUSE OF DATA.
SUPER PLEASED TO BE WORKING WITH
EACH OF SIX NOW ADDING A 7TH
GENERALIST REPOSITORY.
I THINK THAT THE WORK THAT WE
ARE DOING HERE WILL IMPACT MANY
OF OUR DOMAIN SPECIFIC
REPOSITORIES.
WE ARE STARTING WITH OUR
GENERALIST REPOSITORIES AND SOME
OF THESE KEY CAPABILITIES.
THE NEXT SLIDE THIS IS A LITTLE
OUT OF THE BOX FOR DATA SHARING,
THIS IS A PARTNERSHIP WITH
FASEB.
THE FEDERATION OF AMERICAN
SOCIETIES FOR EXPERIMENTAL
BIOLOGY, WE ARE CREATING A NEW
DATA WORKS CHALLENGE.
THIS PRIZE FUELS CONCEPT OF DATA
SHARING AND REUSE, BY PROVIDING
AN ANNUAL CHALLENGE THAT
SHOWCASES BENEFITS OF RESEARCH
DATA MANAGEMENT AND SHARING, AND
REWARDING TEAMS WHO DEMONSTRATE
THE POWER OF DATA SHARING
THROUGH PRACTICES TO ADVANCE
SCIENTIFIC HEALTH AND DISCOVERY.
WE ARE SEEKING NEW INNOVATIVE
APPROACHES TO DATA SHARING.
WE ANTICIPATE 12 MONETARY PRIZES
FOR TOTAL CASH PRIZE PURSE OF
$500,000.
THE REGISTRATION CLOSES NEXT
WEEK ON JUNE 28, THIS IS A TEAM
PRIZE SO TEAMS COME TOGETHER,
THEY DESCRIBE HOW THEY
IMPACTFULLY SHARE OR REUSE DATA
SO IT IS A STORY BASE PRIZE THAT
IS -- WILL BE CLOSE ON JULY 19.
SO I HOPE THAT YOU WILL EXPLORE
THIS A LITTLE BIT MORE, IT IS A
FAIRLY OUT OF THE BOX KIND OF
DATA PRIZE BUT I THINK IT WILL
ENCOURAGE TO THINK ABOUT DATA
SHARING AND PERHAPS EVEN ENTICE
RESEARCHERS TO DEVELOP
REYEAHTIVE DATA MANAGEMENT
SHARING PLANS -- CREATIVE DATA
MANAGEMENT SHARING PLANS.
NEXT SLIDE THAT THERE ARE MANY
WAYS TO SHARE DATA.
YOU CAN SHARE DATA THROUGH
PUBMED CENTER, SUPPLEMENT TO
PUBLICATION.
SHARE DATA IN DOMAIN SPECIFIC
REPOSITORY OR THIRDLY, YOU CAN
SHARE DATA ON THE CLOUD.
SO WE HAVE PARTNERED WITH AWS
GOOGLE MICROSOFT AZURE THROUGH
HOUR STRIDES PROGRAM FORGOT WHAT
STRIDES STANDS FOR, IT IS LIKE
-- SHOOT.
TOTALLY FORGOTTEN.
SORRY ABOUT THAT.
TO PROVIDE DISCOUNTS ON CLOUD
STORAGE AND CLOUD COMPUTE
PROFESSIONAL SERVICES AND
TRAINING COLLABORATIVE
ENGAGEMENTS.
SO YOU CAN SEE SOME OF THE
STATISTICS ON THE RIGHT HAND
SIDE OF THE SLIDE IN TERMS OF
WHAT STRIDES HAS DONE SINCE
INCEPTION IN 2018.
THUS FAR TODAY WE HAVE 173
PEDABYTES OF DATA ACROSS THREE
CLOUD SERVICE PROVIDERS.
50 PEDABYTES GENOMIC DATA
SEQUENCES OF RATS, COWS BIRDS
CHICKENS AND HUMANS.
SO 173 PEDABYTES OF DATA IS
EQUIVALENT TO BASICALLY ALL THE
PRINTED MATERIAL EVER DONE, SO
IT IS IN VERY, VERY LARGE AMOUNT
OF DATA.
MANAGING -- THANK YOU SO MUCH,
ROHAN.
I CANNOT BELIEVE I FORGOT WHAT
IT STOOD FOR.
MANAGING SEARCHING STORING, THIS
AMOUNT OF DATA ACROSS DIFFICULT
WHICH YOU HAVE HAD PROVIDERS IS
REALLY NOT TRIVIAL AND PRODUCES
AN INTERESTING CHALLENGES ON
DATA AND COMPUTATIONAL SCIENCE.
WE ARE WORKING ON HOW THE USAGE
OF PEDABYTES SEQUENCE DATA TO
FUND PARTICULAR SEQUENCES
INTERESTED TO RESEARCH FOR
EVOLUTIONARY BIOLOGY.
SO REALLY COMPELLING AND NOT
EASY CHALLENGE.
IT WILL BE HARD FOR RESEARCH
GROUPS WE WORK WITH ACROSS NIH
AND FUND TO UTILIZE CLOUD FOR
DATA ANALYSIS.
IT IS NOT ALWAYS STRAIGHT
FORWARD AS ONE WOULD HOPE AND
THERE IS CERTAINLY CONCERNS BY
RESEARCHERS ABOUT COST OF CLOUD
COMPUTER, PERSISTENCE OF
CAPABILITIES AS GRANT CYCLES ARE
CYCLIC AND UTILITY, IS THE JUICE
WORTH THE SQUEEZE.
TO HELP ADDRESS ISSUES WE STOOD
UP CLOUD TO HELP RESEARCHERS
GAIN FAMILIARITY WITH CLOUD AND
SAND BOX LIKE APPROACH THAT
PROVIDES CLOUD CREDITS, ABOUT
$500 WHICH IS ENOUGH TO DO A
LARGE ANALYTIC PIPELINE TOOL.
AND PROVIDE TOOLS FOR
RESEARCHERS.
WHAT RESEARCHERS CAN DO IS THEY
CAN EXPERIMENT ON THE CLOUD WITH
SPECIFIC TASKS, SOME CANNED
APPLICATIONS YOU CAN BRING YOUR
OWN APPLICATION.
YOU CAN BUILD OUT PROOF OF
CONCEPT SOLUTIONS AND TEST THEM
IN A CLOUD IN A WAY THAT DOESN'T
COST MONEY SO IT IS A SAND BOX.
IF YOU ARE AN EXPERT DEVELOPER
YOU CAN BENCHMARK TOOLS WITH
CONFIGURATION, DIFFERENT CPUs,
CHIP ARCHITECTURES IN THE CLOUD
AND BENCH MARK COST AND
HOPEFULLY OPTIMIZE PARTICULAR
INFRASTRUCTURE ON YOUR
PARTICULAR CLOUD SERVICE
PROVIDER TO ADDRESS YOUR
ANALYTIC METHODS AN GOALS.
I THINK WE HAVE BEEN DOING A
RELEASE FROM INTRAMURAL RESEARCH
PROGRAM AND I THINK WE ARE ALSO
STARTING TO ENGAGE THE
EXTRAMURAL RESEARCH PROGRAM.
NEXT SLIDE IS SAID THAT IF DATA
IS THE NEW OIL AND SOFTWARE IS
REFINERY SO I WANT TO TELL YOU
SOME OF THE THINGS THAT WE ARE
DOING IN SOFTWARE ENHANCEMENT
STARTING WITH OUR PARTNERSHIP
WITH NSF.
WE HAVE A VERY LONG STANDING
PARTNERSHIP WITH THE COMPUTER
SCIENCE DIRECTOR NSF TO BRING
COMPUTER SCIENTISTS TOGETHER
WITH BIOMEDICAL RESEARCHERS TO
ACCELERATERY SEARCH IN AND
SUPPORT -- RESEARCH IN AND
SUPPORT CAPABILITIES FOR
MEDICINE.
I WILL SHOW YOU THE NEXT SLIDE
WHICH IS SOME STATISTICS.
ALL THE INSTITUTES AND CENTERS
PARTNER WITH US ON SMART
CONNECTED HEALTH AND HERE YOU
CAN SEE THE NUMBER OF AWARDS
ACROSS THE NIH IN TERMS OF THE
INSTITUTES THAT HAVE RECEIVED
THESE AWARDS AND IT IS NOT
SURPRISING THAT OUR INSTITUTE
NIBIB BIOMEDICAL ENGINEERING AND
IMAGING RECEIVED LARGEST NUMBER
BECAUSE THE PROGRAM STARTED OUT
AS A DEVICE FOCUSED PROGRAM
SMART CONNECTED DEVICES AND
EXTENDING NOW INTO DATA SCIENCE
AND ARTIFICIAL INTELLIGENCE SO
ONE MORE CLIP WILL SHOW YOU
DOMAIN SPECIFIC AREAS, SENSING
WEARABLES ROBOTICS IS A LONG
STANDING PART OF THIS PROGRAM.
LAST YEAR WE ADDED ARTIFICIAL
INTELLIGENCE IMAGING ELECTRONIC
HEALTHCARE AND EHR TYPE OF
APPLICATION.
THEN YOU CAN SEE IN THE LAST
COMPONENT HERE THE TYPES OF
DISEASES THAT PEOPLE ARE
INTERESTED IN RESEARCH, THIS IS
AN INVESTIGATOR INITIATED
PROGRAM, RESEARCHERS DO COME
INTO NSF, THIS IS AN NSF LED
PROGRAM APPLICATIONS ARE NSN AND
PANELS BUT NIH CSR APPLICATIONS
ARE PRESENT, APPLICATION FUND
FUNDED BY NSF OR NIH.
.
APPLICATIONS THAT COME TO NIH
ARE BROUGHT IN BY CSR.
YOU DON'T GO THROUGH ANOTHER
REVIEW, THE SUMMARY FROM NSF IS
PORTED TO CSR AND APPLICATIONS
ARE DIRECTLY FUNDED FROM
INSTITUTES THAT CO-FUNDED BY MY
OFFICE.
NEXT SLIDE IT IS HARD FOR
RESEARCHERS TO DEVELOP SOFTWARE
TO ADD IN THAT THIRDING FROM
ENHANCING SOFTWARE TOOLS, TO
REACH BROADER AUDIENCES TO ADAPT
TO NEW HIGH THROUGH PUT
COMPUTING ENVIRONMENTS LIKE
CLOUD OR BRING ON NEW SOFTWARE
ENGINEERS AS COLLABORATORS.
THIS IS A SUPPLEMENTAL PROGRAM
TO SUPPORT EXISTING NIH
RESEARCHERS TO ENHANCE SOFTWARE,
TO REALLY BRING IN THOSE
SOFTWARE ENGINEERS TO PORT
SOFTWARE TO LARGER AUDIENCE AND
EXPLORE CLOUD COMPUTING OR HIGH
PERFORMANCE COMPUTING.
NEXT ILLUSTRATES AWARDEES SO YOU
CAN SEE WHAT RESEARCHERS ARE
DOING WHO ARE SUPPLEMENTED TO
THIS PROGRAM.
I WANT TO HIGHLIGHT DR. CONNIE
SELUM PROFESSOR OF GLOBAL HEALTH
PROFESSOR MEDICINE ALLERGY
DISEASES, PROFESSOR EPIDEMIOLOGY
AND COLLABORATOR DR. JAMES
MULLINS, PROFESSOR OF
MICROBIOLOGY.
THIS PROGRAM SUPPLEMENTED THEIR
WORK ON THE LABORATORY
INFORMATION MANAGEMENT SYSTEM
CALLED BIOVERSE, A PLATFORM THAT
HELPS COLLECTS STORES, RETRIEVAL
ANALYSIS OF SAMPLES A LOT OF
GENOMICS SAMPLES IN BIO VERSE AS
WELL AS OTHER TYPES OF DATA SUCH
AS IMAGE AND CLINICAL DATA SO,
THIS IS TO ENHANCE USABILITY OF
BIOVERSE IN SOUTH AFRICA
PARTICULARLY AND ALSO INCLUDES
TRAINING ANED YOU REACH WITH
SOUTH AFTER CAN STUDENTS.
THIS IS A GOAL TO INCREASE
VISIBILITY, OF EXISTING NIH
SUPPORTED SOFTWARE.
NEXT SLIDE.
DO WANT TO TALK ABOUT CLINICAL
INTEROPERABILITY.
MOSTLY FOCUSING ON LEVERAGING
CAPABILITIES THAT ARE HAPPENING
IN THE HEALTH IT SECTOR,
PARTICULARLY FAST HEALTHCARE
INTEROPERABLE RESOURCES.
AND THE WORK OF THE COMMUNITY HL
7.
SO THE NEXT SLIDE.
FIRE INCREASES ESSENTIALLY ALLOW
HEALTH IT TO MAP DIFFERENT
ELECTRONIC HEALTHCARE RECORDS
ACROSS SYSTEMS.
SO YOU MIGHT BE I 2B 2, FIRE
ALLOWS YOU TO MAP THOSE
ELECTRONIC HEALTHCARE SYSTEMS.
IN TERMS OF RESEARCH, FIRE IS A
GOOD AT INTEROPERABILITY AND
DATA SHARING, IT ALLOWS UPS TO
TRANSLATE DIFFERENT RESEARCH
THAT CAN BE MAPPED INTO
ELECTRONIC HEALTHCARE SYSTEMS IT
ALSO ALLOWS US TO BUILD AND FIND
DATA MORE EASILY, SO GOING TO
SHOW YOU NEXT SLIDE SOME OF THE
WORK WE ARE DOING TO PROMOTE THE
USE OF FIRE FOR RESEARCH.
THIS IS B HAS BEEN ON OUR ROAD
MAP FOR A YEAR AND THERE IS A
NUMBER OF ICs WHO ARE
LEVERAGING FIRE.
FOR EXAMPLE, NIDDK DEVELOPED A
SMART ON FIRE APPLICATION SO
RESEARCHERS WHO ARE INTERESTED
IN US UNDERSTANDING PARTICIPANTS
WITH MULTIPLE CHRONIC DISEASES
CAN DOWNLOADS MODIFIABILITY TO
DO DATA DOWNLOADS.
A LARGE PROGRAM SUPPORTED BY
NHGRI IS FUNDING THE MAP IN A
PHENOTYPIC DATA FROM GENOMIC
SEQUENCES INTO THE FIRE BASE
SCHEMA.
SO THIS IS REALLY DIFFICULT, IT
IS HARD TO MAP PHENOTYPIC DATA
INTO FIRE SCHEMA THAT IS BASED
ON ELECTRONIC HEALTH STANDARDS.
EMERGE IN NUMBER OF OTHER
PROGRAMS ARE DOING THAT WORK AS
WELL AS THE OTHER PROGRAMS
CALLED PHENOPACKETS.
WE ARE ALSO DEVELOPING TOOLS
THROUGH MY OFFICE TO LEVERAGE
FIRE TO FIND AND BUILD COHORT OF
PATIENTS ACROSS MULTIPLE NIH
SUPPORTED PLATFORMS INCLUDING
THE KIDS FIRST PLATFORM CANCER
RESEARCH DATA COMMONS PLATFORM,
BIODATA CATALYST PLATFORM AND
WHEN WE CAN MAP PHENOTYPIC DATA
INTO FIRE WE WILL BE ABLE TO DO
THAT FOR THE G TEXT PLATFORM.
SO THE NEXT SLIDE.
IT IS NOT EASY FOR CLINICAL
RESEARCHERS TO PICK UP FIRE.
IT DOES REQUIRE TRAINING, SO WE
HAVE THIS PAST YEAR DONE A
NUMBER OF TRAINING SESSIONS
FOCUSING FIRST ON NIH INTRAMURAL
RESEARCHERS, WHO ARE INTERESTED
IN UTILIZING FIRE EITHER WITH R
OR PYTHON AND NOW DEVELOPING
TRAINING MATERIALS AND UTILIZING
CLOUD THAT I MENTIONED EARLIER
FOR CLINICAL RESEARCHERS START
WELCOME CSTR AND CTSA AWARDEES.
AND FINALLY, I HOPE THAT YOU
WILL CONTINUE WITH US, ON THE
NEXT SLIDE OUR JOURNEY IN DATA
SHARING DATA REUSE.
EACH MONTH WE HIGHLIGHT IN
DIFFERENT INSTITUTE NIH THEIR
PROGRAMS AND DATA SHOWING DATA
SCIENCE AND PARTICULARLY THEY
ARE FUNDED AWARDEES TO TELL US
ABOUT THEIR RESEARCH AND HOW
THEY ARE SHARING THEIR DATA, HOW
THEY REUSE DATA, WE HAVE AN
MAZING NUMBER OF -- AMAZING
NUMBER OF TALKS FOR THE PAST
YEAR AND A HALF FOR EXAMPLE,
LAST JUNE DR. ROSA ALFASAR
PROFESSOR COMMUNITY COLLEGE AND
SHE IS CREATING A GENOMICS DATA
SHARING PROGRAM AND RESOURCES
AIMED AT COMMUNITY COLLEGES.
SO THIS IS JUST -- SHE IS A
WONDERFUL SPEAKER, HER TALK IS
ARCHIVED ON THE SITE LISTED
BELOW AS WELL AS ALL THE OTHER
TALKS.
WE HAVE HAD OVER 680
PARTICIPANTS OVER THE COURSE OF
THE LAST YEAR.
TYPICALLY 60 TO 100 PARTICIPANTS
PER TALK INCLUDING INTERNATIONAL
PARTICIPANTS FROM ALL OVER THE
WORLD.
THE NEXT SLIDE IS LAST SLIDE,
THAT IS MY STORY, WE ARE WORKING
TO CREATE A MODERNIZE INTEGRATED
FAIR BIOMEDICAL DATA ECOSYSTEM
TO SUPPORT THE WORK THAT YOU ARE
DOING IN DATA AND SCIENCE TO
SUPPORT OUR POLICIES AN DATA
MANAGEMENT AND DATA SHARING.
WITH THAT, I AM HAPPY TO TAKE
QUESTIONS.
OR COMMENTS.
>> THANK YOU, DR. GREGURICK FOR
A VERY NICE PRESENTATION.
WE WILL OPEN UP FOR QUESTIONS
AND COMMENTS.
I WOULD LIKE TO JUST COMMENT
YOUR LAST SLIDE ABOUT DR. ROSA
ALTHAZAR IS A GREAT EXAM HOW
YOUR OFFICE CAN REACH A BROAD
AUDIENCE OF INDIVIDUALS SO HANKS
FOR SHARING THAT.
I WILL GO TO DR. SLEASMAN FIRST.
>> THANK YOU FOR GREAT
PRESENTATION.
GLAD THIS IS KIND OF GOES BACK
TO THE LAST SLIDE.
COMMUNITY COLLEGES, ONE OF MY
CONCERNS ABOUT LARGE SCALE DATA
MANAGEMENT AND IMPLICATIONS FOR
INVESTIGATORS, IS WE REQUIRE
INSTITUTIONAL RESOURCES TO
COMPLY WITH THE NEW GUIDELINES.
WE ALREADY KNOW THAT MUCH OF THE
NIH IS FALLING ON FEWER
INSTITUTIONS AND I WORRY ABOUT
PARTICULAR INSTITUTIONS DOING
RESEARCH AND SERVING UNDERSERVED
POPULATIONS PARTICULARLY HIV
EPIDEMIC IS HOW THESE RESOURCES
BE MADE AVAILABLE TO THOSE
INSTITUTIONS THAT INVOLVED IN
THE EPIDEMIC.
>> THAT IS SUCH A GREAT
QUESTION, SOMETHING THAT WE HAVE
BEEN TALKING ABOUT HERE AT NIH
IS PARTICULARLY WITH THE ADVENT
OF PARTNERING WITH THE CLOUD
INDUSTRIES DISPROPORTIONATE
AMOUNT OF FUNDING AVAILABLE AND
THE REQUIREMENT FOR USING THE
CLOUD SO THIS IS SOMETHING THAT
IS ON OUR RADAR.
IN TERMS OF DATA MANAGEMENT AND
DATA SHARING, I HOPE RESEARCHERS
WILL BE ENCOURAGED TO EXPLORE
EXISTING DATA REPOSITORIES AND
FOR THE HIV COMMUNITY THIS MAY
BE CERTAINLY SOMETHING TO
CONSIDER.
IF THERE ARE ADDITIONAL
REPOSITORIES NEEDED PARTICULARLY
FOR YOUR COMMUNITY.
WHAT IS AVAILABLE IN RESEARCH
COMMUNITY FOR SHARING DATA,
THERE IS ALWAYS THE GENERAL
REPOSITORIES THE SHARE DATA.
WHAT WOULD BE LESS IDEAL IS IF
RESEARCHERS ARE SANDING UP THEIR
OWN FTP SITE TO SHARE DATA THAT
MAKES HARD TO FIND ACCESS DATA
WHEN OTHER RESEARCHERSND WANT TO
FIND IT UNLESS YOU ARE LOOKING
FOR DATA THROUGH PUBLICATIONS IN
WHICH CASE YOU CAN SHARE THROUGH
PUBMED CENTRAL.
SO AS A FIRST PASS I WOULD
ABSOLUTELY LOOK AT WHAT IS
AVAILABLE IN THE COMMUNITY, AND
WITHIN AN INSTITUTION.
HOWEVER, THERE ARE INSTITUTIONS
UNIVERSITY OF CALIFORNIA AS
FAIRLY STRONG LIBRARY SYSTEM
THAT DOES HAVE DATA QUITE DATA
SHARING CAPABILITIES FOR
RESEARCHERS.
I HOPE THAT ADDRESSES YOUR
QUESTION TO SOME EXTENT.
>> WORRIED ABOUT UNDERSERVED
UNDER-REPRESENTED POPULATION.
>> I'M ABSOLUTELY WORKING VERY
HARD WITH OUR INSTITUTES
PARTICULARLY THE INSTITUTE
MINORITY HEALTH AND HEALTH
DISPARITIES AND NIGMS HOW WE CAN
ENABLE GREATER DATA
CAPABILITIES.
IN MINORITY SERVING AND
UNDERREPRESENTED INSTITUTIONS.
THIS IS ON OUR RADAR ABSOLUTELY.
>> ARE THERE OTHER QUESTIONS
THIS TIME?
>> I WANTED TO ADD ON TO THE
COMMENT THAT JOHN MADE.
NICHD WE HAVE A LONG STANDING
POPULATION DYNAMICS RESEARCH
DATA PROGRAM, SEVERAL DECADES
OLD.
DIRECTLY TO ADDRESS JOHN'S
COMMENT IN THE MOST RECENT CYCLE
OF THAT, WE EXPLICITLY REQUIRED
THESE CENTERS NEED TO COME IN
WITH A NEWLY ESTABLISHED
RELATIONSHIP WITH MINORITY
SERVING OR MULTIPLE MINORITY
SERVING INSTITUTIONS.
SOME EXACTLY THAT IS TAKING
THESE ORGANIZATIONS THAT DO A
VERY GOOD JOB OF MANAGING DATA
AND UTILIZING FURTHER FUNDING
ONE OF THE REQUIREMENTS IS THAT
THEY HELP BUILD CAPACITY LESS
WELL FUNDED INSTITUTIONS.
SO WE ARE -- WE JUST STARTED IT
SO HAVEN'T SEEN YET RESULTS OF
IT BUT OBVIOUSLY HOPEFUL THAT
THAT WILL GO IN SMALL WAY TO
HELP ADDRESS THE CONCERNS.
>> THANK YOU, ROHAN.
THAT IS EXCELLENT.
MARGARET.
>> I WAS LOOKING FOR MY RAISED
HAND COUP FIND IT.
THANK YOU FOR A SUPER
INTERESTING PRESENTATION.
WHAT DO YOU THINK FUTURE HOLDS?
WE ARE GRAPPLING WITH YOU HAD ON
YOUR SLIDE PEDABYTES OF DATA AND
ALL KINDS OF THINGS.
WHAT DO YOU THINK HAVE YOU
THOUGHT TO WHAT WE ARE GOING
TOWARD?
I REALIZE WE HAVE MASSIVE
AMOUNTS OF DATA AND LOT OF IT IS
NIH FUNDED RESEARCH.
WE WANT THIS DATA PUBLICLY
ACCESSIBLE BY OTHER RESEARCHERS
AND OTHER PEOPLE.
WHAT DO YOU THINK IS GOING TO
HAPPEN IF YOU COULD HAZARD A
GUESS?
I REALIZE MAYBE THIS IS
UNANSWERABLE
>> LET ME GIVE IT A SHOT AND SEE
WHAT RESONATES.
I THINK WHEN I FIRST STARTED OUT
IN DATA SCIENCE THERE WAS THE
CONCEPT YOU PROBABLY WILL BE
FAMILIAR CREATING THE DATA,
ESSENTIALLY A VERY LARGE AMOUNT
OF DATA STORED PRIMARILY IN THE
CLOUD BECAUSE THIS IS HUGE
AMOUNTS OF DATA.
AND RESEARCHERS SORT OF PUT THE
DATA IN THE DATA LINK AND THEN
THERE'S QUITE A LOT OF GOOD
THINGS THAT HAPPEN THERE.
I THINK REALISTICALLY IN THE
FUTURE, THAT IS PROBABLY NOT
EXACTLY THE SOLUTION THAT IS GO
TO BE EFFECTIVE PARTICULARLY FOR
VERY DIVERSE BIOMEDICAL RESEARCH
COMMUNITY.
SO WHAT WE ARE LOOKING AT NOW,
THIS IS HAPPENING IN INDUSTRY AS
WELL, IS CREATING FEDERATED BUT
INTEROPERABLE DATA CAPABILITIES.
WE HAVE GREAT CAPABILITIES IN
CANCER.
FOR THE CANCER COMMUNITIES.
WE HAVE GREAT CAPABILITIES IN
HEART LUNG AND BLOOD AND THEIR
TEAM FOR CARDIOVASCULAR
RESEARCH, THERE ARE PEOPLE WHO
RESEARCHERS WHO WANT TO LOOK AT
THOSE INTERSECTIONS.
BETWEEN CARDIOVASCULAR RESEARCH
AND CANCER RESEARCH.
THE SOLUTION THAT WE ARE LOOKING
AT IS CREATING INTEROPERABILITY
BETWEEN THOSE DATA SYSTEMS SO
RESEARCHERS CAN LOG IN AND FIND
DATA INTERESTED IN AND PULL INTO
THE ANALYTICS PLATFORM THAT THEY
FEEL COMFORTABLE USING.
SOUNDS EASY BUT THERE'S
TECHNICAL AND SOME SERIOUS
POLICY WORK TO DO.
BUT THIS IS THE CONCEPT OF DATA
MESH CREATE THE SMALL AMOUNT OF
CAPABILITIES ACROSS SYSTEMS THAT
UNITE THEM TOGETHER IN A
MEANINGFUL WAY FOR RESEARCHERS,
THIS WILL REQUIRE US TO AGREE
CERTAIN AMOUNT OF STANDARD
METADATA ACROSS SYSTEMS WHO CAN
TALK TO EACH OTHER AND CERTAIN
AMOUNT OF CAPABILITIES.
THIS IS HAPPENING IN NETFLIX.
US USES DATA MESH IN
ARCHITECTURE, SO THIS IS
SOMETHING WE ARE THINKING OF,
LOOKING AT SOPHISTICATED WAYS TO
FIND AND SEARCH DATA BEYOND WHAT
YOU WOULD DO IN GOOGLE.
RESEARCHERS SIMPLE LINE TEXT
ENTRY, IS NOT HOW RESEARCHERS
WILL FIND DATA AND HAVE
CONFIDENCE IN -- IF THAT DATA IS
TRUE AND NOT LEADING TO FALSE
CLAIMS.
SOPHISTICATED CAPABILITIES IN
SEARCH AND FINDING DATA.
THIS IS ALSO GOING TO REQUIRE
SOME INTERESTING NEW WAYS OF
TRAINING AND BECAUSE OF THE
PANDEMIC WE ARE LOOKING AT WAYS
OF TRAINING THAT ARE INNOVATIVE
AND A LITTLE OUT OF THE BOX.
AS WE ARE SITTING HERE ON ZOOM
WE NEED TO THINK DIFFERENTLY HOW
WE ARE GOING TO TRAIN OUR NEXT
GENERATION OF RESEARCHERS TO
UTILIZE DATA IN WAYS THAT ARE
DIFFERENT THAN BEFORE.
SO THESE ARE SOME OF THE THINGS
WE ARE THINKING IN TERMS OF
CREATING CAPABILITIES THAT
HARNESS WHAT IS HAPPENING
ENHANCE THE COMMUNITIES THAT
KNOW THAT DATA THE BEST BUT ALSO
CREATE SYNERGISTIC COMPLIMENTARY
WAYS TO INTEGRATE ACROSS OUR
DATA SYSTEMS.
>> THANK YOU, VERY INTERESTING.
>> THANKS.
>> DR. GREGURICK, GLAD YOU
MENTIONED TRAINING BECAUSE I
WANT TO FOLLOW-UP.
DURING YOUR PRESENTATION I WAS
THINKING I WOULD IMAGINE OUR
GRADUATE TRAINING PROGRAMS WE
MIGHT NEED TO START CONSIDER HOW
DO WE HAVE OUR NEXT GENERATION
OF TRAINEES FAMILIAR WITH THESE
RESOURCES AND BIG DATA.
AS A BASIC SCIENTIST, I WOULD
IMAGINE I COULD FIND A LOT OF
OPPORTUNITIES IF I KNOW HOW TO
GO ABOUT MINING THE DATABASES
AND THE INFORMATION THERE.
SO MY QUESTION IS CAN YOU
COMMENT ON -- IF YOU ARE OKAY
WITH COMMENTING ON WHAT DO YOU
THINK THAT WE SHOULD BE
CONSIDERING AS WE TRAIN FUTURE
GENERATION OF SCIENTIST,
SOMETHING WE SHOULD START EARLY
IN THE PROCESS OR YEAH SO IF YOU
CAN COMMENT ON THAT, THAT WOULD
BE GREAT.
>> ABSOLUTELY.
THIS SOMETHING ALSO I HAVE HEARD
IN FAIR NUMBER OF WORKSHOPS, WE
NEED TO START TRAINING
RESEARCHERS PRETTY EARLY IN
THEIR UNDERGRADUATE CAREER AND
DATA SCIENCE WHETHER THEY ARE AT
THE BENCH, LIKE MY SON IS OR
MORE LIKE ME SITTING AT A
COMPUTER WHERE I FEEL MUCH MORE
NATURAL.
SO STARTING EARLY IN CONCEPT OF
DATA SCIENCE WHICH ARE CONCEPTS
OF STATISTICS AND A FEW CONCEPTS
OF COMPUTER SCIENCE AS WELL.
AND STUDENTS OFTEN LEARN BY USE
CASES AND REPEATING WHAT HAS
BEEN DONE BY OTHERS BUT IN KNOWN
PREDICTIVE WAYS THIS IS ONE GOAL
CLOUD THAT IS ALSO TRAINING
PLATFORM TO HELP YOUNG PEOPLE
LEARN HOW SCIENCE IS DONE AND
LEARN KEY CONCEPTS BY DOING AS
YOU LEARN.
ALSO WANT TO MENTION THAT WE ARE
WORKING IN AN ENVIRONMENT
RECRUITING THE BEST FOLKS FROM
UNDERSERVED OR AMERICAN INDIAN
OR ALASKA NATIVE POPULATIONS
MEANS THAT WE HAVE TO BE
FLEXIBLE BUT CAN'T ALWAYS COME
TO NIH, WE HAVE A NUMBER OF
PROGRAMS FOR STUDENTS TO COME TO
NIH.
IN SOME CASES THAT IS NOT GOING
TO BE GOOD FIT.
SO WE CREATED PROGRAMS THAT
ALLOW TRAINEES THAT ARE COMMON
TO NIH TO WORK REMOTELY IN THEIR
LOCATIONS AND THEIR HOME SO
NUMBER OF FELLOWS THIS SUMMER
WHO WE STARTED THIS BECAUSE OF
THE PANDEMIC BUT IT IS JUST
WORKING OUT SO WELL THAT WE ARE
GOING TO CONTINUE BECAUSE WE
REALIZED THAT IN OUR BRINGING ON
NEW INTERNS, NEW FELLOWS IF WE
DESIGN PROGRAMS THAT ALLOW FOR
100% REMOTE WORK, WE GET REALLY
GREAT KIDS COMING FROM VERY
DIVERSE BACKGROUNDS.
THAT IS JUST FANTASTIC.
REALLY SATISFYING TO SEE THESE
YOUNG KIDS EXCEL WHEN THEY ARE
-- WHEN THE PROGRAMS ARE FIT FOR
THEIR NEEDS RATHER THAN FIT FOR
OUR NEEDS ENTIRELY.
>> FANTASTIC.
THANK YOU.
JONATHAN.
YOU LOGGED OUT, HEIDI.
>> I'M STILL HERE.
HI.
SO THAT WAS A GREAT PRESENTATION
AND REALLY INTERESTING AND I
APPRECIATE THE GOALS AN
DIRECTION THIS IS IS GOING.
AND I DON'T WANT TO PUT YOU ON
THE SPOT SO THIS WILL BE A
GENERAL COMMENT RATHER THAN
REQUIRING MAIN ANSWER BUT I
WOULD LOVE THE HEAR MORE WHEN
TALKING ABOUT THIS IN THE FUTURE
ABOUT SOME OF THE SPECIFIC
BARRIERS, THERE IS SO MUCH
NUANCE AND SOME PHENOTYPES AN
THINKING PHENOTYPES HAD TO MERGE
TO SELECT TO BE ABLE TO BRING
TOGETHER SOURCES WHERE DATA
QUALITY DIFFERED.
THINGS LIKE WHEN THEY START
TALKING ABOUT HEIGHT AND THINGS
VERY STRAIGHT FORWARD, I THINK
THAT IS GREAT.
BUT FUTURE LOVE TO HEAR MORE
ABOUT HOW TO DEAL WITH SOME OF
THE NUANCES WHERE THE DATA
QUALITY VARIOUS PHENOTYPES
ACROSS THE SYSTEMS ARE SO VERY
DIFFERENT.
SOME REALLY NEED VALIDATION OR
ADJUDICATION IN SOME TYPE TO BE
BELIEVABLE HOW YOU ARE GOING TO
SHOW THAT OR MERGE BUT MAKE SURE
RESEARCHERS ARE REALLY USING THE
QUALITY OF DATA THEY THINK THEY
ARE USING, THERE IS 90 PROBLEMS
AND INTERESTING QUESTIONS THAT
ARISE SO I WANT TO FUTURE
DISCUSSION BECAUSE THAT IS WHERE
MANY CHALLENGES ARE GOING TO BE
IMPLEMENTED AS WELL IS BUT SO
VERY EXCITING SO DON'T TAKE THIS
AS A WET BLANKET JUST LOVE TO
HEAR MORE ABOUT ISSUES AT SOME
POINT.
>> WE ARE LIVING THAT EVERY DAY.
WE HAVE THOUGHT OF COMMON DATA
ELEMENTS THAT ARE SIMILAR.
HEIGHT MEASURE LAYING DOWN,
VERSUS HEIGHT MEASURED STANDING
UP SO THAT DEEP LEVEL OF
METADATA.
>>PROFESSOR: HEIGHT IS EASY.
>> THAT IS THE EASY ONE.
>> WHEN YOU ARE TALKING ABOUT MI
AND CANCER AND ALL THAT, IT IS
SO MUCH MORE COMPLICATED, 100
FOLD.
THOSE NUANCES THAT WE WOULD LOVE
TO LEARN MORE ABOUT.
>> ACTUALLY IT WOULD BE A GREAT
WORKSHOP, GREAT DISCUSSION
BECAUSE THIS IS SOMETHING THAT
WE ARE -- WE ARE STRUGGLING
WITH, I WILL BE HONEST IS JUST
HARMONIZING DATA IS THE HARDEST
THING POSSIBLE, IT ISN'T EASY.
L THERE IS A LOT OF NUANCES IN
THE DATA.
AS YOU JUST DESCRIBED SO WE ARE
LOOK AT THIS, I CAN'T SAY WE
HAVE A SOLUTION BUT WE CERTAINLY
KNOW THE PROBLEM.
KNOWING LEADERSHIP LEVEL THIS IS
SOMETHING IC DIRECTORS ARE
TALKING AS WELL AS IF WE REALLY,
REALLY WANT TO MAKE THE FULL USE
OF DATA, WE HAVE TO DEAL WITH
THIS PROBLEM BUT WE CAN'T DO IT
IN A WAY THAT IS A HAMMER FOR
RESEARCHERS, THAT IS ALSO NOT
GOING TO REALLY WORK.
SO WE HAD A WORKSHOP ON SEARCH
AND ONE OF THE CONCEPTS IS
EMBRACING THE HETEROGENEITY OF
DATA AND TRYING TO DEVELOP
POTENTIALLY A LITTLE MORE
ADVANCE MACHINE LEARNING
ALGORITHMS TO HELP US PULL OUT
SOME OF THESE POINTS.
WHAT IS HARMONIZED, WHAT CAN'T,
WHAT CAN BE CONVERTED WHAT
CAN'T.
THIS IS VERY EARLY DAYS I HAVE
TO SAY.
SO NO SOLUTION BUS AWARENESS OF
THE PROBLEMS SO THANKS FOR
BRINGING THAT UP.
>> I COULDN'T GET TO THE -- I
WANT TO THANK SUSAN AND ALSO
MENTION SINCE SHE BROUGHT UP
ABOUT THE DIGITAL -- CIVIC
DIGITAL FELLOWS THAT WE ARE
THRILLED IN OAR BECAUSE LAST
YEAR INAUGURAL YEAR I THINK
INAUGURAL YEAR WE HAD TWO.
THIS YEAR WE HAD -- WE ARE
HOSTING TWO MORE.
WE ARE JUST THRILLED WITH THEM,
SUSAN.
GREAT PROGRAM.
>> IT IS A GREAT PROGRAM.
THESE ARE UNDERGRADS THEY COME
FROM ACROSS THE COUNTRY, THEY
ARE SOME OF THE BRIGHTEST PEOPLE
IN P COMPUTER SCIENCE
INFORMATION SCIENCE.
DATA SCIENCE AND SOMETIMES THEY
COME FROM UNUSUAL FIELDS LIKE
ECONOMICS OR HISTORY.
ONCE WE HAD AN ART MAJOR BUT
INTERESTING YOUNG PEOPLE SUPER
BRIGHT AND EMBEDDED WITH
INSTITUTE CENTERS AND OFFICES
LIKE OAR TO WORK ON CHALLENGES
THAT IMPACT THE PROGRAM.
EN THEY NOW WORK REMOTE BECAUSE
WE FOUND THEY CAN JUST --
>> YEAH.
>> (OVERLAPPING SPEAKERS)
>> SO IT IS ENCOURAGE YOU IF YOU
ARE THINKING ABOUT BRINGING ON
UNDER-REPRESENTED POPULATIONS
THAT REMOTE IN SOME CASES REMOTE
DOES ALLOW THAT TYPE OF
RECRUITMENT.
>> JUST SO THAT YOU KNOW, SUSAN,
IT WAS KIND OF LIKE BEING BACK
AT THE UNIVERSITY, ONE OF OUR
FULL LOWS LAST YEAR -- FELLOWS
LAST YEAR APPLYING TO BUNCH OF
GRADUATE PROGRAMS SO WE HAD TO
WRITE LETTERS OF RECOMMENDATION.
IT WAS GREAT.
>> VERY FUN.
>> WITH THAT I THINK THAT'S AN
EXCELLENT WAY OF WRAPPING UP THE
SESSION.
AND SO LET'S THANK DR. GREGURICK
AGAIN FOR REALLY AMAZING
PRESENTATION AND A GREAT
DISCUSSION.
SO WE ARE GOING TO TAKE A BREAK
NOW, SO JUST WANT TO REMIND
EVERYONE TO NOT PLEASE DO NOT
LOG OUT OF THE THE ZOOM MEETING.
AND KEEP YOUR CAMERAS OFF.
WE'LL RETURN AT 2 P.M. PROMPTLY.
THANK YOU AGAIN, DR. GREGURICK
AND WE WILL SEE YOU BACK HERE
SOON.
THANKS.
WELCOME BACK EVERYONE.
I HOPE YOU HAD AN OPPORTUNITY TO
GET UP AND MOVE AROUND AND
STRETCH A LITTLE BIT.
NEXT WE WILL HAVE THREE
PRESENTATIONS FROM FOUR
DIFFERENT SPEAKERS, WE WILL
FIRST HEAR FROM MS. KAY HAYES,
DEPUTY ASSISTANT SECRETARY FOR
INFECTIOUS DISEASE AND DIRECTOR
OF OFFICE OF INFECTIOUS DISEASE
HIV AIDS POLICY.
AT OFFICE OF ASSISTANT SECRETARY
OF HEALTH ALSO KNOWN AS OASH.
WE WILL HEAR FROM DR. LAURA
CHEEVER, ASSOCIATE ADMINISTRATOR
HIV AIDS BUREAU OF HEALTH
RESOURCES AND SERVICE
ADMINISTRATION HRSA AND OARAC'S
OWN JONATHAN MIR MEN, RELEASE
ADMIRAL AND U.S. PUBLIC HEALTH
SERVICES SERVES AS DIRECTOR OF
THE CDC NATIONAL CENTER FOR HIV
AIDS VIRAL HEPATITIS, STD AND TB
PREVENTION.
SO DR.S CHEEVER AND MIR MEN
SERVE AS CO-CHAIRS OF THE CHAT
WHICH WE HEARD ABOUT EARLIER IN
MAUREEN'S PRESENTATION.
THE CDC HRSA ADVISORY COMMITTEE
ON HIV VIRAL HEPATITIS AND STD
PREVENTION AND TREATMENT, WE
WILL FINALLY HEAR FROM THE HHS
OFFICE OF GLOBAL AFFAIRS PEPFAR
DIRECTOR DR. JIN PARK, AFTER
THEIR PRESENTATIONS WE WILL HAVE
A PANEL DISCUSSION WITH THE
OARAC MEMBERS.
SO I WILL PROCEED AND READ
INTRODUCTION FOR ALL OF SPEAKERS
AND I WILL PASS OVER MS. HAYES,
THE FIRST IS KAY HAYES DEDICATED
PASSIONATE PUBLIC HEALTH
OFFICIAL WITH 25 YEARS SERVICE
IN THE OASH.
SHE PROVIDES STEADFAST
LEADERSHIP AND POLICY
DEVELOPMENT WHILE ENCOURAGING
COORDINATION AND INNOVATION FROM
VARIOUS PROGRAMS INCLUDING HIV
VACCINES VIRAL HEPATITIS, STI,
BLOOD AND TISSUE SAFETY
ANTIMICROBIAL RHESUS TAN, TICK
BORNE DISEASES AND MORE.
DR. LAURA CHEEVER IS A BOARD
CERTIFIED PHI SESSION IN
INFECTIOUS DISEASE AND
RESPONSIBLE FOR LEADING THE HRSA
RYAN WHITE HIV AIDS PROGRAM AND
PROGRAMMING FOR PEPFAR.
AS EVERYONE KNOWS HERE THE RYAN
WHITE PROGRAM PROVIDES
COMPREHENSIVE SYSTEM OF HIV
PRIMARY MEDICAL CARE MEDICATION
AND ESSENTIAL SUPPORT SERVICES
FOR LOW INCOME PEOPLE WITH HIV
SERVING APPROXIMATELY HALF OF
THE U.S. POPULATION DIAGNOSED
WITH HIV ANNUALLY.
SO REAR ADMIRAL JONATHAN MIR MEN
OVERSEES THE NATIONAL EFFORTS TO
PREVENT HIV VIRAL HEPATITIS,
SEXUALLY TRANSMITTED DISEASES,
TUBERCULOSIS.
HIS DIVISION FOCUSES ON HIGH
IMPACT PREVENTION STRATEGIES
THAT ARE COST EFFECTIVE,
SCALABLE AND GROUNDED IN MANY
THE LATEST RESEARCH.
DR. MERMIN.
LASTLY DR. JIN PARK PROVIDES
COORDINATION AND LEADERSHIP FOR
THE HHS OFFICE OF GLOBAL AFFAIRS
PEPFAR, DEPARTMENT OF STATE
OFFICE OF GLOBAL AIDS
COORDINATOR WHICH IS ALSO KNOWN
AS SGAC AND THE INTERAGENCY
PEPFAR TEAMS.
HE REPRESENTS HHS PEPFAR GLOBAL
FUND AND OTHER INTERNATIONAL
GLOBAL HEALTH AND POLICY
MATTERS.
WITH THAT I WILL PASS IT OVER TO
YOU, MS. HAYES TO -- FOR YOUR
PRESENTATION.
THANK YOU.
>> THANK YOU SO MUCH.
I WOULD LIKE TO SAY THANK YOU TO
DR. MAUREEN GOODENOW FOR THIS
INVITATION TO PRESENT.
ALSO LIKE TO SAY THE WORK WE DO
IS INCREDIBLY IMPORTANT AND
UNDER LEADERSHIP OF ADMIRAL
RACHEL LEVINE WE ARE BUSY BUSY
BUSY.
SO TO GIVE LATE BACKGROUND ABOUT
THE OFFICE OF INFECTIOUS DISEASE
AND HIV AIDS POLICY, WE HAVE OUR
HANDS IN QUITE A LARGE PORTFOLIO
BASICALLY PROVIDING STRATEGIC
LEADERSHIP BUT WE DO A LOT OF
WORK COLLABORATION AND
COORDINATION, AND THAT IS HOW WE
HAVE TO GET OUR WORK DONE.
OIDP, OFFICE WE HAVE FIVE
FEDERAL ADVISORY COMMITTEES THAT
SIT SO WE ARE WORKING ON HIV
WHICH IS THE PRESIDENTIAL
ADVISORY COUNCIL FOR HIV AIDS.
KNOWN AS PACHA.
NATIONAL VACCINE ADVISORY NVAC.
WE HAVE OUR WORK ON OUR
ANTIMICROBIAL RESISTANCE, WORK
THERE AND THEN BLOOD AND TISSUE
SAFETY AND AVAILABILITY.
EXTREMELY BUSY BECAUSE OF THE
BLOOD SHORTAGES AND TICK BORNE
DISEASE WORKING GROUP.
SO WITH OUR FIVE ADVISORY
COMMITTEES STAY INCREDIBLY BUSY.
WE WORK IN A HOST OF DIFFERENT
POLICY INITIATIVES ACROSS I
WOULD THINK MOST IMPORTANTLY ONE
OF THE KEY THINGS WE WORK ON IS
THE MINORITY HIV AIDS FUND LED
BY DR. TIM HARRISSON AN TEAM AND
WITH STRATEGIC PLANS OIDP IS
RESPONSIBLE FOR LAUNCHING FOUR
VEG PLANS.
WE WORK ON HEPATITIS, WORKING
WITH THE WHITE HOUSE ON THE
NATIONAL HIV AIDS STRATEGY,
WORKING ON VACCINE AND THEN ALSO
WITH OUR TICK BORNE AREAS.
THE FIRST EVER SEXUALLY
TRANSMITTED INFECTIONS REPORT.
NEXT SLIDE.
WE WORK THROUGH ENDEMIC APPROACH
THIS IS INCREASINGLY MORE
IMPORTANT AS WE DO OUR WORK
BECAUSE WE CAN'T WORK IN SILOS.
DOESN'T MAKE SENSE TO WE LOOK AT
HIV STI HEP AND VACCINES ENDEMIC
APPROACH, ALSO WITH EYE ON
OPIOID CRISIS, BECAUSE ALL OF
THIS INTERSECTIONALITY INCLUDING
OUR MENTAL HEALTH.
NEXT SLIDE.
WHEN I TALK NATIONAL HIV AIDS
STRATEGY IT WAS RERELEASED
DECEMBER 1, 2021 BY WHITE HOUSE,
COUPLE OF ELEMENTS FOUR GOALS,
21 OBJECTIVES, I WANT TO SPOT WE
WORK ON ONE AGAIN MENTAL
INDICATOR, WORKING WITH THE
WHITE HOUSE CRITICALLY IMPORTANT
I WILL DELVE INTO A LITTLE BIT.
FOR REMINDER THE N HOUSE GOALS
PREVENTIVE WITH HIVE INFECTION,
IMPROVE HI RELATED HEALTH
OUTCOMES FOR PEOPLE LIVING WITH
HIV, REDUCE DISPARITIES, ACHIEVE
INTEGRATED COORDINATED EFFORT
ACROSS HHS AND ALSO LOOKING AT
ADDRESSING THE HIV EPIDEMIC
AMONG PARTNERS AND INTERESTED
PARTIES.
I WANT TO HIGHLIGHT KEY CHANGES
TO UPDATED NHOS.
ONE WE RECOGNIZE AND AMPLIFY
RACISM IS A SERIOUS PUBLIC
HEALTH THREAT THAT IS NOT KNEW
NEWS TO ANYONE ON THIS PLATFORM
BUT IT WAS IMPORTANT TO LET THAT
UP IN THE STRATEGY.
WE WANT TO TALK ABOUT REALLY
STRENGTHENING THE EMPHASIS ON
BETTER INTEGRATION.
THAT IS WHY KEY TO THE ENDEMIC
APPROACH TO WORK WE DO, NOTHING
IS IN ISOLATION.
IMPORTANT ROLE OF HARM WEDUCTION
AND SYRINGE SERVICES PROGRAMS
AND GROWING POPULATION OF PEOPLE
LIVING WITH HIV WHO ARE AGING.
OTHER KEY CHANGE IN UPDATED NHAS
CALLS FOR EXPANDING PEOPLE WITH
LIVED EXPERIENCE SHARING IT,
MAKING SURE THEY ARE INVOLVED IN
RESEARCH, PLANNING, DELIVERY,
ASSESSMENT, ALL ACROSS THE WORK
THAT WE DO.
POPULATIONS LIVING WITH OR
EXPERIENCING RISK FOR HIV AND
UNIQUE EXPERIENCES, AND COME TO
THE TABLE AND SHARE THAT WITH US
IN PLANNING.
WE WANT TO MAKE SURE WE ARE
WEAVING HIV RESEARCH ACROSS OUR
PORTFOLIO.
ONE KEY THING WE HAVE BEEN
WORKING MOST RECENTLY SO
CRITICAL IS OUR WORK ON HIV
CRIMINALIZATION LAWS,
ENCOURAGING REFORM, BECAUSE SO
MUCH OF THAT WORK IS AT THE
STATE LEVEL WE HAVE TO PROVIDE
UPDATED INFORMATION, ENCOURAGE
REFORM.
NEXT SLIDE.
I WOULD SAY SOME OF THE LAST KEY
CHANGES TO THE NHAS IS AS I
MENTIONED QUALITY OF LIFE, FOR
PEOPLE LIVING WITH HIV, THAT WAS
ONE AGAIN DEVELOPMENTAL MEASURES
THAT I TALKED ABOUT IN THIS NEW
NHAS, REALLY SHOUT OUT TO THE
INCREDIBLE WORK DURING COVID-19
AND LESSONS LEARNED IN
SUSTAINING SOME OF WHAT WE
LEARNED DURING COVID-19 AND
WORKING WITH COMMUNITIES.
TO ADDRESSING THE SOCIAL
DETERMINANTS OF HEALTH,
INCREASINGLY ENGAGING OUR WORK
WITH THE PRIVATE SECTOR.
WE SAY THAT IT IS A WHOLE OF
SOCIETY, WHOLE OF COMMUNITY, IT
IS ALL HANDS ON DECK SO
EMPHASIZING OUR WORK WITH THE
PRIVATE SECTOR AND THE WORK THAT
WE DO.
AS I MENTION QUALITY OF LIFE,
INDICATOR WE HAVE A WORK GROUP
AND IT WAS REALLY DESIGNED FOR
PEOPLE WITH HIV REALLY TALKING
ABOUT DATA SOURCES, WHAT IS FAIR
IN DEVELOPING THAT.
WE HAD A WORK GROUP CONVENED
AMONG FEDERAL PARTNERS TO GIVE
DATA FOR THAT AS WE MOVE
FORWARD.
SO THIS IS A ISSUE THAT I KNOW
THE WHITE HOUSE IS REALLY
INTERESTED IN P, AS WE MOVE
FORWARD, COMMUNITY IS VERY
INTERESTED IN, WHAT THAT LOOKS
LIKE, WE ARE STILL WORKING ON
EVERYTHING AROUND IT BUT IT WAS
DETERMINED TO BE DEVELOPMENTAL
INDICATOR.
WE TALK IMPLEMENTATION AS I SAID
WE CAN'T DO THIS ALONE SO
WORKING WITH OUR FEDERAL
PARTNERS, SO I WILL SAY OUR
FEDERAL PARTNERS ARE AMAZING.
AND I SEE DR. CHEEVER HERE, DR.
MERMIN HERE AND WE LEAN ON EACH
OTHER AND SO GRATEFUL FOR THE
WORK THEY ARE DOING AT HRSA AND
CDC AND OTHER FEDERAL PARTNERS,
NIH DR. GOODENOW AND BRINGING
THAT RESEARCH LENS TO WHAT WE
DO.
ALL OF US HAVE TO WORK TOGETHER.
AS I TALK ABOUT ENDING THE HIV
EPIDEMIC WE ARE STILL ON POINT.
OUR GOAL AND STRATEGIES WE ARE
STILL ON COURSE WE ARE LOOK AT
BEST PRACTICE AND WHAT IS
WORKING AND CORRECTIVE NEED BE
ON THINGS NOT WORKING AS WELL AS
WE WOULD LIKE.
DURING A COVID-19 PANDEMIC WE
ARE STILL MOVING FORWARD.
WE ARE ON FOCUS TARGET IN THE
EPIDEMIC BY 90% REDUCTION IN
2030.
OUR STRATEGIES ARE THE SAMEFUL
FOUR PILLARS DIAGNOSE, TREAT,
PREVENT AND RESPOND.
SO THAT IS SORT OF REMINDER OF
THE WORK THAT WE DO, WE HAD SOME
DISCUSSIONS ABOUT HOW WE DOING
IN EACH OF THE AREAS OF OUR
PILLARS, BUT THIS IS THE
FOUNDATION FOR THE ENDING THE
HIV EPIDEMIC.
NEXT SLIDE.
COUPLE OF EHE UPDATES.
WE GET THE QUESTION HOW IS EHE
OR IF IT IS ALIGNED WITH NHAS,
ABSOLUTELY YES.
SO THESE ARE WORKING IN TANDEM,
WE TALK ACCELERATION OF
APPROACHES, AND WE TALK ABOUT
STATUS NEUTRAL APPROACHES NO
WRONG DOOR.
THAT IS A KEY SALIENT POINT
LOOKING AT EHE IN NHAS AND WHICH
WANT TO SHOUT OUT DESPITE
COVID-19 JURISDICTION SOME
JURISDICTIONS HAVE SHOWN
TREMENDOUS PROGRESS.
THE WORK THAT HRSA HAS BEEN
DOING THROUGH LINE FIGHT PROGRAM
SCALING UP NEW CLIENTS REENGAGE
CLIENTS IS STILL KEY.
WE SEE CONTINUOUS SUPPORT
ADMINISTRATION FOR ENDING THE
HIV EPIDEMIC.
I LIKE TO SHARE NEW CAMPAIGN
THAT OIDP LAUNCHED THIS PAST
WEEKEND IN MIAMI.
IT IS A VIRAL SUPPRESSION
CAMPAIGN, I AM A WORK OF ART.
WHEN I TALK ABOUT WORKING
COMMUNITY FROM THE BEGINNING OF
A CAMPAIGN, THIS IS JUST THAT
CAMPAIGN.
OUR PARTNERS IN THE COMMUNITY IS
WHAT WE CALL OUR CREATIVE
PARTNERS.
AND SO NEXT SLIDE.
THIS CAMPAIGN AUDIENCE PEOPLE
DIAGNOSE WITH HIV BUT NOT IN
REGULAR CARE SO WE WANT THAT
TAKE AWAY MESSAGE ONE SEAT CARE,
REMAIN IN CARE AND ACHIEVE VIRAL
SUPPRESSION.
THE LAUNCH IN MIAMI SHOWCASED
OUR CREATIVE PARTNERS SO THEY
CAN TELL THEIR OWN STORY, IN
THEIR OWN WORDS.
IT WAS SO POWERFUL, NEXT SLIDE.
WE ARE TARGETING THIS CAMPAIGN
IMPLEMENTATION IN EIGHT EHE
PRIORITY AREAS.
SO IN THIS AREA WASHINGTON D.C.
BALTIMORE, MARYLAND, ATLANTA,
AND WE LAUNCHED IN MIAMI BUT YOU
WILL SEE WE HAVE EIGHT PRIORITY
AREAS FOR THE I AM A WORK OF ART
CAMPAIGN.
A NICE PLAY ON THE WORDS
ANTI-RETROVIRAL THERAPY.
NEXT SLIDE, SHOWING YOU A COUPLE
OF POSTERS THESE ARE OUR
CREATIVE PARTNERS.
AND THEY DID RADIO INTERVIEWS,
PUSHED OUT THE MESSAGES, AND IF
YOU GO TO HIV.GOV/I AM WORK OF
ART, YOU WILL SEE OUR CAMPAIGN
MATERIALS THERE I WANT TO
SHOWCASE ALL OF OUR CREATIVE
PARTNERS IN THIS CAMPAIGN.
NEXT SLIDE.
CLOSE OUT THE PRESENTATION I
WANT TO TALK ABOUT THE
PRESIDENTIAL ADVISORY COUNCIL
HIV AIDS PACHA, ONE OF THE FIVE
COUNCILS I NEED IN OIDP.
IN THIS HAS BEEN AROUND SINCE
1987.
WHEN RONALD REGAIN CREATED THE
PRESIDENT COMMISSION ON HIV AIDS
EPIDEMIC AT THE TIME.
THE COUNCIL HAS MEMBERSHIP OF
PROMINENT COMMUNITY LEADERS,
SOME FROM ACADEMIA, GLOBAL
HEALTH, IT IS A DIVERSE GROUP OF
LEADERS.
I WOULD SAY THAT IN THIS PAST
YEAR IN AUGUST AND NOVEMBER OF
2021 WE ADDED NEW MEMBERS TO
PACHA.
THE ROSTER REALLY DOES REFLECT
THE RACIAL ETHNIC SEXUAL AND
GENDER MINORITY AND GEOGRAPHIC
DIVERSITY OF THE HIV EPIDEMIC IN
THE U.S. TODAY.
WE ALSO WE HAVE SOME GAPS
STRATEGICALLY ALSO LOOKING TO
FILL.
WE WILL BE HAVING NEW MEMBERS
JOIN WORKING WITH THE WHITE
HOUSE ON THAT NOW.
TO ROUND OUT SO THERE ARE COUPLE
OF AREAS, HIV AND AGING IS ONE,
SO CRITICAL.
THAT WE WANT TO HAVE SOMEONE
WITH THAT EXPERIENCE.
WE ARE LOOKING AT WOMEN IN HIV.
SUBSTANCE MISUSE SYRINGE,CHANGE.
HIV AND HOUSING.
YOUNG PEOPLE WE HAVE MEMBERS
THAT ARE YOUNG AND SOME THAT
WHEN THEY STARTED OUT WITH
PERHAPS YOUNGER BUT WE WANT TO
MAKE SURE WE ARE TARGETING
MAKING SURE WE HAVE THE YOUNGER
VOICE AT THE TABLE HELPING US GO
THANK YOU THESE IMPORTANT
ISSUES.
COUPLE OF RECOMMENDATIONS ONE,
ABOUT THE INCREASE OF UPTAKE IN
READY STEP PREP PROGRAM.
ONLY SURING EQUITY AND JUSTICE
ENDING THE HIV EPIDEMIC.
OUR STIGMA DISPARITIES GROUP
HELD CONVENING A SMALL CONVENING
ON MOLECULAR SURVEILLANCE, SO WE
CAN HEAR FROM COMMUNITY VOICEOR
VOICES ALSO LOOKING AT SOME
OTHER STIGMA IN DISPARITY
ISSUES.
THE IMPACT ON COVID-19 HIV
PREVENTION AND TREATMENT ARE
KEY.
PACHA WORK ON CREATION DUE TO
NATIONAL PREP PROGRAM, EXTREMELY
SUPPORTIVE.
OF THE NATIONAL PREP PROGRAM.
AS I CLOSE OUT THIS I WANT TO
TALK ABOUT PACHA TO THE PEOPLE.
FEDERAL ADVISORY, WE DECIDED TO
TAKE OUR ADVISORY COUNCIL ON THE
ROAD AND OUT OF WASHINGTON D.C.
AREA INTO COMMUNITIES.
BEFORE COVID-19 AND WE WERE
ISOLATING WE WERE IN JACKSON,
MISSISSIPPI MIAMI, FLORIDA AND
WASHINGTON D.C. AS PART OF THAT
WE GO TO COMMUNITY BASED
ORGANIZATIONS AND WE HAVE OUR
FEDERAL PARTNERS AND OUR PACHA
MEMBERS GO ON THESE SITE VISITS
AND HAVE CANDID CONVERSATIONS
WITH COMMUNITY LEADERS.
WE ARE PLANNING NEXT MEETING
LOOKING TO HAVE THAT IN LOS
ANGELES IN SEPTEMBER SO MORE TO
COME ON THAT.
THE SAME SORT OF FORMAT.
WE WILL GO TO COMMUNITY BASED
ORGANIZATIONS AND WORK WITH
REGIONAL COLLEAGUES BUT IT IS
REALLY AN OPPORTUNITY TO GET
DIFFERENT VOICES, NEW VOICES,
THAT COME INTO THIS SPACE AND
PROVIDE COMMENT.
SO IT HAS BEEN A SUCCESSFUL
MODEL WE WILL CONTINUE TO USE.
SEPTEMBER 19 AND 20, IN LA, MORE
TO COME.
THANK YOU FOR THE OPPORTUNITY.
LOOK FORWARD TO ANY QUESTIONS
LATER.
>> THANK YOU MS. HAYES.
WE WILL MOVE AHEAD TO DR. LAURA
CHEEVER.
>> HUE FOR THE INVITA THANK YOU.
(INAUDIBLE) OUR REASON TO
STUDENTS TO ALL AGES AT CENTER
FOR THE UNITED STATES.
WE PROVIDE (INAUDIBLE)
RESOURCES, WE ARE ALSO GOING TO
BE WORKING -- QUALITY CARE IN
THE UNITED STATES IN THE
(INAUDIBLE) PRIMARY CARE FOR
SUPPORT SERVICES.
WE (INAUDIBLE) PATIENT EMERGENCY
HOUSING, EMERGENCY (INAUDIBLE)
CHILD CARE (INAUDIBLE) OUR
GRANTS (INAUDIBLE) CITY STATE
COMMUNITY BASED ORGANIZATIONS
PROVIDE SOCIAL SERVICES.
IMPORTANTLY RECIPIENTS AT LOCAL
LEVEL BASED ON PERCEPTION DEFINE
THEIR FUNDING PRIORITY SO WE DO
NOT HAVE (INAUDIBLE) LAST
RESORT.
BY STATUTE, (INAUDIBLE)
COMPLICATED, FACILITIES PART D
GOES TO STATE AS WELL AS
(INAUDIBLE) PROGRAM, THE
(INAUDIBLE) PROGRAM FUNDS OVER
HALF VIRAL INDUCED IN THE UNITED
STATES (INAUDIBLE) PART C
FUNDING DIRECT TO COMMUNITY
BASED CLINIC PART D FOCUS ON
LIMITS (INAUDIBLE) SPECIFIED
NATIONAL PARTICIPANTS SO WE CAN
(INAUDIBLE) DO NOT HAVE ANY
AUTHORITY TO DO RESEARCH WHICH
IS WHY WE WORK CLOSE WITH
INMATES COLLEAGUES BUT THAT $25
MILLION A YEAR FOR (INAUDIBLE)
GRANTS SMALL PART AND SMALL PART
(INAUDIBLE) HERE YOU SEE BREAK
UP OF APPROPRIATION, MOST --
WHERE THE MONEY DOES GO TO PART
D PROGRAM THE STATE PROGRAM BUT
OF THAT 90 MILLION IS FOR
REQUISITE MEDICATION WHICH MEANS
IF YOU ARE STATE WITHOUT LARGE
CITY, STATES HAVE LIMIT
(INAUDIBLE) MEDICATION.
THE PART A (INAUDIBLE) THE OTHER
IMPORTANT THING I WILL MAKE
ABOUT THIS IS OUR CORPORATION
HAS BEEN MAINTAINED IN THE
FEDERAL GOVERNMENT FOR THE PAST
DECADE WHICH MEANS THAT AS
MEDICINES AND OTHER THINGS
(INAUDIBLE) HAVE NOT BEEN
(INAUDIBLE) I WAS ASKED TO SHOW
HOW ORGANIZED -- SO I HAVE A
SMALL FRONT OFFICE, 30 THE RIGHT
SIDE OF THE SLIDE IS OUR PART C
AND D PROGRAM, ONE DIVISION PART
D PROGRAM IS SECOND DIVISION,
PART A PROGRAM IS THIRD
DIVISION.
DIVISION POLICY AND DATA AND
SPECIAL PROJECTS (INAUDIBLE) WE
HAVE OFFICE OF SUPPORT THAT
COORDINATES TECHNICAL ASSISTANTS
THAT HAPPENS ACROSS OUR BUREAU
AS WELL AS (INAUDIBLE)
>> SO WITHIN THE PROGRAM IN
2020, 561,000 PEOPLE WE DIDN'T
SEE DROP OFF DURING THE
PANDEMIC, NUMBER OF PEEP SERVED.
OF THAT 75% OF OUR CLIENTS ARE
RACIAL ETHNIC MINORITIES.
50 PEST BELOW POVERTY LINE,
AFTER ARE OVER 50 AND THAT IS A
BIG CHANGE, (INAUDIBLE) AND YOU
CAN SEE THERE THAT WE HAVE ABOUT
PEOPLE TEMPORARY OR UNSTABLE
HOUSING.
ON THE SLIDE IT GETS TO THE WORK
THAT WE HAVE BEEN DOING THE LAST
TEN YEARS.
THIS SLIDE SHOW VIRAL
SUPPRESSION RATES AMONG
(INAUDIBLE) PROGRAM MEDICAL
CARE, LOOKING AT COMMUNITY AND
DARK BLUE BARS AND THEN 2020 IN
THE LIGHT BLUE BARS.
SO IN 2010 THIS IS A KEY
POPULATION FAR LEFT-HAND SIDE
OVERALL OUR VIRAL SUPPRESSION
RATE IS 69.5%.
THAT WENT TO 89.4 BY 2020,
FOCUSED VERY MUCH ON (INAUDIBLE)
AS YOU CAN SEE IN THE DASH LOWER
LINE GOING ACROSS WE HAVE
DISPARITYINGS, THE SECOND TO
LAST SET OF BARS, VIRAL
SUPPRESSION RATE WAS 46.6%
DIFFERENCE.
OVERALL BETWEEN 2010 AND 2020
SUPPRESSION WENT UP TO 19 BUT
YOU CAN SEE FOR YOUTH FOR
EXAMPLE THEIR VIRAL SUPPRESSION
INCLUDES 39 -- 34.9 SO WE HAD A
REDUCTION IN THE DISPARITIES
THAT WE SAW IN 2010.
HOWEVER, IF YOU LOOK ACROSS THE
LIGHTER DOTTED LINE AT TOP,
DISPARITIES PERSIST FOR PEOPLE
THAT (INAUDIBLE) SMALL BUT
IMPORTANT DISPARITIES.
SO OUR STRATEGIES PROMOTING
HEALTH EQUITY REDUCING
DISPARITIES FALL INTO FIVE --
ACTIVE PROCESS OF COMMUNITY
ENGAGEMENT, BEFORE PANDEMIC WE
TRAVEL TO ALL EHE -- ENGAGE
COMMUNITIES HERE DIRECTLY -- YOU
WILL HEAR FROM THEM, WE HAVE
DONE THAT VIRTUALLY DURING THE
PANDEMIC AND ONCE YOU GET INPUT
FROM THE COMMUNITY (INAUDIBLE)
IMPORTANT THING WE TELL THE
COMMUNITY WHAT WE DID,
(INAUDIBLE) WE HAVE QUALITY
MANAGERS AS PART OF OUR
LEGISLATION BUT WE SUPPORT
CONSUMER QUALITY IMPROVEMENT.
WE HAVE SERIES OF LARGE
COLLABORATORS FOCUSED ON KEY
POPULATIONS YOUNG BLACK OR
TRANSGENDER FOCUSED ON IMPROVING
VIRAL SUPPRESSION RATES IN
POPULATIONS ACROSS THE COUNTRY
VARIOUS (INAUDIBLE) WE LOOK AT
SERVICE DELIVERY MODELS
INCLUDING THE INTEGRATION OF
SOME OF THESE POTENTIAL SUPPORT
SERVICES THAT HELP ADDRESS
SOCIAL DETERMINANTS OF HEALTH
AND (INAUDIBLE) FOCUS OUR
EFFORTS ON AS WELL AS
(INAUDIBLE) WE HAVE VERY
DELIBERATELY EMPLOYED -- WE
START AT THE LOCATION
(INAUDIBLE) WORKING WITH NIH
COLLEAGUES FROM -- (INAUDIBLE).
IN TERMS OF ENDING THE EPIDEMIC,
PEOPLE STARTED LEFT HAND SIDE
WITH DIFFICULT IMPORTANT PART OF
THE WORK WE HAVE TO DO ENGAGING
PEOPLE WHO KNOW THEY HAVE
(INAUDIBLE) THAT IS REALLY
RETOOLING HOW WE PROVIDE
SERVICES THE SECOND GROUP OF
PEEP DIAGNOSED AS A RESULT OF
EHE MAKING SURE WE HAVE GOOD
ENGAGEMENT PROCESSES AND PROGRAM
AND OPINIONLY WE HAVE STILL
ABOUT 11% PEOPLE IN AND OUTSIDE
OF THE (INAUDIBLE) SO HAVING
LOWER BARRIERS TO BE ABLE TO
IMPROVE THAT LAST (INAUDIBLE).
SO DURING -- IN THE (INAUDIBLE)
FUNDING IN APRIL OF MARCH OF
2020 RIGHT WHEN COVID HIT SO WE
DIDN'T KNOW A LOT WOULD HAPPEN
BUT (INAUDIBLE) PEOPLE WERE ABLE
DO THINGS DIFFERENTLY,
STREAMLINING EARLY EXPERIENCES
AND DEVELOPING (INAUDIBLE) RAPID
ART HAS BEEN A STRATEGY USING IN
A LOT OF RAPID ART (INAUDIBLE)
AND WE KNOW FOR US THE EHE ONE
OF THE MIGHT BE -- IF WE BROUGHT
HOME THOUSAND PEOPLE (INAUDIBLE)
SO WE HAVE BEEN -- IN PARTICULAR
CLEAR NAVIGATORS AND COMMUNITY
HEALTH WORKERS TO REACH PEOPLE
WHO ARE OUT CARE, NOT
(INAUDIBLE) SO THE ADVISORY
COMMITTEE -- WE ARE EXCITED WE
HAVE THIS JOINT COMMITTEE HRSA
AND (INAUDIBLE) PROCESS TOGETHER
AND ON THE ADVISORY COMMITTEE WE
ARE LOOKING AT THE (INAUDIBLE)
HIV VIRAL HEPATITIS AND OTHER
STD ENDEMIC APPROACH, SUPPORT
HEALTH SERVICES FOR PEOPLE WITH
HIV, HEALTH PROFESSIONS AND OR
AGENCIES RESPONSIBLE FOR
PREVENTING HEALTH SERVICE
DELIVERY NEEDS IN THE COMMUNITY.
ONE EXAMPLE OF THINGS -- ONE IS
LOOKING SPECIFICALLY AT
TELEHEALTH, WHAT HAPPENS IN
TELEHEALTH AND HOW DO WE WANT TO
MOVE IT FORWARD FOR THINGS LIKE
HEALTH EQUITY, DIGITAL DIVIDE
QUITE A BIT MORE DISCUSSION.
THINKING HOW WE CAN DO PREP MORE
WITH RESPECT TO TELEHEALTH.
AND STI SCREENING IMPROVING
(INAUDIBLE) SPECIFICALLY AND
FDA.
IN TERMS OF WORK FORCE, THAT IS
ALSO COME UP QUITE A BIT ABOUT
TALKING ABOUT BURN OUT.
HOW WE CAN DO A BETTER JOB
(INAUDIBLE) POPULATION STD
HEPATITIS AND (INAUDIBLE).
NEXT SLIDE.
WITH THAT I WILL CONCLUDE THESE
ARE MY CONTACT INFORMATION AND I
WILL TURN IT OVER TO JOHN.
>> CAPTAIN GLENSHAW CAN YOU HEAR
ME?
OKAY THANK YOU SO MUCH, LAURA.
IT IS A TRUE SIGN OF
COLLABORATION THAT WE REALLY DO
WORK WELL TOGETHER AS FRIENDS,
COLLEAGUES AND AGENCIES, AND I
THINK THE IDEA THAT THERE IS IN
FACT FEDERAL ADVISORY COMMITTEE
THAT CROSSES AGENCIES IS A SIGN
OF HOW IMPORTANT THAT IS AND HOW
HELPFUL IT CAN BE ENCOURAGING
COLLABORATION AND AND WORKING
TOGETHER AND SOLVING PROBLEMS.
I AM -- I HAVE PREVIOUSLY TO
THIS GROUP GIVEN UPDATE ON A LOT
OF WHAT WE ARE DOING FOR HIV
EPIDEMIC SO FOR THIS PARTICULAR
PART OF THIS KIND OF AGENCY
UPDATE I WILL FOCUS ON COUPLE OF
THINGS, ENDEMIC APPROACH WHY IT
IS IMPORTANT FOR US AND KAY AND
LAURA TALKED ABOUT THAT.
SOME UPDATES OF CHAT MEETING,
AND A LITTLE ASSIGNED TASK FROM
DR. GOODENOW WHICH WAS
COLLABORATION WITHIN THE NIH
WHICH ARE EXTENSIVE AND
IMPORTANT.
NEXT SLIDE PLEASE.
THE FIRST IS MY CENTER NATIONAL
CENTER FOR HIV VIRAL HEPATITIS
AND TB PREVENTION GREW OUT OF
THE PAIN OF THE HIV EPIDEMIC AND
IS ALWAYS HAD BOTH VISION OF
TACKLING THESE INFECTIONS BUT
BECAUSE MANY OF THEM ARE CHRONIC
INFECTIOUS DISEASES AND MANY OF
THEM HAVE STIGMA OR
DISCRIMINATION ASSOCIATED, WE
HAVE ALWAYS TAKEN IN THE SOCIAL
DETERMINANTS AND INCORPORATED
INTO HOW WE ARE TRYING TO
ADDRESS SOLVING OR PROBLEMS.
ARE GETTING PERT AT IT.
IT IS A WORKS IN PROGRESS.
I HAVE FIVE DIVISIONS ONE ON HIV
ONE ON STI, ONE ON TD
ELIMINATION VIRAL HEPATITIS AND
ANOTHER DIVISION OF ADOLESCENT
SCHOOL HEALTH THAT WORKS
DIRECTLY WITH EDUCATIONAL
AGENCIES IN THE STATE LOCAL
LEVEL AND PRODUCES CURRICULUM
TOOLS.
AND RUNS YOUTH RISK BEHAVIORAL
SURVEILLANCE SYSTEM WHICH
MONITORS THE HEALTH OF YOUTH IN
THE NATION IN A NATIONALLY
REPRESENTATIVE WAY AND STATE
LEVEL FOR MANY STATES.
SO I WANTED TO TALK ABOUT WHAT I
THINK IT IS A LITTLE BIT TOO
POMPOUS TO CALL THESE ENDEMIC
APPROACH BUT A ENDEMIC APPROACH.
YOU SAW SO MANY DISEASES
RESPONSIBLE BUT THERE IS
POPULATION CLUSTERING OF THE
SOCIAL AND HEALTH ISSUE -- THE
SOCIAL ECONOMIC ISSUES THAT
CAUSE THESE HEALTH ISSUES.
SO I WANT TO HIGHLIGHT WHY
PEOPLE, WHY PLACE, WHY SCIENCE
AND POLICY ALL MATTER WHEN
THINKING ABOUT GETTING THE JOB
DONE THROUGH THIS ENDEMIC
APPROACH.
JOHN DID YOU HAVE YOUR HAND UP?
DID YOU WANT TO SAY SOMETHING
ABOUT MY PRIOR SLIDE?
>> ERROR ON MY PART SORRY.
>> YOU ARE WELCOME.
PEOPLE MATTER.
IT OFTEN SEEING DISPARITIES IN
DISEASE INVIGORATE AS ROBUST
RESPONSE IN US TO THINK IT IS A
REFLECTION OF PUBLIC HEALTH
INJUSTICE AN WE SHOULD CHANGE
THAT.
IT IS AN OPPORTUNITY TO MAKE A
BIGGER DIFFERENCE BECAUSE IF YOU
FOCUS YOUR EFFORTS AND BRING
RESOURCES TO PEOPLE WHO ARE MOST
EFFECT ED YOU WILL GET THE JOB
DONE BETTER.
THAT WE HAVE BEEN ASSIGNED BY
CONGRESS AND AMERICAN PEOPLE SO
ONE JUST TO HIGHLIGHT HOW SOME
OF THE CONCENTRATIONS OF OUR
INFECTIONS FOR MEN WHO HAVE SEX
WITH MEN IN THE UNITED STATES
70% HIV DIAGNOSES ARE AMONG GAY
BISEXUAL MEN, 42% PRIMARY AND
SECONDARY SYPHILIS, 17%
CHLAMYDIA.
PEOPLE WHO INJECT DRUGS MOST
ACUTE NEW HEPATITIS C VIRUS
INFECTIONS AND LARGE PROPORTION
OF HEPATITIS D VIRUS INFECTION
ACQUIRED AMONG YOUNG ADULTS AND
11% OCCUR AMONG PEOPLE WHO
INJECT DRUGS, THERE IS A LARGE
PROPORTION OF OVERDOSE DEATHS.
A GROUP THAT GETS AFFECTED
DEEPLY BY SOME OF THESE
INFECTIONS, IN THE CASE OF
OVERDOSES THERE ARE ALSO STARK
RACIAL ETHNIC DISPARITIES
AFRICAN AMERICANS ARE EIGHT
TIMES HISPANIC LATINOS THREE
TIMES MORE LIKELY TO GET NEW HIV
INFECTION AND MORE THAN A THIRD
OF TB HEPATITIS B AMONG ASIAN
AMERICANS.
AS FOR MANY OF US AS A VERY
IMPORTANT ISSUE JUSTICE INVOLVED
POPULATIONS HAVE HIGHER
INCIDENCE OF ALL THESE
INFECTIONS AND THEN SO MAKING
SURE WHAT WE ARE DOING FROM A
PUBLIC HEALTH STANDPOINT THINKS
ABOUT CORRECTIONAL INSTITUTIONS
AND THEIR OPPORTUNITIES IS
IMPORTANT TOO.
SO I ALSO WANTED TO TALK HOW
PLACE MATTERS.
THIS IS TWO MAPS.
ON THE RIGHT IS MAP OF THE
ENDING HIV EPIDEMIC PRIORITY
AREAS.
IN THIS MAP I WANT YOU TO LOOK
AT THAT TIME DARK BLUE COUNTIES.
THESE DARK BLUE COUNTIES SHOULD
BE HARD TO SEE BECAUSE THERE ARE
ONLY 50 OF THEM, IF YOU INCLUDE
SAWN HON JUAN AND WASHINGTON
D.C. AS COUNTIES AND COMPARED TO
3,300 COUNTIES IN AMERICAN.
SO 50% INFECTIONS ARE IN THE
PRETTY CONCENTRATED INTO THESE
AREAS SO IF WE CAN DO A GOOD JOB
AND FOCUS OUR EFFORTS AT LEAST
DISPROPORTIONATELY IN THOSE
AREAS WE WILL MAKE A DIFFERENCE
FASTER AND BETTER THAN IF WE
DISTRIBUTE WITHOUT THAT IN MIND.
WE ALSO DID INTERNAL CALCULATION
WHERE WE DID SIMILAR CONCEPT FOR
OUR OTHER INFECTIONS TOO SO IF
YOU LOOK AT CHLAMYDIA,
GONORRHEA, SYPHILIS AND TB, IF
YOU ARE IN THE SAME TOP 50% YOUR
COUNTY GETS INCLUDED AND DARKER
COLOR YOU ARE, SO DARK MAGENTA
VERSUS LAUGH DAR, AQUA, MEANS
YOU ARE COUNTY THAT HAS HIGH
NUMBER OF THOSE OTHER INFECTIONS
TOO.
MULTIPLE INFECTIONS, SO WHAT YOU
CAN SEE IS IT IS NOT THAT MANY
COUNTIES AND THERE'S OVERLAP FOR
MANY OF THESE COUNTIES.
SO AGAIN NOT THE JUST
POPULATIONS AND GROUPS OF PEOPLE
DISPROPORTIONATELY AFFECTED BY B
GEOGRAPHIC AREAS.
IT REMIND US OF HOW WE CAN MAKE
A DIFFERENCE BY FOCUSING ON
THAT.
I WILL SAY ALTHOUGH THIS IS
NATIONAL LEVEL FOR EVERY STATE
THEY ALSO CAN BE THINKING ABOUT
HOW AM I DISTRIBUTING MY
RESOURCES?
THERE ARE PRESSURES FROM HEALTH
DEPARTMENTS FROM ALL OVER TO
DISTRIBUTE EQUALLY, TO MAKE SURE
THAT EVERYONE HAS THE CAPACITY,
TO REALLY LOOK CAREFULLY PLACES
DISPROPORTIONATELY AFFECTED IN
POPULATIONS GETTING THE
RESOURCES THEY NEED.
THEN OBVIOUSLY WITHIN LOCAL
JURISDICTIONS, IT IS ALSO NOT
THE SAME.
I LIVE IN DECAB COUNTY, GEORGIA,
THAT IS A HUGE COUNTY, IT IS NOT
ALL DECALB COUNTY, SOMETIMES IT
IS JUST A FEW BLOCKS MAKING SURE
RESOURCES ARE AVAILABLE WHETHER
TESTING TREATMENT OR REMEMBER,
IT CAN MAKE A BIG DIFFERENCE.
SO WHAT ARE POTENTIAL BENEFITS
OF USING THIS ENDEMIC?
ONE IS HOLISTIC SERVICE
DELIVERY.
SO JUST AS A PRIMARY CARE DOC MY
JOB IS TO THINK ABOUT ALL OF THE
HEALTH OF A PATIENT SO THEY CAN
LIVE A LONG HEALTHY LIFE.
IT CAN BE FRUSTRATING IF YOU
HAVE TO GO TO DIFFERENT
SPECIALISTS.
BUT IF YOU CAN BE GUIDE WITH
PRIMARY CARE DOC THAT CAN BE
HELPFUL.
AND PATIENTS OFTEN FRUSTRATED BY
NOT BEING ABLE TO HAVE SOMEONE
CARE ABOUT THEM THEIR WHOLE
SELF.
AND INCLUDING SOME OF THE
FACTORS THAT ARE SOCIAL AROUND
THEM RATHER THAN OR IN THEM OR
IN THEIR COMMUNITY RATHER THAN
JUST MEDICALIZE IT.
THAT ALSO HAPPENS AT A
POPULATION LEVEL, THERE IS A WAY
WE ARE FRUSTRATED WHEN DOING HIV
PROGRAMS, AND WE CAN'T
INCORPORATE SOME OF THE WORK IN
ADJUSTING SOCIAL ECONOMIC
DETERMINANTS.
LAURA HIGHLIGHTED HOW EFFECTIVE
THE RYAN WHITE CARE ACT PROGRAM
HAS BEEN IN REDUCING SOME OF THE
DISPARITIES THAT EXISTED BEFORE
HER ARRIVAL AND FIRST FEW YEARS
OF HER JOB.
SO THAT FOCUS HAS MADE A HUGE
DIFFERENCE.
WHAT IS INTERESTING IS WHAT IS
ABSENT NOW, AND WE CAN TALK
ABOUT THAT LATER IS IF THE RYAN
WHITE PROGRAM IS DOING SO WELL,
WHY IS I'M SORRY DENSE STILL
HIGH?
WHAT IS GOING ON, PEOPLE WHO ARE
CHURNING IN AND OUT CARE OR
PEOPLE WHO AREN'T GET INK TO
CARE GETTING DIAGNOSED IN THE
FIRST PLACE.
SO WE HAVE TO KEEP THAT IN MIND
THAT EVERYONE LIVING HERE
MATTERS.
ENDEMIC APPROACHES CAN INCREASE
COST EFFECTIVENESS, IF THEY ARE
DONE WELL THEY CAN SAVE MONEY.
THEY CAN REDUCE STIGMA, BECAUSE
YOU HAVE A HOLISTIC APPROACH AND
PEOPLE AREN'T JUST GOING TO THE
HIV CLINIC.
SUPPORT FOCUS ON POLICY AND
SOCIAL DETERMINANT OF HEALTH
DRIVERS.
YOU HAVE TO DO THAT.
IF YOU ARE THINKING ABOUT THIS
ENDEMIC APPROACH IN THAT WAY
THAT DOESN'T HAPPEN IF YOU ARE
THINKING MOSTLY FOR CERTAIN
INDIVIDUAL DISEASES, IT FORCES
THIS PERSPECTIVE IN A POSITIVE
WAY.
IT CAN INCREASE FLEXIBILITY BY
ENABLING PARTNERS TO ADAPT AND
IMPLEMENT AND MODIFY INTEGRATED
SERVICES SO THEY CAN BE MORE
RESPONSIVE TO OUTBREAKS OR
CHANGE IN CONTEXT AND PROVIDES
PARTNERS WITH INCREASE CONTRACT
AND ABILITY TO PROVIDE
COMPREHENSIVE SERVICES WHICH CAN
BE BENEFICIAL.
INTERNALLY WE HAVE BEEN THINKING
ABOUT WHAT ARE THE MOST HIGH
IMPACT ENDEMIC STRATEGIES?
BECAUSE NOT EVERYTHING IS GOING
TO MAKE THE GREATEST DIFFERENCE
AND WHAT IS BUBBLELING UP TO THE
TOP IS MULTI-PATHOGEN TESTING.
IT IS PRETTY FREQUENT YOU CAN GO
GET A PLACE ROUTINE HIV
SCREENING IN EMERGENCY
DEPARTMENT AND NOT DOING ROUTINE
HEPATITIS C SCREENING THOUGH NOT
PREVENTED BY U.S. PREVENTIVE
TASK FORCE CDC.
SO AN EXAMPLE OF THINKING
MULTI-PATHOGEN IF YOU ARE GOING
TO DRAW BLOOD OR SET UP A
STANDING ORDER IN THE LAB THAT
IS GOING TO CHECK THE ELECTRONIC
MEDICAL RECORD AND AUTOMATICALLY
ADD ON THE TEST TO YOUR
CHOLESTEROL TEST IF YOU DON'T
HAVE SOMETHING IN RECORD.
DO IT FOR INFECTIONS THAT THAT
POPULATION HAVE A HIGHER
FREQUENCY OF RATHER THAN JUST
ONE.
POLICY CHANGE, THERE IS A LOT OF
THINGS WE CAN DO WHETHER
MEDICAID EXPANSION OR WHETHER
STUDENT SERVICE PROGRAM
LEGISLATION, THERE ARE THINGS
THAT CAN SET ENABLING
ENVIRONMENT AT THE POLICY LEVEL
THAT WILL AFFECT MULTIPLE
OUTCOMES.
NOT JUST INFECTIOUS DISEASE BUT
SOMETIMES SOME OF THOSE CHANGES
AFFECT PEOPLE ENTIRE LIFE
EXEMPTION FANCY AS WELL AS WELL
BEING -- EXPECTANCY AS WELL AS
WELL BEING.
PREVENTION AND OUTBREAKS WE ARE
FRUSTRATED WHEN WE DO OUTBREAK
RESPONSE, FOR EXAMPLE HIV
OUTBREAK AMONG PEOPLE WHO INJECT
DRUGS OR DOING A LOT FOR HIV BUT
MAYBE DIAGNOSING BUT NOT SETTING
UP A TREATMENT PROGRAM AND
MAKING SURE ENABLING THE STATE
OR LOCAL HEALTH DEPARTMENT TO DO
SO SO WE CAN PREVENT MORE THAN
ONE INFECTION.
VENUE AND PROGRAM BASED
MULTI-DISEASE PREVENTION, THE
IDEA IS IF YOU HAVE A VENUE
WHETHER THAT VENUE CAN BE
VETERANS ADMINISTRATION OR
STUDENT SERVICE PROGRAM, SDI
CLINIC.
ARE WE THINKING ENDEMIC
STRATEGY.
DATA SHARING ANAL SEEDS WE HAVE
TALKED' -- ANALYSES, WE HAVE
TALKED ABOUT DISCUSSION ALREADY
THERE IS SPACES WHERE WE CAN DO
BETTER WITH THAT, THEN DIGITAL
COMMUNICATION CAMPAIGNS AND
INTERVENTIONS WE THINK WE HAVE
-- WE WANT TO GROW MORE INTO
THAT ARENA TO BECOME MORE
EFFECTIVE IN AGAIN REACHING
POPULATIONS WHO NEED TO HAVE
ACCESS TO THAT INFORMATION AND
DOING IT IN A VERY ACCEPTED
EXPLICIT WAY THAT WHERE EVERYONE
DOES NEED THE GET THAT
INFORMATION AND WE CAN TALK
ABOUT I THINK MONKEY POX IS A
GREAT EXAMPLE WHERE THERE'S SOME
INFORMATION NEEDS TO GO OUT TO
THE GENERAL PUBLIC BUT RIGHT NOW
WE NEED POPULATION MOST
EFFECTIVE IN THIS CASE IN THE
UNITED STATES AND ELSEWHERE BY
SEXUAL MEN TO GET EXPLICIT ABOUT
WHAT THEY DO TO PROTECT
THEMSELVES AND OTHERS.
MENTION SLIDE PLEASE.
SO SOME OF THE KEY ACTIONS TO
ADDRESSING ENDEMICS PUT PEOPLE
FIRST FOCUS ON EQUITY.
PUT YOUR MONEY WHERE YOUR
EPIDEMIC IS, LEVERAGE POLICIES
TO HEALTH TOOL AND PRIORITIZE
INNOVATION AND THAT IS SOMETHING
THAT NIH AND HRSA HAVE BEEN
DOING ALREADY.
SO THIS IS JUST I HAVE TWO MAYBE
THREE SLIDES ABOUT HIV
SPECIFICALLY BUT THIS SLIDE ON
THE LEFT IS ABOUT INCIDENCE,
ESTIMATED HIV INCIDENCE.
YOU CAN SEE WE HAVE HAD SUCCESS
AS COMMUNITY NATION DECREASING
INCIDENCE OF HIV FROM ABOUT --
IT WAS INTO THE THERE ARE OVER
150,000 INFECTION AS YEAR IN THE
1980s, DOWN TO 50,000, KIND OF
STAYED THAT FOR A WHILE, WE GOT
DOWN TO 39, 40,000 AND WE
LOWERED FEW THOUSAND DOWN TO
34,800 BY 2019.
IT IS TOO SLOW TO ELIMINATE HIV
IF GOING AT THIS RATE.
WE NEED TO DO BETTER.
BUT I THINK IT ALSO HIGHLIGHTS
SEVERAL THINGS.
ONE IS THAT IF THE KIND OF
SUCCESS THAT DR. CHEEVER
HIGHLIGHTED FOR RYAN WHITE
CLIENTS ARE ACHIEVED FOR
EVERYONE WITH HIV IN THE NATION
WE WILL START SEEING THIS GO
DOWN AND IF WE CAN EXPAND OUR
PREP COVERAGE TO BE ON THE 25%
WHO ARE CURRENTLY RECEIVING PREP
OF PEOPLE WHO WE THINK WOULD BE
ELIGIBLE, WE SHOULD SEE THIS GO
DOWN FASTER.
ON THE RIGHT I SHOW PREVENIENCE.
I DO THAT BECAUSE I WANTED TO
HIGHLIGHT THAT THE NUMBER OF
PEOPLE, ABSOLUTE NUMBER OF
PEOPLE WITH HIV IS GOING UP
EVERY YEAR.
MANY THE PEPFAR WORLD WE HAVE
NOT REACHED EPIDEMIC CONTROL YET
BUT IT MEANS THE FASTER WE
REDUCE INCIDENCE THE FASTER THE
OVERALL BURDEN OF HIV IN THE
NATION IS GOING TO GO DOWN.
THAT MEANS WE CAN START
PROVIDING SERVICES TO FEWER
NUMBERS OF PEOPLE AND HELPING
THEM EVEN MORE.
IF WE HAD BEEN ABLE TO DECREASE
HIV MORE, 10, 15 YEARS AGO WE
WOULDN'T HAVE 1.2 MILLION PEOPLE
LIVING WITH HIV.
INFECTIOUS DISEASE THAT SPREADS,
DO GOOD JOB PREVENTING SPREAD WE
CAN REAP THE BENEFITS FROM
PUBLIC HEALTH AND COST BENEFIT
FOR -- PERSPECTIVES FOR YEARS TO
COME.
SO THIS IS SOME OF THE
INNOVATION THAT WE HAVE BEEN
DOING, ONE IS SELF -TESTING, LAST
YEAR WE DISTRIBUTED 150,000 SELF
TESTS, THROUGH THE INTERNET, WE
HAVE DONE PRIOR RANDOMIZE RILES
TO SHOW THAT IT IS EFFECTIVE AND
COST SAVING AND THIS YEAR WE ARE
PLANNING ON 175,000 TESTS IT IS
A USEFUL TOOL TO GET TO PEOPLE
WHO CAN'T OR DON'T GET ACCESS TO
TESTING ABOUT 20% OF THE PEOPLE
WHO GET TESTING THEY HAVE NEVER
HAD HIV TEST BEFOREMENT OF BUT
HELPFUL FOR PEOPLE TO HAVE
FREQUENT TESTING WE RECOMMEND
ONCE EVERY THREE TO SIX MONTHS
BECAUSE IT IS HARD FOR THEM TO
GO TO THE CLINIC EVERY THREE TO
SIX MONTHS BUT THEY CAN GET HIV
TEST IN THEIR HOUSE, IT CAN BE
EFFECTIVE.
THEY ALSO ARE AVON MEN, THESE
ARE PEOPLE WHO CAN ACTUALLY
SHARE TEST KITS BECAUSE WE WILL
SEND TWO IF THEY REQUEST THAT
WITH THEIR FRIENDS AND TRIALS
NOT ONLY SHARE WITH THEIR
FRIENDS BUT FRIENDS DIAGNOSE
THEMSELVES WITH HIV.
SO IT IS FREE DELIVERY FOR
FRUITS FOR US SO BENEFICIAL, IT
IS LIMITED IN SCOPE BECAUSE COST
OF THESE TESTS IS HIGH.
WE ARE EXPANDING STD CLINICS
CAPACITY TO DELIVER PREP AS WELL
AS OTHER SERVICES, AN NOW
ACTUALLY TO EXPAND SOME OF THE
PREVENTIVE TOOLS WE HAVE FOR
MONKEY POX.
WE THINK ABOUT HOW TO USE
PHARMACIES FOR DATA TO CARE WORK
SO THAT WHEN SOMEONE DOESN'T
PICK UP MEDICATION THEY ARE
RAPIDLY CONTACTED.
AND ENCOURAGED WE ESSENTIALLY
HELP THEM OVERCOME WHAT WHATEVER
PREVENTED THEM FROM GETTING
THEIR TREATMENT SO THEY CAN STAY
ON TREATMENT OR SOME CASES STAY
ON PREP.
WE ARE EXPANDING PREP AND WORK
ON CLUSTER DETECTION AN RESPONSE
WORK THAT KAY MENTIONED BUT IT
IS TO MAKE SURE THAT WHEN WE
RESPOND RAPIDLY AND EFFECTIVELY,
TO OUTBREAKS.
RIGHT NOW WE HAVE A CERTAIN
NUMBER OF PEOPLE THAT HAVE TO BE
IN A CLUSTER BEFORE THAT HEALTH
DEPARTMENT TEND TO RESPOND WE
HAVE TO LOWER THAT NUMBER TO
RESPOND MORE EFFECTIVELY BEFORE
THINGS SPREAD.
THIS IS A LIST OF NIH
COLLABORATION FROM BOTH JOINT
FUNDING, LITERALLY JOINED WITH
NIH TO HAVE A JOINT FUNDED NOFO
FOR EXAMPLE ONE TO PREVENT
INFECTIOUS DISEASES PRIMARILY
HEPATITIS C AND HIV IN PEOPLE
INJECT DRUGS IN RURAL US.
COLLABORATIVE RESEARCH WHERE WE
ARE PART OF C FARES WE ARE A CTU
FOR THE CLINICAL TRIALS OR WHERE
WE HAVE COLLABORATIVE --
COLLABORATIONS ON ADOLESCENT
BRAIN COGNITIVE DEVELOPMENT
STUDY WHICH IS A LARGE STUDY RUN
BY NIH THAT HAS COLLABORATING
PARTNERS.
SO WE LIKE TO COLLABORATE ON
RESEARCH AND WE ALSO HAVE NUMBER
OF PARTNERSHIPS WITH DR.
GOODENOW'S GROUP AN MULTIPLE
OTHER PARTS OF NIH AND CONTINUE
TO HAVE EVEN RETREATS WITH
COLLEAGUES AT NIH WHERE WE TRY
TO DETERMINE WHAT ARE MOST
IMPORTANT RESEARCH PRIORITIES
AND SHARE INFORMATION WHAT WE
ARE DOING SO WE DON'T OVERLAP.
AND THAT WE ALSO SOMETIMES
LEVERAGE EACH OTHER CAPACITY TO
ANSWER QUESTIONS FASTER.
OF BECAUSE WE HAVE EXISTING
GRANTS OR BECAUSE WE HAVE RAPID
MECHANISM TO GET THE RESEARCH
DONE.
THIS IS HIGHLIGHTS, OF THE CHAT
MEETING.
WE HAD ONE SESSION ON LEVERAGING
POLICY TO ADVANCE HIV VIRAL
HEPATITIS AND STI PRIORITIES, I
DID INCLUDE TB BECAUSE IT HAS
SEPARATE FEDERAL ADVISORY
COMMITTEE.
SO THIS CHAT IS PRIMARILY
FOCUSED ON THESE THREE
INFECTIONS.
IT WAS HELPFUL SOME OF THE MAJOR
PRIORITIES THAT CAME UP AS BEING
MOST EFFECTIVE WOULD BE NOT
REMOVING MEDICAID AND PRIVATE
INSURANCE TREATMENT
RESTRICTIONS, THAT PREVENT
PEOPLE WITH HEPATITIS C FROM
GETTING TREATMENT THOSE
RESTRICTIONS ARE PUT INTO PLACE
NOT FOR PATIENTS HEALTH BUT TO
SAVE MONEY.
FOR THE INSURERS.
THEY HAVE BEEN SHOWN TO RESULT
IN MORBIDITY AND MORTALITY OF
PATIENTS WITH HEPATITIS C BUT
STILL ONLY SMALL PROPORTION OF
PEOPLE WITH HEAP C WHO ARE
DIAGNOSED AND ARE IN CARE GET
CURED THOUGH IT IS 8 TO 12 WEEKS
ORAL REGIMEN.
BECAUSE RESTRICTIONS MAKE IT
DIFFICULT.
EVEN IF IT IS JUST PAPERWORK
DIFFICULT BUT SOMETIMES IT IS
RESTRICTION YOU HAVE TO HAVE
SEVERE DISEASE OR YOU CAN BE
TREATED BY G, DOC OR INFECTIOUS
DISEASE DOC SO A VARIETY ARE PUT
INTO PLACE.
REMOVING THOSE COULD MAKE A
DIFFERENCE.
POLICY CHANGES CALIFORNIA PASSED
LEGISLATION THAT ALLOWS
PHARMACISTS TO PROVIDE HEAP
AND/OR PREP, THERE'S A
REQUIREMENT THAT HEALTH PLANS
COVER AT HOME TEST FOR HIV STD
AND THERE IS LIABILITY
PROTECTION FOR DISPENSING
EXPEDITED PARTNER THERAPY FOR
STI, EASIER TO GET PEOPLE
TREATMENT PARTNER EXPOSED BUT
PARTNER CAN'T COME INTO THE
CLINIC.
WE HAD PRESENTATION FROM
LOUISIANA ON THEIR HCV TREATMENT
NETFLIX MODEL FOR WAYS REDUCING
ESSENTIALLY THE BARRIERS FOR
ACCESSING TREATMENT BECAUSE IF
IT COMES FREE TO THE CLINIC OR
USER TO BE ABLE TO GET ACCESS
INSTEAD OF BEING OBSTACLE
BECAUSE IT IS PAID AT THE STATE
LEVEL TO COVER THIS IN -- IF --
AND THE INCENTIVE IN LOUISIANA
PROGRAM, IS DIAGNOSE TREAT AND
MANY PEOPLE AS POSSIBLE.
BECAUSE THE DRUGS AREN'T RIGHT
NOW IT IS ESSENTIALLY BECAUSE WE
PAID FOR CERTAIN MINIMUM AMOUNT
AND ANY MORE PEOPLE WHO TREAT IT
DOESN'T COST THE STATE
GOVERNMENT ANY MORE.
THEN THERE IS ANOTHER ASPECT
WHICH IS FEDERAL LEGISLATION ON
MEDICAID WHICH IS THAT ANYONE
NCI INCARCERATED IS EXCLUDED
FROM HAVING ACCESS TO MEDICAID
THAT CAUSES TWO PROBLEMS, IT
MAKES CORRECTIONAL INSTITUTIONS
LIKE TO SCREEN PEOPLE HIV OR
HEAP C BECAUSE THEY ARE
RESPONSIBLE FOR TREATING THEM.
AND THEN THE OTHER IS THAT WHEN
PEOPLE, THEIR MEDICAID STOPS
THEY HAVE TO RESTART WHEN THEY
REENTER SOCIETY AND RELEASED
FROM CORRECTIONS AND WHEN THAT
HAPPENS IT IS HARDER TO ACCESS.
THERE ARE STATES WITH CERTAIN
PROGRAMS THAT CAN HAVE
SUSPENSION OF MEDICAID SUCH THAT
ACTUALLY STOPPING AN RESTARTS
AUTOMATICALLY WHEN THEY LEAVE
BUT THIS IS AN AREA THAT IS KIND
OF WELL KNOWN IF YOU ARE IN THAT
WORLD BUT IF NOT, IT IS NOT
FOCUSED ON.
NEXT SLIDE PLEASE.
THEN THIS IS -- WE HAD EXAMPLES
OF APPLIED ENDEMIC APPROACH A
COMPREHENSIVE SYRINGE SERVICE
PROGRAMS IN NEW MEXICO THEY
INCORPORATE NOT JUST SCREENING
FOR INFECTIOUS DISEASE BUT ALSO
TREATMENT.
T AND PARTNER SERVICES, THERE IS
A NICE PRESENTATION IN NORTH
DAKOTA WHAT THEY HAVE BEEN ABLE
TO DO IN CORRECTIONS, SAN
FRANCISCO HAD UNIFIED SCHOOL
DISTRICTS COMMUNITY PARTNERSHIPS
WITH SCHOOLS AND HEALTH
DEPARTMENTS TO PROVIDE
COMPREHENSIVE SEXUAL HEALTH
SERVICES TO ADOLESCENTS AND THEN
AS MENTIONED WE HAVE ENDEMIC
APPROACHES TO CLUSTER DETECTION
AND RESPONSE FOR OUTBREAKS.
WE ALSO HAD A SESSION ON
SELF-TESTING AND A LOT OF THE
OBSTACLES TO HIV SELF-TESTING
STEMS FROM THE FACT THAT BECAUSE
FOR HISTORICAL REASONS HIV
DIAGNOSTIC TESTS HAVE BEEN CLASS
3 DEVICES AT THE FDA.
PUT IN PERSPECTIVE MOST CLASS 3
DEVICES ARE LIKE CARDIAC STINTS.
THEY ARE NOT TESTS BUT THAT IS
BECAUSE FOR VARIETY OF REASONS
WE CAN TALK ABOUT.
FDA HAS BEEN RETHINKING FOR
DECADES ABOUT TRYING TO CHANGE
THIS BUT IT HAS BEEN A SLOW
PROCESS.
AND THOUGH THEY MODIFIED SOME OF
THE TESTS, AND ANTICIPATE
MODIFYING BECAUSE THERE IS A
FEDERAL REGISTER NOTICE ABOUT
THE ANTIVIRAL LOADS AND ALLOWING
THEM TO BE CLASS 2 DEVICES,
SELF-TESTING FOR HIV.
IS STILL CLASS 3 DEVICE.
SO THAT MEANS THAT TO GET IT
DONE TO GET IT PAST FDA APPROVED
IS FAR MORE COSTLY BOTH IN TERMS
OF KINDS OF STUDIES THAT NEED TO
BE CONDUCTED AND FEES THEMSELVES
AS PMA THAN IT IS CLASS 2
DEVICE.
SO HOPEFULLY THAT CAN CHANGE
OVER TIME.
WE HAD A PRESENTATION THAT
INCLUDED FDA TALKING ABOUT SOME
OF THE ISSUES AND THE
PERSPECTIVES THAT THEY HAVE
ABOUT THIS.
NEXT SLIDE PLEASE.
I THINK I'M DONE WITH MY
SECTION.
>> THANK YOU H. JONATHAN, I
THINK MR. JIN PARK IS NEXT.
>> HOPING YOU CAN HEAR ME.
>> WE CAN.
>> I'LL GET STARTED.
MY ASSIGNMENT WAS TO TALK ABOUT
OJ AND THE ROLE OF OJ IN PEP FAR
TO TAKE A MOMENT, WHEN I TRAVEL
ABROAD, THE QUESTION IS SO WHAT
IS OGA AND HOW DOES IT INVOLVE
ITSELF IN PEPFAR?
I THIS I THAT IS REST OF THE
PRESENTATION JUST
SET THE HIGHLIGHTS ABOUT
HETEROGENEITY AND SOME THINGS
THAT I THINK TODAY LAURA AND
JOHN HAVE IN THEIR PRESENTATIONS
ABILITY COLLABORATIONS AND
COORDINATION AS AN INTERAGENCY
BODY.
>> JUST AS A SUMMARY, PEPFAR
STANDS TORR EMERGENCY
(INAUDIBLE) LAUNCHED IN 2003 BY
GEORGE BUSH AND IT'S SOMEWHAT
UNIQUE IN THE SENSE THAT IT HAS
BEEN INTERAGENCY BODY THAT
IMPLEMENTS A PEP FAR PROGRAM
COORDINATED BY OFFICE OF AIDS
COORDINATOR AT THE STATE
DEPARTMENT AND POSITION ITSELF
AS RANK OF AMBASSADOR TO ENSURE
THERE IS COLLABORATION AT A
BILATERAL LEVEL, DIPLOMACY LEVEL
TO ENSURE THERE THERE'S GOOD
WORK AND IMPLEMENTATION PROGRAMS
ON THE GROUND.
SO NEXT SLIDE PLEASE.
I THINK THE BIG UPDATE FOR US IS
THE SQUARENING OF (INAUDIBLE)
NEW AIDS COORDINATOR AND SERVES
AS A SPECIAL REPRESENTATIVE FOR
GLOBAL HEALTH DIPLOMACY FOR THE
U.S. AND STATE DEPARTMENT.
ARRIVAL WORKER ON COORDINATOR
AND HAS DONE IMPRESSIVE JOB
ENSURING OUR PROGRAM IS ONGOING
AND AS WE WENT THROUGH THIS
TRANSITION BUT I THINK OVERALL
EXCITED.
THE FACT HE WAS SWORN IN LAST
WEEK, IS MEETING WITH FOLKS AND
GETTING A SENSE OF THE
PRIORITIES OR CONSTITUENCY AND
THINKING ABOUT WHAT IS NEXT
PHASE OF THE PLATFORM.
NEXT SLIDE PLEASE.
SO I LIKE THIS SLIDE BECAUSE IT
GIVES A SENSE OF PEPFAR, ONGOING
FOR 20 YEARS.
THERE IS ISSUE IN 2003 BUT
PRESIDENT BUSH, FOR ME T THE
TIME I SAW STATE OF THE UNION
AND NATURALLY ANNOUNCED PEP FAR
WHICH WAS GREAT AT THE TIME, $15
BILLION OVER FIVE YEARS,
INCREDIBLE HONOR SUM OF MONEY AT
THE TIME ESPECIALLY FOR GLOBAL
HEALTH AND JUST IN TERMS OF
QUESTION IS COMPARISON, I
ACTUALLY HAVE NOT WORKED ON A
PROJECT IN THE ADMINISTRATION
INITIATIVE.
$100 MILLION PREVENTION
TRANSMISSION.
SO AGAIN WE HAD A LONG HISTORY
OF PEP FAR LEADERS AN NOW
CURRENT ADMINISTRATION IS
TALKING ABOUT HOW DO WE SUPPORT
PROGRAMS (INAUDIBLE) PROGRESSION
IN EVOLUTION OF THESE PROGRAMS
AND SUCCESS THAT WE HAVE
ACHIEVED.
JUST ALONG THAT LINE I WANT TO
SHARE THAT THIS IS DATA FROM THE
WORLD AIDS DAY PEPFAR RESULTS
FROM LAST YEAR.
AS I NOTED, A LOT OF COUNTRIES
HAVE REACHED CONTROL SO 20
COUNTRIES THAT HAS ACHIEVED
ACADEMIC CONTROL HAS REACHED THE
9090 TARGETS ORGANIZED BY UN
AIDS.
IN ADDITION TO THAT IN TERMS OF
(INAUDIBLE) 1900 PEOPLE ON ARV.
COMPARED TO 17.2 MILLION
REPORTED LAST YERKES THIS IS AT
THE SAME TIME MANAGING THE COVID
RESPONSE SOP TALKS REPRESENTS
THE RESILIENCY OF THE PROGRAM ON
THE GROUND.
I THINK IN TERMS OF HOW WE GOT
(INAUDIBLE) TREATMENT, THIS
SLIDE INDICATES SO THE
COMPARISON OF OUR RESULTS
COMPARE TO THE BUDGETS, SO THE
BLUE LINE REPRESENTS THE PEPFAR
BUDGET.
SO THE PEPFAR BUDGET IS STEADY
SINCE 2009 AROUND $6 BILLION
ANNUALLY AND THAT INCLUDES THE
U.S. CONTRIBUTION TO GLOBAL
(INAUDIBLE) $2 BILLION.
I THINK THE KEY THING IS THAT
GIVEN FLAT BUDGET FOR OVER A
DECADE, INCREASE NUMBER OF
PEOPLE IN TREATMENT AS WELL AS
IN THIS CASE NUMBER OF PEOPLE
THAT RECEIVED VOLUNTARY
CIRCUMCISION IN SERVICES.
NEXT SLIDE.
SO HOW WE GET THERE?
ONE OF THE THINGS WHICH I
REALIZE THAT HAVING WORKED ON
PEPFAR A LOT OF YEARS IS THAT I
HAVE BECOME EXPERT IN IT
BASICALLY.
SO IN TERMS OF HOW WE ESTABLISH
THIS, THERE IS ACTUALLY A
PROCESS CALLED OPERATIONAL PLAN,
SO IT IS A UNIQUE IN A SENSE
THAT BRINGS IN COUNTRY PARTNERS,
COORDINATOR ACROSS THE U.S.
AGENCY, CIVIL SOCIETY,
MULTI-LEVEL STAKEHOLDERS
INCLUDING (INAUDIBLE) SIT IN A
LOOM TO TALK COUNTRY PROGRAM
WHAT COUNTRY PLATFORM IS WORKING
IN AND DOING IT IN A NATIONALLY
(INAUDIBLE) ROLE CONTRIBUTIONS
THAT ARE PART OF THIS SEASONED
GOING REALLY DEEP AND COURSE
CORRECTING AND ENSURING THE
PROGRAM (INAUDIBLE) FOR THE
EPIDEMIC CONFRONTING AT THE
TIME.
IN ADDITION TO THE PROCESS,
THERE IS A REGULAR REVIEW
PROCESS WORK -- PEPFAR
ACCOUNTABILITY REPORTING TEAM SO
USING DATA TO INFLUENCE A
PROGRAM REAL TIME IS FROM
PEPFAR.
ASSURE THIS SLIDE ACTUALLY
SHARED SIMILAR FROM HIS PROGRAMS
AND FROM THE PEP FAR PER
SPECKTIVE PERSON CENTERED
APPROACH EVIDENCE DATA
TRAVERSING GENEROUS
RESPONSIVENESS, ALL THESE THINGS
ARE KEY TO THE PEPFAR PROGRAM
THAT IS GOING TO BE IMPORTANT
FOR ANY GLOBAL HEALTH PROGRAMS
OR DOMESTIC PROGRAMS FOR THAT
MATTER IN TERMS OF PROVIDING
SERVICES TO THE PEOPLE.
SO PEP FAR IS AN INTERAGENCY
ORGANIZATION OR INTERAGENCY
PROGRAM THIS GIVES YOU SNAP SHOT
OF AGENCIES THAT ARE
PARTICIPATING IN OUR PROGRAM,
LEARNING THAT HUB IS OFFICE
COORDINATOR SATE DEPARTMENT,
(INAUDIBLE) TO COORDINATE THE
PEPFAR PROGRAM IN OUR AGENCY.
HHS PROBABLY SERVES AS THE
UMBRELLA FOR VARIOUS (INAUDIBLE)
PROGRAM BUT IN TERMS OF NATIONAL
IMPLEMENTATION AS WELL AS
(INAUDIBLE) CDC AND BRB BIGGEST
PARTICIPANTS ON THE (INAUDIBLE)
PROGRAMS.
NEXT SLIDE.
SO HOW DOES PEP FAR OR PEP FAR
ORGANIZE THEMSELVES IN THESE
PROGRAMS?
AND IT IS STRUCTURED THROUGH THE
PEPFAR PRINCIPLES SO THE KEY
PARTNERS, KEY DEPARTMENT AGENCY
PARTNERS HAS REPRESENTATIVE IN
THEIR PURCHASE PRINCIPLES
CONSISTENTLY TO MEET ON
QUARTERLY BASIS, THEY MEET ON
REGULAR BASIS TO DISCUSS POLICY
ISSUES AND PRIORITIES ON THE
PROGRAM TO ENSURE PEOPLE ARE
AWARE VARIOUS AGENCIES ARE WARE,
AT THE SAME TIME HAVING AGENCIES
CONTRIBUTE TO THE PROGRESSION
AND GOALS OF THE PEPFAR PROGRAM.
THE NEXT LEVEL, DEPUTY
PRINCIPLES MORE OF THE SENIOR
CLINICAL LEADERSHIP WITHIN THE
AGENCIES.
WE ADDRESS A LOT OF ISSUES
IMPACTING THE PEPFAR PROGRAM IN
THE NEAR TERM.
SO BASICALLY THE KEY PIECE IN
GENERAL TO ENSURE COORDINATION
AND ENSURE IMPLEMENTATION
POLICIES ARE TAKING PLACE
THROUGH THEIR PARTNERS.
IN TERMS OF THE PROGRAMMATIC
OVERSIGHT AND PROGRAMMATIC
SUPPORT PEPFAR MANAGES
(INAUDIBLE) TEAM ADDRESSES
PROGRAMMATIC GAPS THAT ARE
ENSURING THAT THE BEST EVIDENCE
IN INNER AGENCIES TO ADDRESS
THESE ISSUES REAL TIME AND ONCE
THE ISSUE IS ADDRESSED THEN
(INAUDIBLE) TO SOLVE AND
BASICALLY BACK TO
RESPONSIBILITIES.
THE ONGOING ENGAGEMENT OF INNER
AGENCY IS MANAGED THROUGH THE
(INAUDIBLE) SUPPORT ALSO KNOWN
AS CAS.
SO THESE ARE INTERAGENCY
REPRESENTATIVES THAT SUPPORT
DIRECTLY SUPPORT THE
(INAUDIBLE).
T THEY WOULD BE PART OF PROCESS
POINT PROCESS AND SOMETIMES
PROCESS TO ENSURE THE AGENCIES
ARE SUPPORTED AT -- ON THE
GROUND AND BASICALLY MAKING SURE
THAT IT IS ALIGNED WITH THE
(INAUDIBLE) AS A WHOLE.
NOW SHIFTING GEARS TO TALK ABOUT
OJ OFFICE OF GLOBAL AFFAIRS, OJ
RESIDES (INAUDIBLE) SECRETARY
PRIMARY FUNCTION TO PROVIDE
DIPLOMATIC OUTREACH, BILATERAL
PARTNERS, MULTI -LATERAL AGENCIES
TO ENSURE WE ARE ACTUALLY
PROMOTING BIG SCIENCE AND
EVIDENCE IN SUPPORT OF THE
DEPARTMENT AND OFFICE ITSELF IS
DIVIDED BETWEEN REGIONAL OFFICES
AND THEN AS WELL AS THE POLICY
PROGRAM OFFICE, PEP FAR PROGRAM
AND THESE ARE (INAUDIBLE)
PROGRAM OFFICE.
ONE OF THE THINGS THAT HAPPENED
IS AGAIN OJ PARTICIPATION IN WHO
SO THAT IS MANAGED THROUGH OUR
MULTI-LATERAL AFFAIRS OFFICE, AT
THE G 7 G 20 NOW RESIDES IN THE
NEW YORK MALAYSIA OFFICE.
RETURN TO COVID RESPONSE A LOT
OF THAT RESPONSIBILITY FALLS
UNDER THE (INAUDIBLE) HEALTH
DEPARTMENT OFFICEGA.
WE COVER A RANGE OF ACTIVITIES
IN SUPPORT OF THE DEPARTMENT.
IN TERMS OF PEP FAR I MENTIONED
BEFORE, THE GOVERNANCE STRUCTURE
IS MANAGED IN PRESENCE BILLS AND
HHS PERSPECTIVE REPRESENTED FDA
AND HIV AND OREGON SMALLER
AGENCIES BUT OTHER AGENCIES THAT
DO NOT HAVE ON THE GROUND
PRESENCE.
CKC AND HRSA HAS PRINCIPLE LEVEL
AS WELL AS U.S. PEACE CORPS BUT
IN TERMS OF OUR LEADERSHIP, WE
ENSURE THAT THE COORDINATION
ACROSS THE DEPARTMENTS IN
CENTRAL PART ARE CORE FUNCTION
AND ENSURE PEP FAR IS PART OF A
CORE COLLABORATION, SOME
EXAMPLES IN THE SLIDE BUT IN
ADDITION TO OUR SUPPORTING PEP
FAR PRINCIPLES, ASSISTANT SEC
FOR GLOBAL AFFAIRS SENDS
(INAUDIBLE) APPROVAL AS WELL SO
THE PRINCIPLE BOARD MEMBER OF
THE U.S. IS DR. (INAUDIBLE) AT
THE OFFICE OF COORDINATOR BUT WE
WORK TOGETHER IN COLLABORATION
TO ENSURE THAT THE PEP FAR
PROGRAM WORK IN HARMONY AND
NAMHC DISTINCT TRANSACTIONAL WAY
(INAUDIBLE).
THIS HIGHLIGHTS SOME OF OUR OGA
PEP FAR PRIORITIES WE ARE TRYING
TO USE TO GAIN THE BEST OF HHS
TO INFORM PROGRAMS AND POLICIES
FOR PEP FAR.
WHEN IT COMES IN APPROACH HHS,
HHS AND SPECTRUM, WE NEED TO
ENSURE SPECTRUM ADDRESSING THE
ISSUES FOR EXAMPLE, OUR
ENGAGEMENT WITH FDA MAKING SURE
THE FDA IS ON THE -- AT THE
TABLE WITH DISCUSSION AROUND
REGULATORY CAPACITY BUILDING,
WHEN (INAUDIBLE) IS TAKING
PLACE.
AGAIN ENGAGING NATIONAL
INSTITUTE OF MENTAL HEALTH, AS
WELL AS SAM TO ADDRESS MENTAL
HEALTH SERVICES PROGRAM
ASSOCIATED WITH HIV PROGRAMS.
WE HAD EXAMPLES OF -- WE SUPPORT
WITH OGA.
IN ADDITION TO ENGAGEMENT AND
BRINGING (INAUDIBLE) TO BEAR WE
SUPPORTED LEADERSHIP THAT THEY
ARE AWARE OF PRIORITIES FOR
PEPFAR OTHER POLICY ISSUES AND
ENSURING THAT ASSISTANT
SECRETARY AS WELL AS (INAUDIBLE)
IS AWARE OF OUTCOME ISSUES.
LAST THING, IF YOU CAN REFER
BACK TO OUR THINK ABOUT THE ORG
CHART HHS SERVES AS UMBRELLA FOR
THE DEPARTMENT OF -- VARIOUS
OFFICES SO PEPFAR FUNDS ARE
MANAGED THROUGH MULTIPLE
BARRIERS AND ENSURES THAT OUR
OFFICE ENSURES THE FUNDS ARE
DIRECTED TO THE APPROPRIATE --
AND MONITOR AND KNOW
ACCORDINGLY.
SO AS I WAS MENTIONING BEFORE,
OUR EXAMPLES OF SOME OF THE OGA
ROLE IN COLLABORATION, MAYBE
WORKING WITH KAY HAYES TO
ORGANIZE A BIDIRECTIONAL SESSION
NATIONAL AIDS (INAUDIBLE) TAKING
PLACE IN MONTREAL, THEY THINK
THAT JUST RECOGNIZING WHERE OGA
RESIDES, WE BRUNCH GLOBAL
DOMESTIC IN TERMS OF HEALTH, WE
SUPPORT VARIOUS OUTPUTS, IT IS A
UNIQUE PLACE TO SIT IN.
AND I THINK THAT MANY WAYS
NATURALLY LEVERAGE OUR
EXPERIENCE WITH GLOBAL AND
DOMESTIC AND DOMESTIC TO GLOBAL
AND INCLUDING A FORM FOR THESE
TO TAKE PLACE HARK ARE THE
INITIATIVES AND OGA THAT IS
SUPPORTING TO ENSURE THERE IS A
GOOD OPPORTUNITY FOR US TO
(INAUDIBLE) MAKING SURE SHARING
OUR EXPERIENCES KNOWLEDGE AND
EXPERTISE FOR VARIOUS TECHNICAL
AREAS.
(INAUDIBLE) FOR EXAMPLE, THIS
SATELLITE SESSION WE ARE GOING
TO BE -- TOPICS OF CONVERSATION
FOCUS AROUND PREP AND UMBRELLAS
SO CREATING FURTHER
COLLABORATION. I HAVE ALSO
MENTIONED THE FACT THAT WE ARE
CREATING -- TRYING TO CREATE
OPPORTUNITIES FOR PEOPLE
INSURANCE PREMIUMS ACROSS THE
BOARD WHETHER DOMESTIC AND
GLOBAL ISSUES FROM MENTAL HEALTH
AND (INAUDIBLE) CAPACITY, THOSE
ARE EXAMPLES OF WHERE WE TRY TO
ENCOURAGE PROGRAMS TO THINK
ABOUT BEYOND JUST THEIR
INDIVIDUAL PRY YOUR I IT IS AND
MAKING POWER HOLISTIC IN A
SENSE, AS COUNTRIES ACHIEVE
CONTROL THINK ABOUT LONG
(INAUDIBLE) ABILITY OF THESE
PROGRAMS.
SO I WILL STOP THERE, AND TURN
IT BACK OVER TO YOU.
>> THANK YOU.
LET'S THANK ALL THE PRESENTERS
IN THIS SESSION.
THAT WAS REALLY NICE TO SEE THE
DEGREES OF SYNERGY AND
CONNECTIVE THEMES THROUGHOUT THE
DIFFERENT TALKS.
SO I WANT TO OPEN UP NOW FOR
COMMENTS OR QUESTIONS, WE HAVE A
FEW MINUTE BEFORE THE NEXT
SESSION.
>> DR. SLEASMAN.
YOU ARE MUTED.
>> (INAUDIBLE) I JUST WANTED TO
CIRCLE BACK, GREAT PRESENTATIONS
AN CIRCLE BACK TO THE WHOLE
INTERFACE BETWEEN BAC NIH AND
BRIAN WHITE.
HISTORICAL PERSPECTIVE,
TESTIFIED BEFORE CONGRESS IN
1995 RE-AUTHORIZATION RYAN WHITE
CARIS ACT.
AND FOR -- CARES ACT.
FOR THOSE THAT DON'T KNOW WHAT
WAS HAPPENING THAT TIME, THAT
WAS PEAK OF MATERNAL TO
CHILDHOOD TRANSMISSION, ROLL OUT
IN 1994 AND WE DID NOT HAVE
ANTI-RETROVIRAL THERAPY FOR
CHILDREN.
AND HIV AIDS WAS A MAJOR CAUSE
OF DEATH IN CHILDREN
PARTICULARLY UNDERSERVED
CHILDREN.
SO THE ADVENT OF RYAN WHITE WAS
EXTREMELY IMPORTANT PROVIDING
FAMILY CARE RETROVIRALS AS WELL
AS IDENTIFYING HIV INFECTED
WOMEN THROUGHOUT THE COUNTRY.
I THINK RIGHT NOW WE HAVE
ANOTHER OPPORTUNITY.
I WANTED TO REACH OUT
PARTICULARLY TO LAURA AND SAY
ASK HER IF THAT SAMEIUS OF
RESOURCES THAT ARE WITHIN THE
RYAN WHITE CARES ACT IS BEING
FULLY IMPLEMENTED IN TERMS OF
THE PARTNERSHIP WITH NIH AND
STOPPING THE CURRENT EPIDEMIC.
AND HOW CAN WE DO BETTER.
>> I THINK OVER THE YEARS WE
LOOKED CLOSELY AT NIH AND VERY
SPECIFIC (INAUDIBLE) FUNDED
RESEARCH APPLICABLE IN REAL LIFE
CLINICAL STUDIES AND THAT
(INAUDIBLE) EXISTING THROUGHOUT
THE VARIOUS MODELS (INAUDIBLE)
CDC.
(INAUDIBLE) GETTING WORK DONE
(INAUDIBLE).
I THINK WHERE WE HAVE GONE NOW
IS REALLY EXCITING IN THE
(INAUDIBLE) PEP FAR PROGRAM AND
(INAUDIBLE) WORKING WITH HEALTH
DEPARTMENTS IN DIFFERENT PLACES.
AND JUST LIKE CDC WE ARE
(INAUDIBLE) WORK OF (INAUDIBLE)
WE HAVE HAD GOOD SUCCESS WITH
THE PEPFAR.
I THINK WE HAVE USUALLY MUCH
MORE -- NIH FOR HIV THAT WOULD
BE SPECIFIC BUT SURE -- BUT
SHORT OF THAT HAVING (INAUDIBLE)
HAS NOT BEEN -- BIG RISE IN --
IN PARTICULAR BUT (INAUDIBLE)
HAVE THE GROUP TRY TO BE MORE
PRACTICAL IN TERMS OF --
>> I WAS GOING TO SAY THERE WAS
A TIME YOU WEREN'T ALLOWED TO
SAY IMPLEMENTATION IN NIH GRANT.
I THINK THAT THAT'S BEEN A MAJOR
CHANGE, IF WE THINK ABOUT SOME
OF THE THINGS THAT JONATHAN WAS
MENTIONING LIKE POINT OF CARE,
TESTING, COMMUNITY BASED
DELIVERY, ENGAGEMENT IN OTHER
LOCATIONS, TALKED ABOUT GETTING
MORE HEALTHCARE DELIVERY INTO
TARGETED COMMUNITIES, THOSE
WOULD SEEM TO ME SOMETHING THAT
NIH SPEAKING TO MAUREEN NOW OF
COURSE.
NIH SHOULD CONSIDER LOOKING TO
THEIR EXPANDING (INAUDIBLE) --
>> (INAUDIBLE) HIV -- BARRIERS
TO (INAUDIBLE) HOW TO DO THAT
BETTER I DON'T KNOW IF THAT IS
NIH TACKLING (INAUDIBLE) FROM
OTHERS BUT I THINK NIMH
(INAUDIBLE) CARE AND HOW TO
ADDRESS THEM HOW TO ENGAGE WITH
PEOPLE WHO MIGHT HAVE AVOIDANCE
COPING MECHANISMS (INAUDIBLE)
THERE IS THIS KIND OF SPECIFIC
AREAS WHERE (INAUDIBLE)
>> DR. BRANDEAU.
>> I HAVE A QUESTION FOR DR.
MERMIN.
THANK YOU FOR THE INTERESTING
PRESENTATION.
SO U YOU TALKED ABOUT THE FOCUS
ON ENDEMICS WHICH EVERYONE
REALIZES IS SO IMPORTANT BECAUSE
NOBODY HAS ONE HEALTH CONDITION
IN THE SILO.
MY QUESTION YOU DIDN'T MENTION
IT AND I'M WONDERING THE EXTENT
TO WHICH YOU VIEW DRUG USE
DISORDER AND OPIOID ADDICTION AS
ANOTHER ENDEMIC DISEASE.
>> I INCLUDED IT.
I MUST HAVE MISSED IT.
>> BUT WE -- IT IS ACTUALLY --
IT IS THE MOST COMMONLY
DISCUSSED CONDITION BUT RECENTLY
STARTED TO WONDER WHETHER EVEN
THAT TERMINOLOGY, THERE -- IT
MAY BE THAT POOR MENTAL HEALTH
OR SOME OTHER TERM MENTAL
UNHEALTH, WHATEVER IT IS
SUBSTANCE USE BECOME A CONDITION
IN AN ENVIRONMENT THAT
INTERSECTS IN THE SAME WAY AND
YOU CAN THEN START THINKING
ABOUT OTHER THINGS LIKE POVERTY.
OR THESE OTHER RACISM, ITSELF IS
A ENDEMIC OR EPIDEMIC -- NOT
SURE ABOUT TERMINOLOGY,
SOMETIMES WE ARE IN THE WAKE OF
CHANGING TERMINOLOGY IN THE REST
OF SOCIETY AND WE FOLLOW ALONG
AND SOMETIMES WE CAN THINK
CREATIVELY IN ADVANCE AND CHANGE
THE LANGUAGE ITSELF.
NOT SURE WHERE WE ARE WITH THIS
BUT I SUPPORT YOUR POINT.
T IF WE ONLY THINK FROM A
DISEASE INFECTIOUS DISEASE
STANDPOINT WE ARE GOING TO MISS
SOME OF THE REALLY IMPORTANT
CONDITIONS EPIDEMICS INFLUENCING
AND WE WON'T COME UP WITH
SOLUTIONS.
>> I TOTALLY AGREE YOU ABOUT
BROADER SOCIAL PROBLEMS, THAT IS
THE HIGHLIGHT OF WHAT WE SAID
TODAY.
YOU HAVE PROBABLY SEEN IT BETTER
RECENT REPORT OF LANSETT OPIOID
COMMISSION, WE TALK ABOUT
ENVIRONMENTAL FACTOR AND IT IS
ON POINT WITH EVERYTHING YOU
SAID NOW.
THANK YOU.
>> THAT WAS A GREAT SUPPORT.
THANKS FOR THE TIME.
IF IT IS OKAY JOHN IF I CAN ALSO
-- SUSAN, I THINK THAT IT IS
REALLY INTERESTING, THERE IS
PERFECTION IN ORGANIZATIONAL
STRUCTURES AND DICHOTEMIZING
WORK CAN CREATE PROBLEMS SO WILL
IS A -- IF YOU TAKE THE HIV
WORLD, I THINK IN TERMS OF WHERE
IS THE RESEARCH?
WELL, NIH TENDS TOWARDS BASIC
APPLIED RESEARCH WITH SOME
IMPLEMENTATION RESEARCH.
LAURA IS TALKING ABOUT HOW HRSA
AT LEAST THE RYAN WHITE PROGRAM
FOCUSES ON CREATIVE PROGRAMS
EVALUATING THE PROGRAMS,
THINKING ABOUT HOW WE CAN LEARN
FROM THAT AND DOING BETTER.
SO ESSENTIALLY IMPLEMENTATION
SCIENCE.
AND PROGRAM -- EVIDENCE BASED
PROGRAM IMPLEMENTATION.
CDC WHAT WE SEE IS WE CAN CROSS
-- WE DON'T TEND TO DO BASIC
STUFF, THOUGH MAYBE IN
DIAGNOSTICS WE DO THAT BUT
MOSTLY WE DO APPLIED RESEARCH UP
UNTIL IMPLEMENTATION AN PROGRAM
EVALUATION.
AND I THINK IT IS OUR DIFFERENT
PERSPECTIVES OF WHAT WE ARE
DOING AS LONG AS WE SHARE IDEAS,
WE SAY HEY SOMEONE ELSE YOU CAN
DO BETTER THAN IF YOU ARE SAYING
NO, THE ONLY THING NIH SHOULD BE
DOING IS BASIC SCIENCE, ANYTHING
ELSE NO, CDC SHOULDN'T BE DOING
THIS, SOMETIMES HAS MORE MONEY
OR CREATIVE LABORATORY OR STAFF,
BUT IT IS ALSO WHERE THE
QUESTIONS COMING FROM SO WE SEE
THIS CONTINUUM BETWEEN IF YOU
FAULK TO THE PEOPLE WHO ARE OUT
THERE, EXPERIENCING THE
OBSTACLES, WHETHER PROVIDERS OR
CLIENTS, THEY WILL TELL YOU THE
PROBLEMS AND YOU CAN DESIGN
STUDIES THAT ENUP AND CONDUCT
RESEARCH THAT WILL ANSWER SOME
OF THOSE PROBLEMS AND YOU CHANGE
THAT WITH GUIDELINES AND
PROGRAMS, AND THEN THAT CYCLE
CONTINUES.
I THINK THAT IS HOW WE DEAL WITH
A LOT OF THE EQUITY ISSUES,
BECAUSE IF YOU JUST -- IF YOU
ARE NOT LISTENING TO PEOPLE YOU
WILL MAKE MISTAKES.
BUT IT ALSO ALLOWS US TO TO BE
MORE EFFECTIVE AS COLLABORATING
GROUPS SO WE ARE BETTER THAN
WHEN YOU DESCRIBE THE SITUATION
OR CALL TO CONGRESS TO TRY TO --
BUT I ACTUALLY THINK THAT IT IS
-- BUT IT HAS TO CONTINUE, HAS
TO CONTINUE AND SOMETIMES IT
ALWAYS COMES UP, SOMEONE SAYING
WHY IS THIS AGENCY DOING THAT?
AND YOU FEEL LIKE SAYING WHY ONE
SPOUSE DOING THE DISHES AND THE
OTHER COOKING?
THAT IS WHAT WORKED FOR OUR
FAMILY AND WE ARE GETTING THE
JOB DONE P AND THERE'S SOMETHING
ABOUT THAT HERE TOO.
>> I THINK IT IS IMPORTANT TO
POINT OUT COMMUNITY ENGAGEMENT
HAS TO BE BIDIRECTIONAL.
THAT IS SOMETHING HELLS
PARTICULARLY C FAR COMMUNITY
ADVISORY BOARD, BECOMING MORE
AND MORE BIDIRECTIONAL.
WE HAVE TO KEEP THAT IN MINE AS
WELL.
>> MAUREEN.
>> I WANTED TO JUMP IN QUICKLY
ABOUT TRANSITIONS IN ACTIVITIES
AND YOU THINK EARLY ON -- THIS
IS FROM THE NIH POINT OF VIEW,
BASIC RESEARCH IS REALLY
IMPORTANT GETTING THE INITIAL
WORK DONE IN THE HIV FIELD AND
AS THE PRODUCTS DRUGS AND
DIAGNOSISSICS WERE DEVELOPED IT
WAS FOUND NUMBER ONE THAT IT WAS
HARD TO GET APPROVED BECAUSE
THERE WERE NO CLINICAL TRIAL
NETWORKS WITHIN THE NIH AT THAT
TIME WHEN PHARMA WASN'T
INTERESTED, ALONG THE WAY THIS
CATALYZED A LOT OF DEVELOPMENT
OF THE CLINICAL TRIAL NETWORKS
WITHIN THE NIH.
BOTH HIV AND LOT OF OTHER
CONDITIONS AS WELL.
WHAT IS TURNED OUT PARTICULARLY
WITH AS OTHER USES IMPROVEMENTS
MANY THE CARE AND TYPES OF
PRODUCTS THERE IS NOW AN
UNDERSTANDING THAT WE NEED TO
FOCUS ON HAVING PEOPLE
UNDERSTAND WHAT THESE ARE AND BE
WILLING TO SEE TO UNDERSTAND THE
BENEFITS THAT WOULD MAKE THEM
WILLING TO BE UPTAKE THESE
ADVANCES.
SO THE IMPLEMENTATION SCIENCE
PIECE FOR THE HIV PROGRAM IS --
HAS DEVELOPED ALONG THIS PATHWAY
IF YOU WILL, BUT THERE IS A LOT
OF IMPLEMENTATION SCIENCE
RESEARCH AT THE NIH IN OTHER
AREAS, CANCER IS A BIG ONE,
NATIONAL INSTITUTE OF MENTAL
HEALTH BOTH OUTSIDE AND WITHIN
THEIR NIH PROGRAM REALLY HAVE
BEEN LEADERS AND CONTINUE TO BE
LEADERS BUT THEN IT IS AGAIN
DIFFERENT PATCHES OR DIFFERENT
AREAS OF EXPERTISE ACROSS THE
NIH AND SO WHAT WE ARE DOING NOW
IS REALLY BUILDING UP THE
CAPACITY AND APPLYING WHAT IS
KNOWN ABOUT IMPLEMENTATION
SCIENCE RESEARCH AND WHAT WORKED
IN OTHER AREAS, TO THE HIV FIELD
AS WE FIND OUT.
OUT WHERE GAPS ARE
AND PROVIDE THOSE RESULTS AND
THAT OUTCOME -- THOSE OUTCOMES
FROM RESEARCH FOR THE PARTNERS
THAT YOU HEARD ABOUT TODAY WHO
ARE ON THE GROUND.
TAKING ADVANTAGE OF THIS AND
HELPING UNDERSTAND WHAT IT IS
DIFFERENT COMMUNITIES AND
DIFFERENT NEEDS DIFFERENT AREAS.
KAY SAID THIS, IT IS NOT ONE
SIZE PITTS ALL, YOU HAVE TO
FIGURE HOW TO DO THIS IN
DIFFERENT COMMUNITIES BUT THE
WORK GOING ON IN THESE
COMMUNITY, AT OTHER PARTS OF THE
NIH WE CAN CERTAINLY LEVERAGE
THAT FOR THE HIV -- LEVERAGE
THAT FOR THE HIV FIELD.
>> THANK YOU, MAUREEN.
KAY.
>> I WANTED TO CHIME IN AND TALK
ABOUT THE NIH AND HOW INCREDIBLY
HELPFUL MAUREEN WAS WHEN WE TALK
ABOUT STIGMA.
AND THE RESEARCH THAT NIH REALLY
HELPED US WE START TALKING ABOUT
STIGMA, STIGMA IT IS
A TOUCH ISSUES IN COMMUNITIES
BUT SO CRITICAL MANY THE PIECE
OF WORK THAT WE DO AND ALSO
WANTED TO CHIME IN BECAUSE WE DO
INCORPORATE THE OPIOID CRISIS IN
THE WORK FROM THIS ENDEMIC
APPROACH BUT WE ARE TALKING ALSO
HOUSING MENTAL HEALTH, IT IS NOT
JUST -- UNFORTUNATELY THERE'S
LOTS OF ISSUES THAT IMPACT THE
OUTCOMES OF THE WORK WE DO SO
DEFINITELY LOOKING AT ENDEMIC OR
HOLISTIC APPROACH IN THE WORK
THAT WE DO BECAUSE THERE'S SO
MANY FACTORS THAT ARE IMPACTED.
>> THANK YOU, KAY.
JIN.
>> I WANT TO REFLECT ON IN TERMS
OF (INAUDIBLE) HAVING THIS SPACE
TO LEARN, I THINK MANY WAYS TO
BE LOCAL OR GLOBAL.
WE NEED TO MAKE SURE WE ARE
THERE IS HAVING WORKED UNDER DR.
CHEEVER, LAURA, AT HRSA THERE
WAS SO MUCH THAT WENT FROM
DOMESTIC TO GLOBAL, LEVEL OF
MATURITY IN THE PROGRAM, WE HAVE
MANY LESSONS TO BE LEARNED FROM
THE GLOBAL SECTOR TO DOMESTIC
AND THE SHARED UNDERSTAND,
SHARED INFORMATION ACROSS THE
BOARD P. BASICALLY EXPANDING
COMMUNITY BASE
>> SO WE'LL TAKE ONE MORE
COMMENT FROM JONATHAN.
BEFORE YOU COMMENT I HAD A QUICK
QUESTION I WANT TO TRY AND SLIDE
INTO YOU.
WITH YOUR ENDEMIC APPROACH WITH
HOLISTIC STRATEGY YOU DESCRIBE
EARLIER, IS THERE ONE COMPONENT
THAT YOU FIND MORE EFFECTIVE
TELEHEALTH VERSUS TESTING AT
HOME, CAN YOU COMMENT ON THAT
AND PLEASE SHARE YOUR COMMENT OR
QUESTION.
>> I THINK WE KNOW FOR CERTAIN
SPECIFIC MORE SMALLER SCALE
PROBLEMS WHAT MIGHT BE BETTER,
LIKE MULTI -INFECTIOUS SCREENING
THROUGH STANDING ORDER.
THAT WORKS.
THEN THERE IS A LARGER SCALE
ABOUT DON'T FORGET POLICIES, AND
YOU CAN DO PILOT PROGRAMS NEVER
-- OR CHANGE THE LAW IN YOUR
STATE OR NATION.
THAT STUFF APPLIES BUT THERE IS
ALSO A LOT WE DON'T KNOW.
AND THERE'S CERTAINLY SOME
RESEARCH THAT CAN BE CONDUCTED
TONS OF RESEARCH, LOOKING AT
WHAT CHANGES WHERE WE HAVE DATA
OR PROSPECTIVELY DESIGNING
STUDIES THAT ARE MULTI-LEVEL
MODELING THAT ENABLE US TO LEARN
QUICKLY.
I TAKE THAT AS A CHALLENGE
BECAUSE I CAN'T ANSWER.
BUT I ALSO -- I WANT TO SAY
THINKING RESEARCH I ALSO I FEEL
LIKE JUST AS RYAN WHITE IS
PRACTICALLY IMPROVING EQUITY BY
THINKING ABOUT A LOT OF THESE
ISSUES AND PLEA AGREEMENTINGS
PROGRAMS EFFECTIVELY, I THINK
RESEARCH ALSO CAN BE A TOOL FOR
EQUITY.
IF WE KNOW ABOUT THE PROBLEMS
THAT ARE BEING CREATED THAT
PREVENT PEOPLE FROM LEADING THE
HEALTHIEST LIFE THEY CAN OR
GETTING HIV, YOU CAN DO DEVELOP
NEW TECHNOLOGIES OR CONDUCT
STUDIES GOING TO MAKE IT EASIER
TO OVERCOME THAT TRADITION.
SOME EXAMPLES ANTI-RETROVIRAL
THERAPY ITSELF, ONCE A DAY ART.
PREP, IF PREP DIDN'T EXIST IT
WAS MOUSE ONCE A DAY PILL FOR
PREP, INJECTABLE PREP, PROBABLY
NICHE MARKET SOME WAYS THERE'S
CERTAINLY PEOPLE WHO REQUEST
THAT, EASIER FOR THEM TO HEAR
AND IMPLANT LONG ACTING AGENTS,
ARE THEIR SCIENCE TIGHT MUST
MOSTIC SUIT TALKED ABOUT BUT
THEY WILL OVERCOME BARRIERS THAT
ALLOW US TOP REDUCE DISPARITIES
THAT WE ARE SEEING IN HIV AND
OTHER INFECTIONS THAT IS HOW WE
ARE THINKING SOME OF THE
SELF-TESTING TOO.
YOU CAN BRING TESTING TO PEOPLE,
EASILY THAN REDUCE OBSTACLES,
THEY WILL GET TESTED MORE.
>> ALL RIGHT.
SO WE WILL MOVE ON.
I WANT TO THANK ALL THE SPEAKERS
AGAIN, IN THE LAST SESSION.
THIS HAS BEEN A RICH DISCUSSION.
SO WE WILL MOVE AHEAD WITH THE
AGENDA.
OUR NEXT SESSION WILL HAVE
UPDATES FROM THE HIV CLINICAL
GUIDELINES WORKING GROUP, THESE
INCLUDE GUIDELINES AND PANEL
UPDATES SO WE HAVE TWO
PRESENTERS, DR. HENRY MASUR AND
DR. ROHAN HAZRA.
DR. MASUR IS CHIEF OF THE
CRITICAL CARE MEDICINE
DEPARTMENT OF THE CLINICAL
CENTER ANOTHER NIH, MASUR WELL
KNOWN FOR MANAGEMENT AND
EXPERTISE THIS HIV AND CO-MORE
BITTIES AND EXPERTISE IN I
CRACKU RELATED INFECTION.
-- ICU INFECTIONS.
TRAUMA SURDR. MASUR, OVER TO YO.
>> EACH OF THE INFECTION GUIDE
PIPELINES ARE VERY MUCH USED --
GUIDELINES ARE USED AS I WILL
SHOW YOU THE DATA AND WE MAKE A
REAL EFFORT TO KEEP THEM CURRENT
AND KEEP THEM GUIDELINE FOCUSED
RATHER THAN -- SO WHAT I WILL
SHOW YOU IN FIVE SLIDES IS JUST
HOW MUCH THEY ARE USED AND WHAT
CHANGES WE MADE OVER THE LAST
YEAR.
SHOW THE NEXT SLIDE.
THIS SHOWS USAGE OVER THE LAST
CALENDAR YEAR, FOR THE
GUIDELINES,YOU MAY SEE THIS
AGAIN FROM ROHAN BUT THIS WAS --
YOU CAN LOOK DOWNLOADS, LOOK AT
VARIETY OF ISSUES BUT GETTING
400,000 PAGE VIEWS WE THINK IS
EVIDENCE THESE ARE WIDELY USED,
WE HAVE DATA ABOUT WHAT THE
GLOBAL DISTRIBUTION LARGELY U.S.
NOT EXCLUSIVELY AND WHILE THE
ANNUAL RETROVIRAL GUIDELINES GET
PRIZE FOR MOST USE, THE OTHER
GUIDELINE NIH DOES COVID
GUIDELINE IS IN THE TENS OF
MILLIONS.
WE THINK THIS STILL SHOWS THERE
IS A NEED FOR THIS EVEN THOUGH
TEXT BOOKS EXIST ONLINE
RESOURCES UP TO DATE, PEOPLE
REFER TO THESE GUIDELINES.
THIS SHOWS THE USE OF THE
GUIDELINES OVER LAST FIVE YEARS.
YOU CAN SEE THE NUMBERS ARE
RELATIVELY FLAT.
AGAIN, WE THINK THERE IS STILL
NEED FOR THESE NIH STILL HAS
REPUTATION FOR PRODUCING USEFUL
BUT UNBIASED GUIDELINES WE ARE
CONSTANTLY ASKING WHETHER OR NOT
TO SUNSET THESE.
AT THIS POINT WE THINK THAT WE
SHOULD CONTINUE AND WOULD BE
INTERESTED IN YOUR FEEDBACK ON
THAT.
NEXT SLIDE.
IF YOU LOOK AT THE PAGES THAT
ARE LOOKED AT, IT IS INTERESTING
THAT FOCUS IS REALLY ON THE SAME
INFECTIONS FOCUS ON THE LAST 30
YEARS.
THOUGH LESS PNEUMOSISTIS AND
MYCOBACTERIUM AND THERE BEING
SEEN IN TERMS OF CASES IN THE
UNITED STATES, MIGHT EMPHASIZE
FOR THOSE WHO ARE NEW, OUR
GUIDELINES ARE FOCUS ON THE
UNITED STATES, WERE ARE NOT
CONSTITUTED IN TERMS OF MEMBERS
NOR WE THINK WE HAVE ANY REAL
AUTHORITY TO PERUSE GUIDELINES
TO THE WORLD, WE DON'T WANT TO
COMPETE WITH WHO SO THESE ARE
SUPPOSED TO BE FOCUSED ON THE
UNITED STATES, EVEN THOUGH AGAIN
THEY ARE LOOKED AT OUTSIDE SO
YOU CAN SEE COMMON AIDS RELATED
OPPORTUNITY INFECTIONS, ARE MOST
COMMONLY USED.
AND EVEN FOR SOME OF THE ONES
BOTTOM OF THE LIST THAT ARE NOT
LOOKED AT AZON, THESE ARE
IMPORTANT BECAUSE FOR SOME OF
THESE WHETHER YOU TAKE SOMETHING
OBSCURE LIKE (INDISCERNIBLE)
WHEN CLINICIANS SEE ONE OF THESE
UNUSUAL CASES THEY REALLY NEED A
PLACE TO LOOK FOR QUICK GUIDANCE
ON WHAT TO DO.
WE THINK IN SOME WAYS THEY ARE
JUST AS IMPORTANT AS THE MORE
COMMONLY USED OPPORTUNITIES BASE
SO AGAIN WE TRY TO MAKE SURE
THESE SECTIONS ARE BEING USED.
PART OF THE GUIDELINE IS TO
ALERT READERS AS TO WHAT IS NEW.
ALERT YOU AS TO WHAT IS NEW.
WE HAVE A PROCESS WHERE EVERY
THREE MONTHS WITH WE MEET WITH
SUBJECT GROUP LEAVES AND SMALL
COMMITTEE OF CONTENT EXPERTS AND
EACH QUARTER WE ASK WHETHER OR
NOT ANYTHING NEEDS TO BE
REVIEWED.
NEEDS TO BE UPDATED.
IF THERE IS WE GO OVER WHAT THE
SCHEDULE IS AND MAKE EFFORTS TO
TRY TO GET THAT UPDATED AS
RAPIDLY AS FEASIBLE GIVEN THE
FACT THESE ARE VOLUNTEER,
ESPECIALLY DURING THE COVID ERA
WHO ARE VERY BUSY.
BUT WE MOVE THIS ALONG AND WE
MAKE SURE THAT THESE ARE
ACCEPTABLE TO OUR CO-CHAIRS WHO
REPRESENT IN OUR CASE NIH IGSA
FISMA AND CDC.
IN TERMS OF ENTERIC INFECTION
THIS AREA WE UPDATED WHAT WE SAY
ABOUT C DIFFICILE WHICH IS NOT
AN INFECTION BUT COMMON IN THE
DIFFERENTIAL AND AMONG PATIENTS
WITH HIV WE DO HAVE A SECTION
THAT WE JUST MADE THAT
COMPATIBLE WITH THE OTHER IGSP
RECOMMENDATIONS WITH NEWER
DRUGS.
WE ARE BACK TO UPDATE HEPATITIS
B SECTION AND IMMUNIZATION
SECTION.
THERE IS LOT OF WHAT IS OPTIMAL
RATES RENEWS AN COMMITTEE
DECIDES THOUGH ACIP AND CDC
DON'T NECESSARILY SEE IT EXACTLY
THE SAME WAY, THAT THE OUR
GUIDELINE RECOMMEND, THE DOUBLE
DOSE PRE-DOSE REGIMEN, WE TALK
EXTENSIVELY WITH THE CDC AND
WHERE WE DISAGREE WITH CDC OR
ACIP WE AGREE WE WILL LET
CONTENT EXPERTS LOOK AT IT,
COMMENT ON IT AND THEN JUST IN A
COLLEGIAL WAY RECOGNIZE THAT
THERE IS A DIFFERENCE OF
OPINION.
BUT THIS IS OUR OPINION.
THEY HAVE THEIR OPINION.
OBVIOUSLY EVERYBODY IS LOOKING
AT THE SAME DATA AS A MATTER OF
FACT OF HOW YOU INTERPRET THAT
DATA.
IN THE IMMUNIZATION SECTION IN
ADDITION TO REITERATING WHAT WE
SAY ABOUT HEPATIZETIS B AS YOU
KNOW THERE'S NEWER
RECOMMENDATIONS ON PNEUMOCOCCAL
VACCINE, PARTICULARLY 15 AND 20
SO WE UPDATED THAT TO ALIGN WITH
CDC AND ACIP SO NOTHING IS
DIFFERENT FROM WHAT WE DO AND
WHAT CDC OR ACIP.
WE CAN SKIP THIS.
IN THE NEAR FUTURE IMMUNIZATION
WILL BE UPDATED AGAIN, HEPATITIS
B PNEUMOCOCCUS ARE MAJOR
CHANGES, I MENTIONED HEPATITIS B
MY MOANIA, THAT OVERLAPS WITH
PNEUMOCOCCAL IMMUNIZATION SO
THAT IS GOING TO BE UPDATED TO
BE HARMONIZED WITH THE
IMMUNIZATION SECTION.
THERE IS DATA ABOUT THE SPECTRUM
OF PATHOGENS AND SUSCEPTIBILITY
AND RECOMMENDED DRUGS.
THESE AGAIN ARE GOING TO BE
HARMONIZED WITH OTHER UPDATES TO
OTHER IGSA AND COMMUNITY
ACQUIRED GUIDELINES.
THEN A VARY SELL LA, NEW
INFORMATION INCLUDING AGE RAGE
FOR VA VERISELLA.
WITH THAT I WILL TURN IT TO
ROHAN AND THEN ANSWER QUESTIONS.
>> WE WILL HAVE A BRIEF CHANGE
IN THE AGENDA, WE WILL COME BACK
TO DR. HAZRA.
RIGHT NOW I WANT TO INTRODUCE
DR. LIGHTFOOT AND ALLOW HER
UPDATE.
SO DR. LIGHTFOOT SERVES AS
ASSOCIATE DEAN FOR OREGON HEALTH
AND SCIENCE UNIVERSITY PORTLAND
STATE UNIVERSITY SCHOOL OF
PUBLIC HEALTH.
HER COMMUNITY ENGAGE RESEARCH
FOCUSES ON IMPROVING THE HEALTH
AND WELL BEING OF ADOLESCENTS
AND YOUNG ADULTS.
AS WELL AS THE DEVELOPMENT OF
CULTURALLY COMPETENT EFFICACIOUS
ENTERMITT TENSE TO REDUCE
ACQUISITION TRANSMISSION OF HIV
AMONG POPULATIONS
DISPROPORTIONATELY BURDENED BY
THE EPIDEMIC.
SO THANK YOU WE WILL HEAR FROM
YOU NOW.
>> THANK YOU, DR. TOLBERT.
APPRECIATE THE FLEXIBILITY YOU
ARE HAVING TODAY.
APOLOGIES NOT ABLE TO JOIN THE
WHOLE MEETING TODAY.
I APPRECIATE PROVIDING THIS
UPDATE EARLIER ON THE AGENDA.
NEXT SLIDE PLEASE.
TO GIVE YOU ALL A LITTLE BIT OF
UPDATE ON WHAT IS GOING ON WITH
NIMH, THIS FIRST SLIDE BASICALLY
GOES OVER DIRECTORS UPDATE.
SO HIGHLIGHTS THAT I WANTED TO
BRING TO YOUR ATTENTION UNDER
THE UNITY AGENDA, THE
PRESIDENT'S BUDGET REQUEST, AS
Y'ALL KNOW THE PRESIDENT
ANNOUNCED BIPARTISAN STRATEGY TO
RESPOND TO THE NATIONAL MENTAL
HEALTH AND SUBSTANCE USE
DISORDER CRISIS AS PART OF ITS
UNITY AGENDA, AS PART OF THAT,
THE PRESIDENT'S BUDGET REQUEST
FOR NIMH FOR FY 23 INCLUDES $5
MILLION IN RESEARCH FOR
INNOVATIVE TREATMENT MODELS AND
$5 MILLION TOWARDS ADVANCING
RESEARCH ON SOCIAL MEDIA.
IMPACTS.
IN TERMS OF CONGRESSIONAL
INTERACTIONS NIMH HAD WITH
CONGRESS, COUPLE OF TO BRING TO
YOUR ATTENTION, THE DIRECTOR
TESTIFIED BEFORE THE SENATE
COMMITTEE ON HEALTH EDUCATION
LABOR INTENTION -- AND PENSIONS
THE HEARING WAS ON STRENGTHENING
FEDERAL MENTAL HEALTH AND
SUBSTANCE USE DISORDER PROGRAMS,
ALSO TESTIFIED BEFORE THE SENATE
APPROPRIATION SUBCOMMITTEE ON
LABOR HEALTH AND HUMAN SERVICES
EDUCATION RELATED AGENCIES.
ON THE PROPOSED FY 2023 BUDGET
FOR NIH.
IN TERMS OF EXPANDING THE WHITE
HOUSE OFFICE OR ENGAGING WITH
THE WHITE HOUSE OFFICE OF
SCIENCE AND TECHNOLOGY POLICY,
NIMH PARTICIPATED IN A VIRTUAL
FIRE SIDE CHAT WITH THE WHITE
HOUSE OSTP TO DISCUSS ADOLESCENT
BRAIN DEVELOPMENT IMPACTS OF
STRESS, THE COVID-19 PANDEMIC
AND SOCIAL MEDIA.
LOOKING AGENT THAT FROM THE
PERSPECTIVE OF YOUNG PEOPLE.
AS YOU MAY KNOW, THE OMNIBUS
SPENDING PACKAGE 1.5 TRILLION
PACKAGE PROVIDED NIH WITH $45
BILLION BUT ALSO NIMH WITH
$2.2 BILLION.
ONE IS ALSO YOU WILL KNOW HHS IS
CURRENTLY ON THIS NATIONAL TOUR
TO STRENGTHEN HEALTH MENTAL
HEALTH.
SO THAT WAS ANNOUNCED AND WILL
BE FOCUSING ON THE WORK OF NIH
THINKING NATIONAL STRATEGIES FOR
STRENGTHENING MENTAL HEALTH IN
OUR COUNTRY.
IN TERMS OF NIMH STRATEGIC PLAN,
THERE WAS UPDATE TO THE
STRATEGIC PLAN IN 2021.
SOME OF THOSE CHANGES INCLUDED
EXPANDING INFORMATION ON
DIVERSITY EQUITY INCLUSION
ACCESS EFFORTS.
OTHER CHANGES INCLUDED LINKING
THE PLAN TO NIMH MORE CLEARLY
LINKING THE PLAN TO NIMH
APPROACH TO MENTAL HEALTH
DISPARITIES RESEARCH AND
INCLUDED INFO ON THE NEW NIH
CLIMATE CHANGE AND HEALTH
INITIATIVE.
AS WELL AS TWO NEW INTEREST
AREAS FOCUSING ON ECONOMIC
FACTORS.
AS PARTS OF THAT PLANNING AND
UPDATING PROCESS, THEY ALSO
RELEASED THE 2021 STRATEGIC PLAN
PROGRESS REPORT.
LASTLY THE DIRECTOR TALKED ABOUT
WHAT NIMH IS DOING IN TERMS OF
ALIGNING WITH NIH RACIAL ETHNIC
EQUITY PLAN.
AS YOU MAY KNOW THAT RACIAL --
NIH PLAN HAS THREE GOALS, THE
FIRST GOAL IS AROUND APPLYING
THE RACIAL ETHNIC EQUITY LENS
FRAMEWORK TO THE IC WORK FORCE
STRUCTURES AND SYSTEMS NIMH,
THIS GOAL FOCUSING ON LEVERAGING
EXISTING DATA TO IMPROVE NEW
INITIATIVES AND SUPPORT SYSTEMS.
THE SECOND GOAL OF THE NIH
RACIAL EQUITY PLAN IDENTIFY
DISMANTLE RACIAL ETHNIC
DISPARITIES IN THE IC WORK FORCE
NIMH FOCUSES ON USING STAFF
FEEDBACK TO ADDRESS RACIAL
DISPARITIES RELATED TO
LEADERSHIP TRUST REPRIZALS AND
ANTI-HARASSMENT.
THE THIRD GOAL OF THE NIH PLAN
ENHANCING DIVERSITY OF WORK
FORCE, NIMH GOAL IS IMPROVING
RETENTION AND RECRUITMENT
PROCESSES SO BEGINNING TO LAY
OUT TACTICS AND STRATEGIES TO
MITOSOME OF THOSE GOALS.
NIMH HAS DIVISION OF AIDS
RESEARCH AS YOU KNOW ABOUT THE
NIH STRATEGY OR NATIONAL HIV
STRATEGY HIV EPIDEMIC
INITIATIVES GOALS AROUND
REDUCING TRANSMISSION BY 75% BY
2025 AND BY 90% IN 2030, THE
DIVISION OF NIMH DIVISION OF
OFFICE RESEARCH HAS BEEN
THINKING ABOUT STRATEGIC PLAN IN
ORDER TO BE CONSISTENT WITH BOTH
ALIGNING WITH THE STRATEGY AS
WELL AS ALIGNING WITH NIH
STRATEGIC PLAN AND SO IN THAT
NIMH STRATEGIC PLAN FOCUSING ON
PREVENTION, AROUND BEHAVIORAL
BIOMEDICAL INTERVENTION,
FOCUSING ON TREATMENT, ABOUT
IMPROVING HEALTH OUTCOMES AND
PREVENTING FURTHER TRANSMISSION.
AND THE INTERVENTION TARGETS
THAT THEY ARE HIGHLIGHTING OR
INDIVIDUAL COMMUNITY STRUCTURAL
LEVEL AS WELL AS KEY POPULATIONS
AT HIGH RISK.
ALSO FOCUS ON IMPLEMENTATION
SCIENCE, ABOUT BRINGING
EFFECTIVE INTERVENTION TO SCALE
MORE BROADLY.
THEY WILL BE FOCUSING ON NIMH
NEURAL HIV SO THE IMPACT OF HIV
ON PATHOLOGY AND FUNCTION
BIORESERVOIRS AS WELL AS CURE
RESEARCH.
NEXT SLIDE PLEASE.
GIVEN THE IMPACT OF HIV ON SOME
POPULATIONS NIMH BEGINNING TO
LOOK AT WHAT KEY POPULATIONS
THEY ARE WANTING TO FOCUS ON AS
I MENTIONED EARLIER, ONE OF
THOSE POPULATIONS IS TRANSGENDER
POPULATIONS IN PARTICULAR.
OF PROBABLY PRODONE NEED TO
PROVIDE Y'ALL WITH THE RATIONALE
FOR DOING THAT.
IN TERMS OF NUMBERS OF FOLKS IN
TRANSGENDER POPULATION IMPACTED
BY HIV SO THIS SLIDE GIVES YOU A
LITTLE SUMMARY OF SOME OF THE
THINGS DIVISION OF AIDS RESEARCH
IS DOING TO FOCUS ON THIS
POPULATION AND THEIR RESEARCH
THEY ARE FUNDING.
SO IT WILL INCLUDE THINGS LIKE
MOBILE TECHNOLOGY, LOOK AT PEER
NAVIGATION AS WAY OF REACHING
COMMUNITIES, AS WELL AS A LOT OF
WORK AROUND HIV AND TRANSGENDER
POPULATION FOCUSED ON
TRANSGENDER WOMEN, SO BRINGING
ATTENTION TO TRANSGENDER MEN AS
WELL.
AND FUNDED STUDIES AROUND PREP
DELIVERY TO TRANSGENDER
POPULATIONS.
LASTLY I WANT TO SHARE WITH
Y'ALL RECENT RFAs REVIEWED BY
NIMH SO THEY JUST FINISHED
REVIEWING AN RFA AROUND
EXPANDING DIFFERENTIATED CARE
APPROACHES FOR AS LENT SENTS
LIVING WITH HIV THAT WAS A
ROBUST APPLICANT POOL RESPONDING
TO THAT.
SO THAT IS A DECISION MAKING
PROCESS NOW.
THE SECOND RFA THAT DIVISION OF
AIDS RESEARCH NIMH RELEASED AND
FINISHED THE REVIEW PROCESS FOR
IMMUNE CNS INTERACTIONS IN
PEOPLE LIVING WITH HIV ON
ANTI-RETROVIRAL THERAPY.
FROM THESE RFAs HOW THEY ARE
IMPLEMENTING STRATEGIC PLANNING
THINGS THAT I WAS TALKING ABOUT
BEFORE.
THAT IS ALL.
THANK YOU VERY MUCH FOR YOUR
TIME AND ATTENTION.
>> THANK YOU, DR. LIGHTFOOT.
ARE THERE ANY QUESTIONS FOR DR.
LIGHTFOOT BEFORE WE MOVE ON TO
THE AGENDA?
HEARING NO QUESTIONS, DR.
GANDHI.
YOU ARE MUTED.
>> I WAS WONDERING IF THERE WERE
DESIGNATED FUNDS PUT INTO THE
MENTAL HEALTH ADOLESCENCE WITH
COVID PANDEMIC AND SOCIAL MEDIA,
THESE ARE NEW FUNDS THAT ARE
ADDED RECOGNIZING THIS MENTAL
HEALTH CRISIS IN OUR COUNTRY.
OF YOUNG PEOPLE.
>> YES.
>> REALLY GREAT.
>> AS YOU MENTION SO NEEDED.
>> THANK YOU AGAIN, DR.
LIGHTFOOT.
WE ARE GOING TO MOVE ON WITH THE
AGENDA.
SO BACK TO THE GUIDELINES AND
DR. HAZRA.
SO DR. HAZRA IS THE DIRECTOR OF
THE DIVISION OF EXTRAMURAL
RESEARCH AT NICHD.
HE PROVIDES SCIENTIFIC
LEADERSHIP DOMESTIC
INTERNATIONAL RESEARCH, RESEARCH
TRAINING AND CAREER DEVELOPMENT
PROGRAMS RELATED TO
EPIDEMIOLOGY, DIAGNOSIS,
PATHOGENESIS, TRANSMISSIONING
TREATMENT PREVENTION OF HIV AND
COMPLICATIONS, AS WELL AS
PATHOGENS IN INFANTS, CHILDREN,
ADOLESCENTS AND PREGNANT
INDIVIDUALS.
WITH THAT DR. HAZRA I WILL HAND
TO YOU.
>> THANK YOU VERY MUCH, GOOD
AFTERNOON.
EVERYONE, I WANT TO HIGHLIGHT
TWO SETS OF GUIDELINES ON THE
PEDIATRIC SIDE.
FIRST PEDIATRIC FIDE LINES I
WANT TO THANK DEB STORM WHO IS A
LONG TIME COLLABORATOR EDITOR
COORDINATOR STANDARDIZE NOT ONLY
WITHIN PEDIATRIC GUIDELINES AND
PERINATAL GUIDELINES BUT ACROSS
BOTH THOSE SETS OF GUIDELINES,
ALSO ACKNOWLEDGE HER.
IN PEDIATRIC GUIDELINES FOR MANY
YEARS WE AIMED TO HAVE AN ANNUAL
UPDATE SOON
CROW SO WE GET SET TO PUBLISH
MAKE SURE THERE IS NOTHING
ABSOLUTELY NEW OR GROUND
BREAKING AT CROW, INCLUDE THAT
WHEN POSSIBLE, PUBLISH.
THESE WERE PUBLISHED PROBABLY IN
APRIL.
WE DO -- THE SCHEDULE DOES ALLOW
TO DO RAPID UPDATES IF THERE IS
SOMETHING COMPELLING THAT COMES
UP IN THE INTERIM BUT OTHERWISE
WE DO CONCENTRATE STILL ON
ANNUAL UPDATE.
SO FULL GUIDELINES THEY PUBLISH
APRIL 11, WE DO HAVE VERY MUCH
THANKS TO DEB SWARM'S HELP WITH
THIS, SOME SECTIONS WE SHARE
WITH THE PERINATAL GUIDELINES,
THESE ARE BASICALLY SECTIONS
THAT UNDERGO REVIEW IN PARALLEL
BY BOTH GROUPS.
AND THEN THOSE WERE PUBLISHED
BACK IN PERINATAL GUIDELINES
PUBLISHED THE END OF LAST YEAR.
OUR BIG ISSUE IS TO MAJOR ISSUE
FOR US PEDIATRIC ANTI-RETROVIRAL
AND HAS EVOLVED SINCE I FIRST
STARTED BECOMING ASSOCIATED WITH
GUIDELINES BACK IN 2007.
I THINK AT THE BEGINNING, WE
WERE VERY MUCH A PLACE WHERE WE
HAD EXPERT INPUT, PREDOMINANTLY
WHAT THE FDA SAID.
WE REALLY EVOLVED NOW, WHERE WE
ARE IN VERY CLOSE CONSULTATION
AND COLLABORATION WITH FDA,
BEING ABLE TO MAKE SOME OTHER
JUDGMENTS THAT MAY BE NOT IN
ALIGNMENT WITH WHAT THE FDA
PROCESS HAS BEEN.
AS I SAID, I EMPHASIZE THAT AS A
TRUE COLLABORATION WITH FDA
STAFF AND WANT TO ACKNOWLEDGE
DR. (INAUDIBLE) WHO HELPS US
NAVIGATE SOME OF THOSE ISSUES.
FORTUNATELY WITH THESE FIXED
DOSE COMBINATIONS COMING OUT
MORE RECENTLY IN PEDIATRIC
DOSAGE FORMS, THOSE HAVE BEEN
RELATIVELY STRAIGHT FORWARD.
SO FOR THE LAST YEAR OUR UPDATES
ARE MATCHED WHAT WAS APPROVED BY
THE FDA.
SO THERE IS THE TAP FTC, THE
30-MILLIGRAM CONTAINING
COMBINATION AND THEN THE FTC SO
WE UPDATED THE GUIDELINES OF
INFORMATION ABOUT THAT.
I WILL HAVE MORE DETAILS AROUND
THOSE.
AS I MENTION WE WILL PLAN
POTENTIALLY SOME REAL TIME
UPDATES SO WE INCORPORATE THE
LONG ACTING INJECTABLES AND NEW
DISPERSIBLE (INAUDIBLE) FIXED
DOSE COMBINATION AS WELL SO THAT
IS REALLY EXITING.
THAT IS BASED UPON NIH IMPACT
2019 TRIAL.
THESE UPDATED RECOMMENDATIONS
MORE DETAIL HERE, FOR THE --
PEEDIA I CAN TRICK FORMULATION
NOW IS APPROVED DOWN TO AGE 2
BUT IMPORTANTLY 14-KILOGRAMS SO
GENERALLY GOING TO BE OLDER THAN
TWO YEARS OF AGE.
BECAUSE OF PEDIATRIC FORMULATION
ALLOWED US TO DO THIS,
PREVIOUSLY LIMITED TO USE IN
CHILDREN GREATER THAN OR EQUAL
TO SIX AND WEIGH 25 KILOS.
THE (INAUDIBLE) FIXED DOSE
COMBINATION IS RECOMMENDED AS
ALTERNATIVE.
FOR CHILDREN GREATER THAN OR
EQUAL TO 35 KILOS I SHOULD
HIGHLIGHT THERE THAT'S BASED
UPON DATA FROM IMPACT TRIAL AS
WELL.
THIS FTC TAF PEDIATRIC
FORMULATION FIX DOSE
COMBINATION.
SO ALLOWS US TO NOW SAY TO
PREFER DUAL NRTI FOR CHILDREN
DOWN TO 14 KILOS PREVIOUSLY
LIMITED TO CHILDREN WEIGHING 25
KILOS. THEN ANOTHER THING WHEN
I MENTION HERE, ABACOVIR, FDA
APPROVED FOR THREE MONTHS OF AGE
AND BEYOND.
BUT WHAT WE NOW HAVE BECAUSE
USED PRIMARILY IN INTERNATIONAL
SETTING AND ENDORSED BY WHO, A
FAIR AMOUNT OF DATA BOTH FOR
SAFETY AND EFFICACY BUT ALSO
SOME PHARMACO KINETICS STUDIES
AS WELL DONE PRIMARILY IN THE
CURE SETTING EARLY TREATMENT
SETTING WE HAVE MORE DATA.
SO HERE IS AN EXAMPLE OF WHERE
WE ARE NOW ENDORSING ABACAVIR ON
FULL TERM INFANTS FROM BIT ON
THOUGH FDA APPROVAL IS THREE
MONTHS OF AGE AND OVER.
THIS IS BASED UPON SOME COMING
FROM PHARMACOKINETIC STUDIES AND
MODELING AND THIS APPROACH IS
ALSO ENDORSED BY THE WHO SOME
OTHER UPDATES SECTIONS UPDATED,
WE HAVE A SPECIAL CONSIDERATION
ARD AND ADOLESCENTS INCLUDES
ADDITIONAL CONTENT ABOUT
SUBSTANCE USE CONCERNS.
TESTIFY SECTION WAS RESLIDESSED
TO PROVIDE RECENT DATA, MOST
STUDIES ARE INTERNATIONAL.
BUT DATA RELEVANT TO ADOLESCENT
POPULATION BUT AROUND SMART
PHONE BASED REMINDERS, PEER
SUPPORT INTERVENTIONS, SO WE
UPDATED FROM THOSE AREAS.
DIFFERENT ARV, I ALREADY
MENTIONED CHANGING
RECOMMENDATION ABOUT WHEN TO
USE, WE HAD TO MAKE CHANGES IN
OTHER SECTIONS AS WELL ABOUT
MANAGEMENT OF ANTI-RETROVIRAL
THERAPY, WITH TOXICITY SECTION
SO THOSE CHANGES ARE MADE
THROUGHOUT.
AS I MENTION THE TABLES FOR
TOXICITIES MANAGING ADVERSE
EFFECTS WE REVIEW THOSE, REALLY
NOT MUCH CHANGE BUT WE DO UPDATE
THOSE. INCREASINGLY THERE IS
FAIR AMOUNT USED SO THERE IS
REALLY NOW I THINK SUBSTANTIAL
DATA SHOWING THE NEED FOR
VITAMIN D SUPPLEMENTATION IN
CHILDREN.
THIS HAS BEEN AN ISSUE ABOUT
VITAMIN D DEFICIENCY, ONGOING
DEBATE WITHIN THE GUIDELINES.
THERE ARE CERTAINLY SOME
PEDIATRIC HIV EXPERTS IN THE
UNITED STATES THAT ROUTINELY
TEST THEIR CLINIC POPULATION,
FOR VITAMIN D DEFICIENCY AND
OTHERS THAT DON'T ROUTINELY DO
SO.
SO WE HAVE BEEN SOMEWHAT LOOSE,
WHERE WE SAY SOME EXPERTS DO IT
SOME DON'T.
NOW SPECIFICALLY FOR (INAUDIBLE)
BASED UPON DATA FROM ADULTS, BUT
ALSO SOME PEDIATRIC DATA AS WELL
THAT WE ARE RECOMMENDING IT.
NEXT SLIDE.
THIS IS -- THE FIRST BULLET
SAYING CHANGES ABOUT DRUG
APPROVALS ANTI-RETROVIRAL DRUG
BUT THE SECOND BULLET IS
INTERESTING.
AS FOLK KNOW NOW WE CAN PUT
TOGETHER A REGIMEN FOR FULL TERM
INFANTS.
OPTIONS ARE (INAUDIBLE) AMONG
WOMEN WITH HIV, IS ABOUT DOUBLE
WHAT IT IS AMONG WOMEN WHO DO
NOT HAVE HIV.
SO THE NEED FOR DOSING AND
PREMATURE BABIES IS SUBSTANTIAL.
THIS IS ACTUALLY BASED UPON
IMPACT STUDY 1106 DONE IN SOUTH
AFRICA, THEY HAVE DONE A FAIR
AMOUNT OF PHARMACOKINETIC
STUDIES AND WITH MODELING SO
WITH THAT INFORMATION WE ARE
ABLE TO RECOMMEND A DOSE OF
(INAUDIBLE) DOWN TO INFANTS AT
32 WEEKS GESTATIONAL AGE.
AGAIN, THIS IS ANOTHER EXAMPLE
OF WHERE WE ARE RECOMMENDING
SOMETHING BASED UPON MORE RECENT
DATA THAT IS NOT IN THE FDA
LABEL BUT CERTAINLY ENDORSED
INTELLECTUALLY BY THE FDA
THROUGH THEIR REPRESENTATION ON
THE GUIDELINES.
I PROBABLY SHOULDN'T SAY
ANYTHING ABOUT FDA ENDORSING
SOMETHING, THAT IS BEYOND MY PAY
GRADE.
I'M STRETCHING TO SAY ANYTHING
FOR THE FDA BUT ACKNOWLEDGE THE
IMPORTANCE OF DR. (INAUDIBLE) ON
THE TABID LINES PANEL.
THAT IS A PEDIATRIC GUIDELINE
UPDATE.
ON BEHALF OF BILL, I WILL GIVE
PEDIATRIC OI UPDATES, NEXT SLIDE
PLEASE.
BILL HASN'T PAST SHARED
PEDIATRIC O, WENT THREW A
MEETING PROCESS TO LOOK AT
RESCOPING THEIR GUIDELINES.
REALLY LOOKING AT AGAIN HOW MUCH
DO WE NEED A SEPARATE PEDIATRIC
OI GUIDELINE AND IMPORTANTLY
WHAT THE AREAS IF WE ARE GOING
TO CONTINUE TO HAVE ONE WE NEED
TO SPEND TIME AND EFFORT ON.
SO THAT RESCOPING WAS
SUCCESSFULLY DONE.
THERE IS NEW STANDARD OPERATING
PROCEDURE WITH UPDATED SECTION
REVISION C FREQUENCY BASED ON
EPIDEMIOLOGY NEW ADVANCE SIMILAR
TO WHAT HENRY DOES WITH ADULT OI
AND THEY HAVE DONE A NICE JOB OF
EXPANDING THE PANEL MEMBERSHIP
AND ALSO SHOW THAT IS ALSO BEING
ABLE TO SERVE AS RESOURCE FOR
OTHER GROUPS AS WELL, ALSO SET
UP WITH SUPPORT INFRASTRUCTURE
AND REVISIONS UNDERWAY FOR THE
VACCINE SECTION TB AND CMV.
AS I MENTION SUCCESSFUL
SOLICITATION FOR PANEL
MEMBERSHIP AND FOR THE
LEADERSHIP GROUP THEY HAD EIGHT
QUALIFIED APPLICANTS, TWO ROUNDS
OF INTERVIEWS, ONE MORE IS
PENDING.
FOR SECTION AUTHORSHIP 13
QUALIFIED APPLICANTS AND
SELECTION FOR INTERVIEWS ARE
UNDERWAY.
NEXT SLIDE PLEASE.
CURRENTLY HERE IS THE
LEADERSHIP, EXTENDED LEADERSHIP
EXECUTIVE SECRETARY FOR NICHD,
CO-CHAIRS ARE DR.S EKERT AND
RODRIGUEZ AND CORE LEADERSHIP
GROUP BOTH ACADEMIC CLINICAL
CENTERS AS WELL AS FROM THE CDC
AND HERE I WILL ACKNOWLEDGE THE
RETIREMENT OF STEVE (INAUDIBLE)
BOTH LONG TIME COLLEAGUE AND
COLLABORATOR ON THE PEDIATRIC
GUIDELINES AS WELL AS BEAR NATAL
GUIDELINES AND ALL AROUND GOOD
GUY SO WANT TO ACKNOWLEDGE HOW
MUCH HE HAS MEANT TO OUR FIELD.
NEXT SLIDE PLEASE.
AS I MENTION THIS NEW EXPANDED
GROUP IS ALSO SERVING AS A
RESOURCE FOR OREGONS.
BILL IS NIH LIAISON TO AMERICAN
ACADEMY OF PEDIATRICS COMMITTEE
FOR INFECTIOUS DISEASE WHICH IS
CHAIRED BY DAVID TIMBERLAND.
WHO IS ALSO THE EDITOR FOR --
MAY NOT CHAIR THAT GROUP BUT
CERTAINLY ON IT BUT HE IS EDITOR
FOR RED BOOK RECOGNIZING THAT
THERE IS NOW THIS EXPANDED GROUP
ON PEDIATRIC OPPORTUNISTIC
INFECTIONS AND LOT OF NEED TO
REVIEW CHAPTERS IN THE RED BOOK
THESE GROUPS COME TOGETHER IN
THE -- OI GROUP PROVIDED
CRITICAL REVIEWS OF 13 CHAPTERS
IN THE RED BOOK THAT HAVE
CORRESPONDING SECTIONS WITHIN
THE GUIDELINES.
THAT WAS A NICE WAY TO LEVERAGE
EXPERTISE ACROSS THE TWO GROUPS.
HERE IS THE DATA FROM THE
DOWNLOADS.
HENRY SHOWED, CERTAINLY THE
PEDIATRIC GUIDELINES ARE USED
MUCH LESS EXTENSIVELY BUT
REFLECTS THE FACT THAT HIV
DESPITE 10% WHAT THE ADULT
POPULATION IS BUT AS HENRY
SHOWED ADULT OI GUIDELINES IT IS
STEADY SO YOU CAN SEE CLOSE TO
4600 DOWNLOADS IN 2020 AND SAME
IN 2021.
THESE ARE INDIVIDUAL PAGES
INTERESTING SAME COMMENT THAT IN
FACT I FEEL LIKE ORDER IS
SIMILAR TO WHAT HENRY SHOWED AS
WELL WITH PNEUMOSIS AT THIS
BEING NUMBER ONE BUT RARE
PATHOGENS WHEN SOMEONE IS
CONFRONTED WITH THEM IT IS
IMPORTANT TO HAVE THIS RESOURCE.
NEXT SLIDE.
THESE ARE JUST ANCILLARY PAGE
VIEWS AS WELL HIGHLIGHTED THERE,
THE IMPORTANCE OF IMMUNIZATION
SCHEDULE IN THE VACCINE SECTION.
I THINK THAT IS IT.
I WANTED LIKE HENRY WANT TO
ACKNOWLEDGE THE VOLUNTEERS.
I THINK ACROSS THE FIVE
GUIDELINES PANELS IT IS OVER 200
VOLUNTEERS, IT IS A LABOR OF
LOVE BUT THESE ARE JUST VERY
DEDICATED PEOPLE, BUT ALSO I
HAVE TO SAY A TREMENDOUS
ACTIVITY TO BE PART OF.
NUMBER OF FOLKS ON THE OARAC
HAVE BEEN PART OF THE GUIDELINES
IT IS A FULFILLING ACTIVITY.
SO GLAD TO BE ABLE TO PRESENT
THESE UPDATES.
BACK TO YOU BLANTON.
>> THANK YOU, DR. HAZRA.
WE WILL NOW TAKE QUESTIONS ABOUT
THE GUIDELINES FOR DR. MASUR AND
HAZRA, IF THERE ARE ANY
QUESTIONS RAISE YOUR HAND.
IF THERE ARE NO QUESTIONS THANK
YOU AGAIN DR. HAS RA AND MASUR
FOR THE UPDATES TO -- HAZRA AND
MASUR TO THE UPDATE TO FIDE
LINES.
WE WILL MOVE WITH OUR AGENDA AND
IN THE SAKE OF TIME I WILL
INTRODUCE THE NEXT SPEAKERS
ADVISORY COUNCIL REPRESENTATIVES
AND I ASK THAT YOU PLEASE LOOK
IN THE BRIEFING BOOK TO SEE THE
FULL BIOE.
WE WILL HEAR FROM DR. MONICA
GANDHI, REPRESENTING THE AIDS
RESEARCH ADVISORY COMMITTEE.
WE WILL NEXT HEAR FROM DR.
REDONNA CHANDLER WHO IS
REPRESENTING THE NATIONAL
ADVISORY COUNCIL ON DRUG ABUSE.
THAT WILL BE FOLLOWED BY DR.
YARCHOAN, NATIONAL CANCER
ADVISORY BOARD AND THEN LASTLY
DR. JULIO ALBERTI FROM NATIONAL
AIDS EXECUTIVE COMMITTEE.
DR. GANDHI, PASS IT OVER TO YOU
NOW.
THANKS.
>> I WILL BE FROM THE NINE
ADVISORY COUNCIL TO OARAC SO WE
ALSO LOOK AT THE BUDGET,
EVERYONE LOOKING AT THE BUDGET,
WAS HOPEFUL TO SEE THAT NIAID
FUNDING ACTUALLY SOMETHING ART
FACTUAL HAPPENED THAT LOOKED
LIKE DECREASE BUT IT INCREASED
BY 4.2%.
I WOULD COMMENT HERE THAT ECTG
AND COMMUNITY IS VERY INTERESTED
IN AGING AGENDA SO HAPPY TO SEE
THE INCREASE IN NATIONAL
INSTITUTE OF AGING BUDGET HERE
IN THE CONGRESS BUDGET.
NEXT SLIDE.
ALSO GRATIFIED THAT WE -- THAT
FINANCIAL PAY LINES WERE
RELEASED FROM NIAID AND YOU CAN
SEE THE RO1 PAY LINES RIGHT NOW
ALWAYS ANNOUNCED AT NIAID THAW
POST THEM AND IT IS 12
PERCENTILE ESTABLISHED PIs AND
NEW PIs ARE 16 PERCENTILE.
SO THAT GIVES SUCCESS RATE OF
RO1s 18 TO 22% WHICH WAS
ENCOURAGING FOR THIS PHASE OF
POST PANDEMIC.
ONE THING ALSO THAT IS NOT ON
THE SLIDE IS THE KAY PAY LINE
BOTHST PROKED BY NIAID AT 20,
IMPROVEMENT FROM 18.
THERE IS A LOT OF PRAISE OF THE
INSTITUTE FOR THIS.
THERE IS SPECIFIC EARMARKED AN
NON-EARMARKED IN TERMS OF
CONGRESSIONAL NIAID BUDGET.
THE EARMARK RESEARCH IS VERY
IMPORTANT SPECIFICALLY ENDING
THE HIV EPIDEMIC MONEY SO THAT
GOES TOWARD CFAR SUPPLEMENTS AND
OTHER C FAR GRANTS BASICALLY GO
TOWARDS -- THE NIH ITSELF BEYOND
CDC AND HRSA NIH GETTING
RESEARCH MONEY IMPLEMENTATION
SCIENCE FOCUSED TO WORK ON THE
PILLARS OF ENDING HIV EPIDEMIC
PREVENTION TREATMENT RETENTION
OUTBREAK INVESTIGATION.
QUITE A BIT FOR UNIVERSAL
INFLUENZA VACCINE WE NEED TICK
BORN DISEASE FOR ANTIMICROBIAL
RESISTANCE OF COVID FUNDING
STAYED FLAT BUT IMMUNITY LAB AND
REGIONAL BIOCONTAINMENT AND FOOD
ALLERGY RESEARCH WENT UP QUITE A
BIT.
SO JUST LIKE THE REPORT FROM
MARGUERITA ABOUT NIMH THERE IS
ATTEMPT BY NIAID AND THE NIH IN
GENERAL, INSTITUTIONS SHOULD
FOLLOW SUIT TO NOT ONLY WORK ON
DIVERSITY EQUITY INCLUSION
ACCESSIBILITY WITH A SPECIFIC
COUNCIL FOR THAT, BUT WORKPLACE
CIVILITY TASK FORCE WHICH WAS
AMAZING AND SENT TO OUR DEAN
HERE.
ANYONE GET NIH FUNDING WE SHOULD
BE WORKING ON NATURAL BEHAVIOR.
THE NEXT SLIDE SHOWS WHAT THAT
MEANS.
NEXT SLIDE PLEASE.
WORKPLACE CIVILITY TASK FORCE IS
EXPECTATION STATEMENT TO CREATE
A CIVIL WORKPLACE NIAID EXPECTS
STAFF REGARDLESS OF POSITION TO
ACT WITH PROFESSIONALISM AND
RESPECT LISTEN WITH OPEN MIND
COMMUNICATE CONSTRUCTIVELY AND
WORK COLLABORATIVELY.
YOU CAN SO THESE PRINCIPLES ON
THE RIGHT OF A CIVIL WORK FORCE.
I THINK I JUST THINK THIS IS AN
AMAZING THING FOR THE NIH TO DO
ESPECIALLY DURING THESE
POLARIZING DIFFICULT TIMES.
AND ENCOURAGE INSTITUTIONS THAT
ACCEPT NIH FUNDING TO ADOPT
SIMILAR PLEDGE.
.
PEOPLE HAVE HAVE TO SIGN THIS
PLEDGE.
IN ADDITION THE DEIA COUNCIL IS
REALLY TO FUNDAMENTALLY BOTH
WORK INTERNALLY AND WITH
EXTERNAL EXTRAMURAL WORKPLACE
FUNDING TO WORK ON DIVERSE
INCLUSIVE WORKPLACE AND WORK
STAFF FOR ALL RESEARCHERS.
IN TERMS OF ONE MORE DIVERSITY
INITIATIVE I SHOULD MENTION
WHICH IS A BRAIN DIVERSITY
INITIATIVE BUT ESSENTIALLY THAT
ANYONE APPLYING FOR ANY RANGE OF
FUNDING HAS TO WORK ON MORE
DIVERSE PERSPECTIVES ABOUT
CULTURE CHANGE THAT IS NECESSARY
TO ADDRESS OUR INEQUITIES AND
SOCIETY AND SYSTEMIC BIASES IN
BIOMEDICAL RESEARCH AND I WILL
TALK LATER VERY IMPRESSIVE RO1
OPPORTUNITY AT NIAID AND
CROSSING ENTIRE INSTITUTE
WORKING ON DIVERSITY AND
EXTRAMURAL APPLICATIONS.
NEXT SLIDE.
ACTUALLY, THIS IS MORE ON HOW
IMPORTANT INFRASTRUCTURE IS TO
-- THAT EVERYONE WILL HAVE TO
INCLUDE IN BRAIN INITIATIVE
GRANTS, ONE PAGE ADDITION TO
EXPLAIN HOW TO MAXIMIZE
PARTICIPATION OF INVESTIGATORS
FROM DIVERSE BACKGROUNDS AND
ENGAGE WITH DIFFERENT TYPES OF
INSTITUTIONS, BLACK HISPANIC
ORGANIZATIONS FOR EXAMPLE THAT
AND COMMUNITY BASED
ORGANIZATIONS THAT SERVE DIVERSE
RESEARCH INFRASTRUCTURE.
THIS IS A VERY EXCITING NEW
RESEARCH OPPORTUNITY THAT WAS
ANNOUNCED ACROSS NIAID.
THIS WOULD BE BOTH IN DADE AND
DMID ACROSS THE ENTIRE INSTITUTE
WHICH IS ESSENTIALLY AN RO1
AWARD THAT IS SPECIFICALLY
TARGETED AS MUCH AS POSSIBLE
TOWARD RESEARCHERS FROM DIVERSE
BACKGROUNDS.
SO IT IS RO1 WHICH IS AMAZING
BECAUSE THAT IS WHAT PEOPLE
NEED.
TO MAKE THAT NEXT STEP, IT IS
YOU CAN'T SPECIFICALLY WRITE
EXAMLY THAT YOU CAN ONLY BE FROM
CERTAIN GROUPS, IT IS TO
ENCOURAGE CERTAIN
UNDER-REPRESENTED GROUPS IN
RESEARCH TO APPLY.
AND IT CAN BE ANY TOPIC IN
INFECTIOUS DISEASE AND I THINK
THIS IS THE KIND OF -- THIS IS
ONLY BEEN DONE TWICE BEFORE ONCE
IN 2004 I BELIEVE AND ONCE IN
2009 I BELIEVE AND IT JUST IS A
INCREDIBLE BOON TO HELP WORK ON
GETTING MORE INVESTIGATORS
FROMTY VERSE BACKGROUNDS TO RO1
LEVEL RESEARCH.
THEN THE NEXT TOPIC WE DISCUSSED
AT THIS MEETING IS REALLY THE
FOCUS IN C FAR EARMARKED MONEY
FOR END THE HIV EPIDEMIC GRAB.
SO THESE ARE SUPPLEMENT GRABS,
FIVE AWARDED, EVERYONE HEARD
ABOUT IT YESTERDAY AND THESE ARE
REALLY IMPORTANT GRANTS TO WORK
ON EQUITY FOCUSED APPROACHES, TO
REDUCE HEALTH DISPARITIES
BEHAVIORAL ECONOMIC APPROACH ON
HIV TEST AND PREVENTION AND
COURSE, STRATEGIC ALLIANCE,
ACROSS IMPLEMENTATION SCIENCE,
RESEARCH AND IMPLEMENTATION
STRATEGIES AND PLANNING
PROJECTS.
SO THESE ARE ALL GIVEN OUT NOW
BOUGHING THE TO BE 135 OF EHE
SUPPLEMENTS ACROSS C FAR.
THEN REALLY DISCUSSED THE
RENEWAL OF THE NIH C FAR GRANT
AWARDS WHICH IS REALLY HIGH
IMPACT.
AND REISSUE OF THAT FOR FIVE
YEAR AWARDS AND HOPEFULLY EXPAND
SOME C FARES AND EXPAND ALLOW
MORE INSTITUTION C FAR PROGRAM.
BECAUSE C FARES ARE SO
MULTI-DISCIPLINARY THIS IS
REALLY THE CO-FUNDED BY 11 NIH
INSTITUTES SO NOT JUST NIAID
THAT PUTS THE MAJORITY OF THE
FUNDING IN IN AND SO BECAUSE OF
THAT WE TRY TO BE
INTERDISCIPLINARY IN OUR CFR
INITIATIVES.
THESE ARE THE C FARES AROUND THE
COUNTRY, THERE ARE DIFFERENT
TIERS OF TYPE C FARES AND ALSO
DEVELOPMENTAL C FAR SITES.
SOME REALLY EXPANDING AROUND THE
COUNTRY AND AMAZING TO BE PART
OF THE C FAR PROGRAM.
IMPORTANTLY THERE WAS JUST A NEW
INITIATIVE STARTED TO ENHANCE
DIVERSITY EQUITY INCLUSION AT C
FARES FOR EARLY PIPELINE
INVESTIGATORS, THESE ARE
UNDERGRADUATES MASTER STUDENTS
AT HISTORICALLY BLACK HISPANIC
INSTITUTIONS AND THIS IS REALLY
IMPORTANT WE LAUNCHED OUR C FAR
SCHOLAR PROGRAM BECAUSE WE GOT
ONE OF THESE GRANTS AND STARTED
SCHOLARS OFF RESEARCH PROJECTS
FOR SAN FRANCISCO STATE THIS
SUMMER.
A COUPLE OF RFAs I WILL END
WITH THAT WERE ANNOUNCED THAT
ARE IMPORTANT.
ONE DEFINING NOT HIV INDUCED
INFLAMMATION BUT THE MECHANISMS
HIV INDUCED IMPLEMENTATION AND
IMMUNE ACTIVATION DURING
SUPPRESSIVE ART.
STILL ONGOING IMPLEMENTATION
DURING THIS TIME AND SO WHAT ARE
THE MECHANISMS OF THAT, THIS IS
AN R 61 R 33 TYPE PROPOSAL
MECHANISM.
NEXT SLIDE.
SPECIFICALLY IT IS TO EFFECT
PEOPLE SUPPRESSIVE ART AND VERY
INTERESTING MECHANISM WHICH
FIRST THREE YEARS ARE BASIC
RESEARCH TO DETERMINE LANDSCAPE
AND DIFFERENT CELLULAR
POPULATIONS, THE NEXT TWO YEARS
ARE APPLIED RESEARCH TO DEVELOP
NOVEL THERAPEUTICS TO WORK
AGAINST -- COUNTER THIS IMMUNE
ACTIVATION AND ON SUPPRESSIVE
ART.
NEXT RFA ANNOUNCED WHICH IS
INTERESTING WHICH IS EARLY
EVENTS IN TB AND TB HIV
INFECTION SO THIS IS EVEN
ESSENTIALLY IMMUNOPATHOGENESIS
MECHANISMS IN VERY EARLY
INFECTION.
AND THE IDEA IS NOT TO -- TO
ESSENTIALLY IDENTIFY NOVEL
TARGETS FOR NEW INTERVENTIONS.
FOR THE HOST TO PREVENTED LONG
TERM DAMAGE.
FROM TUBERCULOSIS.
NEXT SLIDE SHOWS THE ACTUAL
MECHANISTIC STUDIES ENCOURAGED.
BEFORE YOU ETCH GET INTO
ADAPTIVE IMMUNE FUNCTION, WHAT
ARE ALL THE INFLAMMATION
MECHANISMS THAT OCCUR IN TB THAT
CAN LEADS TO FIBROSIS AND OTHER
LUNG DAMAGE, THE IDEA WOULD BE
TRY AGAIN BASIC -- THESE
PRE-CLINICAL STUDIES, YOU WANT
NOVEL THERAPY TARGETS TO
INTERACT EVEN PRIOR TO STARTING
TREATMENT.
NEXT SLIDE.
THERE SEARCH AND SEIZURE TWO
OTHER INITIATIVES WHICH I WILL
JUST MENTION, ONE IS CELLULAR
IMMUNOLOGY CORE LABORATORY,
PROVIDE CENTRALIZED LABORATORY
TO MEASURE CELLULAR IMMUNITY, WE
HAVE GOTTEN INTEREST THE COVID
VACCINES ON SPECIFIC HOW MUCH
CELLULAR IMMUNITY MATTERS AND B
CELL IMMUNITY, THIS IS FOR NOT
COVID BUT PRE-CLINICAL AIDS
VACCINE STUDIES.
THESE ASSAYS ARE ESSENTIAL TO
DEVELOP NOT JUST AGAIN ANTIBODY
RESPONSE BUT CELLULAR IMMUNE
RESPONSES FROM CANDIDATE AIDS
VACCINE.
THIS IS AN NO 1 MECHANISM.
THIS CORE LABORATORY WILL BE --
BECAUSE HIV VACCINE DEVELOPING
INTO CORE PRIORITY FOR HIV AND
NIAID, THIS IS GOING TO BE A
INTERNAL CELLULAR IMMUNE
LABORATORY TO STUDY PARTICULAR
VACCINE CANDIDATES IN THE
PRE-CLINICAL PHASE AND LOOK AT
WHAT HAPPENS WITH CELLULAR
IMMUNITY.
NEXT SLIDE.
ONE FINAL INITIATIVE WHICH IS
MYCOBACTERIUM TB QUALITY
ASSESSMENT PROGRAM TO PROVIDE
RESOURCE IN NO 1 CONTRACT OVER
SEVEN YEARS TO SUPPORT THE
ABILITY OF LABS TO RELIABLY
PERFORM STUDIES SPECIFIED MTB
TESTS AND THIS IS NOT JUST NTB
WHOLE HOST OF ASSAYS BUT NTB
ASSAY TESTING THERE IS
EFFICIENCY LAP TO ENSURING LABS
DEVELOPING THESE ASSAYS HAVE
HIGH LEVEL QUALITY EFFICIENCY
TESTING.
SO NEXT SLIDE SHOWS KEY TASK
PERFORMANCE EXTERNAL QUALITY
ASSURANCE OF LABS AND ASSET
VALIDATION AT PARTICIPATING LABS
SO THIS IS SUPPORT EXTENDED TO
ALL THINGS SUPPORTED
INVESTIGATORS.
AND I BELIEVE THAT'S THE LAST
SLIDE.
THIS IS SUMMARIZES THE ONE MORE
IDEA ACT EXTERNAL QUALITY
ASSURANCE PROGRAM OVERSIGHT
LABORATORY AND THIS IS TO LOOK
AT QUALITY ASSURANCE PROGRAMS
THAT FOR LABS THAT ARE INVOLVED
IN HIV RESEARCH, THIS IS OUR
THIRD NO 1 CONTRACT THAT HAS
BEEN ANNOUNCED THIS IS
SPECIFICALLY RENEWAL, NOT DE
NOVO LIKE THE OTHER TWO.
AND THE NEXT SLIDE REALLY
EXPLAINS WHAT THE DADE
LABORATORY OVERSIGHT DOES, THE
MISSION OF THIS PROGRAM.
FOR EXAMPLE CPQA I REPORT TO AS
A PHARMACOLOGY LAB, DOES -- IS
EM BED WITHIN THIS PROGRAM THESE
ARE ESSENTIALLY DADE OVERSIGHT
SUPPORT PROGRAMS THAT PERFORM
EFFICIENCY TESTING FOR ALL SORTS
OF HIV RELATED VIROLOGY
PHARMACOLOGY TB AND OTHER
ASSESSMENT LABORATORY TESTS TO
ENSURE WE ARE DOING HIGH QUALITY
WORK.
I WILL END THERE.
THANK YOU SO MUCH.
>> THANK YOU DR. GANDHI, ANY
QUESTIONS BEFORE WE MOVE ON?
IN THE AGENDA?
OKAY.
HEARING NONE I WILL MOVE ON NOW
TO DR. CHANDLER, DIRECTOR OF
AIDS RESEARCH PROGRAM AT NIDA.
SO WELCOME WE LOOK FORWARD TO
YOUR REPORT.
SO THANK YOU VERY MUCH.
NEXT SLIDE.
I WANT TO START BY THANKING CA
DEL RIO WHO FINISHED HIS TERM IN
DRUG ABUSE COUNCIL ON MAY, HE
SERVED A YOU ARE TO YEAR TERM
AND THANKS FOR HIS DIDCATION FOR
FUTURE RESEARCH BUT ALSO HIV AND
REPRESENTED NIDA WELL ON OARAC
SO WE WISH HIM THE BEST.
WE ARE GOING TO MISS HIM IN BOTH
OF THESE ROLES AND NIDA IS IN
THE PROCESS OF GETTING APPROVAL
FOR NEW COUNCIL MEMBER THAT WILL
HAVE HIV EXPERTISE AND WE LOOK
FORWARD TO THAT PERSON JOINING
US SOON.
NEXT SLIDE.
I WANT THE START BY HIGHLIGHTING
PUBLICATION THAT WAS BROUGHT
ATTENTION OF ADVISORY COUNCIL.
THAT REALLY SPEAKS TO THE
IMPORTANCE OF CONSIDERING
INTERVENING SOCIAL DETERMINANTS
OF HEALTH WHEN TRYING TO ADDRESS
HIV AND OTHER INFECTIOUS
DISEASES LIKE HEPATITIS C.
THIS PARTICULAR STUDY LOOKED AT
THE ROLE OF HOUSING ON HIV AND
HEP C TRANSMISSION AMONG PEOPLE
WHO INJECT DRUGS GLOBALLY.
FROM AMONG PEOPLE WHO INJECT
DRUGS HIV AND HCD INFECTIONS ARE
COMMON AND MANY INDIVIDUALS ARE
UNSTABLY HOUSED AND AT RISK OF
INFECTION.
THIS STUDY USE MODELING ESTIMATE
THE PROPORTION OF HIV HCV
INFECTIONS PREDICTED TO OCCUR AS
A RESULT OF HOUSING INSTABILITY
AMONG PEOPLE WHO INJECT DRUGS
FROM 2020 THROUGH 2029 AND 58
COUNTRIES.
INVOLVED IN ANOTHER STUDY COUNTY
AND 58 COUNTRIES AROUND THE
WORLD WHERE DATA WERE AVAILABLE.
NEXT SLIDE.
THIS IS THE FIRST STUDY TO
ESTIMATE THE GLOBAL CONTRIBUTION
OF UNSTABLE HOUSING TO THE
TRANSMISSION OF ANY INFECTION
AND IT ADDS TO SMALL BUT GROWING
BODY OF EVIDENCE THAT LOOK AT
SOCIAL DETERMINANTS OF HEALTH,
HOUSING INSTABILITY, FOOD
INSECURITY TRANSPORTATION OR
INCARCERATION AND THE
CONTRIBUTION MADE ON INFECTIOUS
DISEASE INCLUDING HIV AND HCV.
AND FOCUSING ON HIGH RISK
POPULATIONS LIKE PEOPLE WHO
INJECT DRUGS.
YOU SEE IN THE RESULTS THIS
MODELS PREDICTS UNSTABLE HOUSING
WHETHER CONTRIBUTE 8% NEW HIV
INFECTION AND OVER 11% HCV
INFECTION WORLDS WIDE AMONG
PEOPLE WHO INJECT DRUGS ACROSS
THE 2020.
ACROSS REGIONS THE MAIN
TRANSMISSION POPULATION
ATTRIBUTABLE FRACTION RANKS AND
VARIES FROM 2.2 PERSON IN
EASTERN EUROPE TO 20% IN NORTH
AMERICA.
FOR HIV AND FOR HCB IT RANGES
FROM 2.8% IN EASTERN GROUP TO
26.2% IN NORTH AMERICA.
AND FOR BOTH HIV AND HCV AND
HIGH INCOME COUNTRIES WERE OVER
DOUBLE THOSE IN LOW AND MIDDLE
INCOME COUNTRIES.
SO AGAIN REALLY HIGHLIGHTS THE
IMPORTANCE OF FOCUSING ON THIS
TYPE OF RESEARCH AND IN TRYING
TO DEVELOP INTERVENTIONS THAT
WILL IMPACT ON THE SOCIAL
DETERMINANTS OF HEALTH
ASSOCIATED WITH HIGH RISK
BEHAVIOR AMONG GROUPS INCLUDING
PEOPLE WHO INJECT DRUGS.
SO NEXT SLIDE.
THIS SLIDE INCLUDES CONCEPTS
THAT WERE APPROVED BY OUR
NATIONAL ADVISORY COUNCIL IN
MAY.
YOU WILL SEE RANGE OF DIFFERENT
TOPICS THAT INCLUDES EVERYTHING
FROM MECHANISTIC AND BASIC
SCIENCE STUDIES TO A FOCUS ON
THE CRIMINAL JUSTICE POPULATION
IN ORDER TO END HIV EPIDEMIC.
NEXT SLIDE.
THIS LAST SLIDE HAS SOME
CURRENTLY OPEN FUNDING
OPPORTUNITIES ANNOUNCEMENTS, THE
RFA AGAIN ON RANGE OF TOPICS
FROM ADDRESSING THE INTERSECTION
OF STIMULANT USE IN HIV TO
IMPLEMENTING COMPREHENSIVE HIV
SERVICES AND HARM REDUCTION
PROGRAMS LIKE SERVICE PROGRAMS,
INCREASING ENGAGEMENT AND
RETENTION IN HIV TREATMENT WITH
PEOPLE WHO ARE USING SUBSTANCES,
AND THEN PATHOGENIC MECHANISMS
THAT INFLUENCE BLOOD BRAIN
BARRIER FUNCTION IN HIV AND
SUBSTANCE USE DISORDERS.
THAT'S MY LAST SLIDE.
>> THANK YOU, DR. CHANDLER.
ARE THERE ANY QUESTIONS?
ON THE COMMITTEE.
MOVING ON.
NEXT WE WILL HEAR FROM DR.
YARCHOAN.
OVER TO YOU.
>> THANK YOU.
I WANT TO THANK DR. FRANCIS
ALI-'SMAN FOR HIS SERVING NCAB
AND REPRESENTING THE THE NCI ON
OARAC.
HE ASKED IF I CAN GIVE UPDATE
TODAY AND SO I WILL GIVE A SHORT
UPDATE ON THREE TOPICS.
NEXT SLIDE.
THE FIRST IS AN RFA THAT WAS
APPROVED BY OUR COUNSEL BY THE
BSA.
BASIC TRANSLATIONAL RESEARCH ON
HEALTH DISPARITIES AND HIV AIDS
AND CANCER.
THIS RFA WILL FOCUS ON
BIOLOGICAL INTERACTION OF CANCER
HEALTH DISPARITIES IN
MARGINALIZED POPULATIONS WITH AN
UNDERLYING HIV INFECTION THROUGH
BASIC MECHANISMS TRANSLATIONAL
STUDIES.
IT WILL INVESTIGATE HOW HIV
INTERACTS WITH THE DISPARITIES
TO PROMOTE CANCER.
NEXT SLIDE.
SOME OF THE POSSIBLE SUBJECTS
TOPICS THAT WILL BE FUNDED WITH
THIS INCLUDES STUDIES HEALTH
DISPARITIES INTERACT WITH HIV TO
CAUSE CANCER TO INVESTIGATIONS
CAUSAL ONSET OF CANCER, GENETIC
OR SUSCEPTIBILITY RESPONSES,
HOST TO CANCER MICROBIOME
MAILSIS AND STUDIES OF VARIOUS
ONCOGENIC VIRAL CO-INFECTION.
THESE ARE SOME OF THE SPECIFICS
FOR THE RFA, IT INCLUDES RO1 AND
R21 ANTICIPATED RECEIPT DATES
DECEMBER OF 22 AND DECEMBER OF
23.
ANTICIPATED FUNDING IS 7 TO 8
RO1s AND 5 TO 6 R21
APPLICATIONS PER YEAR FOR TWO
YEARS AND TOTAL OF 59 A YEAR FOR
TOTAL OF 25 MILLION TOTAL COSTS.
ANOTHER THING I WANT TO SHARE
WITH YOU, LAST OCTOBER THE NCI
SPONSORED A MEETING TO EXPLORE
POSSIBILITY OF KSHV OR CAP SEIZE
SARCOMA ASSOCIATED HERPES VIRUS
VACCINE DEVELOPMENT AND THIS WAS
DISCUSSED THE POSSIBILITY THE
APPROACHES AND PRACTICALITY OF
DEVELOPING A VACCINE AGAINST
KHSV.
IT INCLUDED 65 INVITED
PARTICIPANTS AND ALSO OPEN TO
THE RESEARCH COMMUNITY.
SOME OF THE AREAS COVERED
INCLUDE KSHV TRANSMISSION AND
EPIDEMIOLOGY, IMMUNITY TO HERPES
VIRUSES, LESSONS LEARNED FROM
VACCINE DEVELOPMENT TO OTHER
VIRUSES.
AND THEN PRACTICAL ISSUES
RELATED TO DEVELOPING
IMPLEMENTING KSHV VACCINE.
NEXT SLIDE.
A LITTLE BIT ON THE RECENT
DEVELOPMENTS IN KS AN KSHV
EPIDEMIOLOGY, RIGHT NOW IN THE
UNITED STATES CAP SEIZE SARCOMA
DISPROPORTIONATELY AFFECTS AFTER
CAN AMERICAN MEN IN THE SOUTH
PARTICULARLY YOUNG MEN, THEY
HAVE WORST PROGNOSIS WHEN THEY
DEVELOP KS SEEN BY THE GRAPH IN
THE LOWER LEFT AND ALSO WHILE
INCIDENCE OF KS IS DECREASING
SLOWLY IN OTHER PARTS OF THE
COUNTRY IT IS INCREASING IN
YOUNG BLACK MEN IN THE SOUTH.
PERHAPS MOST IMPORTANT IN
SUB-SAHARAN AFRICA, KS CONTINUES
TO BE AN IMPORTANT CAUSE OF
MORBIDITY MORTALITY AND IN THREE
COUNTRIES IN SUB -SAHARAN AFRICA
IT IS THE MOST COMMON TUMOR
OVERALL IN MEN.
AND ALSO AGAIN KS REALLY
DISPROPORTIONATELY AFFECTS
PEOPLE WITH HIV.
THIS IS A STUDY FROM SOUTH
AFRICA AND IT SHOWS THE HIV
PREVALENCE IN CANCER PATIENTS
AND BLACK MALES, WITH KS AND
OTHER CANCERS COMPARED TO THE
BLACK MALES IN TOTAL.
AND THIS CAN BE SEEN IN THE
DIAGONAL STRIPED BARS BETWEEN 96
AND 100% KS PATIENTS WERE
INFECTED WITH HIV COMPARED TO
MUCH LOWER PERCENTAGE OF OTHER
CANCERS IN TOTAL.
THIS VACCINE MEETING, IT WAS
DISCUSSED A KSHV VACCINE
PREVENTS SARCOMA IN OTHER KSHV
RELATED DISEASES.
IT WAS ACKNOWLEDGED THAT
SCIENTIFIC PRACTICAL
IMPLEMENTATION CHALLENGES BUT
THE PARTICIPANT CONSENSUS AT THE
MEETING WAS QUITE OPTIMISTIC
ABOUT THE FEASIBILITY OF
DEVELOPING SUCH A VACCINE AND
THERE WAS A LOT OF ENTHUSIASM
AND THIS WAS IN PART BECAUSE
BASED ON THE OBSERVATION THE
VIRUS IS MUCH LESS TRANSMISSIBLE
HAHN OTHER HERPES VIRUS AND
CONSIDERATION WAS GIVEN TO
STERILIZING VACCINE OR ONE
PREVENTING DEVELOPMENT OF
DISEASE.
GIVEN THE KS SUSCEPTIBLE TO
IMMUNE CONTROL, EITHER APPROACH
MARKEDLY REDUCE DEVELOPMENT OF
KS.
AND THE MAJOR SPEAKERS AT THE
MEETING ARE IN THE PROCESS OF
PREPARING AND READYING FOR
PUBLICATION MANUSCRIPT
DESCRIBING THE MEETING.
THEN FINALLY I WANT TO MENTION
THE ANCHOR TRIAL WHICH WAS A
STUDY TO SHOW THE TREATMENT OF H
CELL, ANAL CANCER PRECURSOR CAN
PREVENT ANAL CANCER.
SOME OF THE IMPETUS FOR THIS
TRIAL IS SEEN HERE.
BETWEEN 91 AND PARTICULARLY
AFTER 96 UNTIL 2005 OR SO THERE
WAS DRAMATIC INCREASE IN THE
INCIDENCE AND THE NUMBER OF
CASES OF ANAL CANCER IN PEOPLE
WITH AIDS IN THE UNITED STATES.
IT IS SORT OF LEVELED OFF SINCE
THEN, BUT REMAINED HIGH LEVEL.
NEXT SLIDE.
THE ANCHOR TRIAL WAS DEVELOPED
TO SEE IF TREATMENT OF H CELL OR
HIGH GRADE SQUAMOUS
INTEREPITHELIAL LESIONS OF THE
ANUS WOULD PREVENT ANAL CANCER.
AND THERE WERE 4,000 PEOPLE
ENTERED IN THIS RANDOMIZE STUDY,
THEY WERE RANDOMIZED BETWEEN
OBSERVATION AND TREATMENT OF THE
LESION AND AS CAN BE SEEN HERE
STATISTICALLY SIGNIFICANT THAT
THE TREATMENT PREVENTEDDED ANAL
CANCER.
THIS WAS PUBLISHED ON JUNE 16 IN
THE NEW ENGLAND JOURNAL OF
MEDICINE WITH (INAUDIBLE) AS
LEAD AUTHOR.
IT IS VERY LIKELY THAT THIS
AFFECTS GUIDELINES FOR SCREENING
FOR H CELL, NO REASON TO SCREEN
IF IT WASN'T SHOWING THE
TREATING IT PREVENT ANAL CANCER
BECAUSE H CELL BY ITSELF IS NOT
A PROBLEM IN PATIENTS SO I THINK
IT WILL CERTAINLY AFFECT THE
GUIDELINES FOR SCREENING IN
PEOPLE WITH HIV WHICH HIGHEST
RISK OF DEVELOPING ANAL CANCER
AND HAVING H CELL AND POSSIBLY
OTHER GROUPS AS WELCH SO I WILL
END AT THIS POINT.
THE NCI THANKS THE OFFICE OF
AIDS RESEARCH FOR THEIR SUPPORT
OF THIS STUDY, IT WAS IMPORTANT
GETTING THIS STUDY OFF THE
GROUNDS IN THE NCI.
AND IT WAS THE LARGEST CANCER
TRIAL TO DATE IN PEOPLE WITH HIV
AND WE ALSO WANT TO THANK THE
PARTICIPANTS IN THE TRIAL.
WHILE TRIAL STUDIED TREATMENT OF
ANAL H CELL IT PROVIDES
RATIONALE FOR SCREENING.
NEXT STEPS INDICATE CORRELATIVE
STUDIES BASED ON SAMPLES
COLLECTED, RESEARCH AND IMPROVED
TREATMENT WHICH IS NOW IS AN
IMPORTANT AREA, AND RESEARCH
SHOULD DETERMINE THE BEST
ALGORITHM TO PRIORITIZE HIGH
RESOLUTION TO DIAGNOSE H CELLOR
CELL AND IT WILL BE IMPORTANT TO
TRAIN MORE PRACTITIONERS TO DO
HIGH RESOLUTION SO LIKE ANY GOOD
STUDY OPEN IT IS DOOR FOR MORE
RESEARCH AND MORE IMPROVEMENT.
NEXT SLIDE.
NOW I WILL END AND TURN IT OVER
TO QUESTION.
>> THANK YOU FOR THE UPDATE DR.
YARCHOAN.
YOUR DATA THE RESULTS YOU SHOWED
ON KARPASES SARCOMA AND ONE
COULD ASK ABOUT SOME OF THE
DRIVERS BEHIND THAT.
BUT OUT OF CURIOSITY DO YOU SEE
ANY CORRELATIONS BETWEEN KS AND
BLACK MEN AND PROSTATE CANCER
AND ARE THERE EPIDEMIOLOGICAL
MODELS THAT CAN ACCOUNT FOR
MAYBE SCREENING RATES AND LEVELS
OF DIAGNOSIS?
>> I'M NOT AWARE OF -- BOTH
DISEASES ARE NOW OCCURRING
DISPROPORTIONATELY IN BLACK
MALES.
REASON FOR PROSTATE CANCER NOT
SURE I DON'T PERSONALLY KNOW THE
REASONS FOR THIS AND I'M NOT
SURE COMPLETELY HOW WELL THIS IS
UNDERSTOOD.
WITH KS, IT IS -- KS IS LARGELY
DUE TO ACQUISITION DURING LIFE.
WE DON'T HAVE A SENSE IT IS ALL
IMPORTANT.
MY GUESS IS WHAT IS HAPPENING
THOUGH NOT INVESTIGATED IS THAT
THIS IS THE AREA HIGHEST
PREVALENCE OF HIV ACQUISITION WE
HAVE SEEN HIV ACQUIRED IN THIS
AREA, SEEN HIV ACQUIRED IN P
BLACK MALE, FOR VARIETY OF
REASONS NOT GETTING TREATED
ADEQUATELY FOR HIV.
THERE IS PROBABLY MANYOR MEN WHO
HAVE SEX WITH MEN IN THAT GROUP
ARE OFTEN STILL STIGMATIZED AND
DON'T SEEK HELP AND THEREFORE
YOU SEE THIS EXPLOSION OF
CAPASES SARCOMA.
THAT IS MY BEST UNDERSTANDING,
AGAIN THERE IS A FAIR AMOUNT OF
CONJECTURE BECAUSE PEOPLE
HAVEN'T PROBED IF SOCIO LOGICAL
REASONS FOR IT.
>> THANK YOU.
TOTALLY UNDERSTAND.
>> LIZ (INAUDIBLE) MD ANDERSON
IS SPEARHEADING A LOT OF THIS
RESEARCH.
>> ANY OTHER QUESTIONS FOR DR.
YARCHOAN?
WE WILL MOVE ON WITH THE NEXT
UPDATE FROM DR. JULIO ALBERTI,
HE IS NEW TO US.
SO JUST AS BY WAY OF BRIEF
INTRODUCTION SENIOR SCIENCE
ADVISOR AT THE OAR.
DR. ALBERTI IS IMMUNOLOGIST WITH
EXPERIENCE IN A RANGE OF
INFECTIOUS DISEASES AND
INCLUDING HIV.
HE SPENT TIME IN ACADEMIA AS
WELL AS NIAID -- NIAID BEFORE
COMING TO THE OAR.
SO IT IS A PLEASURE TO ARE YOU
WITH US.
>> THANK YOU VERY MUCH.
HAVE THE NEXT SLIDE PLEASE.
I WILL GIVE BRIEF OVERVIEW AND
THANK YOU TO DR. LIGHT FOOD, DR.
GANDHI AND DR. YARCHOAN AND
CHANDLER MADE MY JOB SIMPLE
HERE.
WITH CONCEPTS CLEARED.
NIAID HAD FOUR NEW CONSENTS
CLEAR AND FOUR REISSUED.
NIDA HAS THREE NEW CONCEPTS NIMH
HAS FLOWEROR FOUR.
NCI ONE NEW CONCEPT.
AND OFFICE OF RESEARCH
INFRASTRUCTURE PROGRAM HAS THREE
NEW REISSUED PROGRAMS.
NEXT SLIDE.
THESE CONCEPTS CLEARED AT THE
COUNCIL AT NIAID HAVE BEEN
ALREADY PRESENTED BY DR. GANDHI.
THESE NEW CONCEPTS BY NIMH,
THERE IS THE FIRST ONE IS
EPIGENETIC MECHANISM REGULATING
HIV IN THE CENTRAL NERVOUS
SYSTEM LATENCY AND
NEUROPATHOGENESIS USING NOVEL
SINGLE CELL TECHNOLOGIES.
THE SECOND CONCEPT IS
UNDERSTANDING GUT IMMUNE AT THIS
FUNCTION AND MICROBIOME IN
PATHOYENSIS IN MENTAL HEALTH
OUTCOMES OF PEOPLE LIVING WITH
HIV.
THIRD IS EXPANDING COLLABORATIVE
IMPLEMENTATION SCIENCE FOR THE
END OF HIV EPIDEMIC PLAN FOR
AMERICA.
AND THE LAST CONCEPT IS
IMPROVING UPTAKE OF PERSISTENCE
ON NOVEL TREATMENT AND
PREVENTION OPTIONS.
NEW CONCEPT BY NIDA.
DR. CHANDLER PRESENTED AND DR.
(INAUDIBLE) PRESENTED NATIONAL
CANCER INSTITUTE.
NEXT SLIDE.
CONCEPTS REISSUED OF THOSE HAVE
BEEN PRESENTED BY DR. GANDHI FOR
NIAID.
AND FOR OARAC THESE THREE NEW --
REISSUED CONCEPTS HAVE BEEN
APPROVED.
THE FIRST ONE IS HIV AIDS
SCHOLARS USING NON-HUMAN PRIMATE
MODELS.
SECOND EARLY STAGE INVESTIGATOR
HIV AIDS RESEARCH USING
NON-HUMAN PRIMATE MODELS R21.
DEVELOPMENT OF APPROXIMATE MALL
MODELS AND RELATED MATERIALS FOR
HIV RESEARCH AIDS AS AN NOVEL
THERAPEUTIC.
THERE WAS A RECENTLY PUBLISHED
FUNDING OPPORTUNITY, THIS PAR
22-181 THESE ARE SPONSORED BY
NIDA NIMH AND NINDS.
AND PROVIDES RESEARCH
OPPORTUNITIES FOR NEW AND AT
RISK INVESTIGATORS TO PROMOTE
WORK FORCE DIVERSITY.
IT IS AN RO1.
THERE IS A RECENT ARTICLE IN
SCIENCE ADDRESSING THIS NEW
OPPORTUNITY AND PUTTING IT ON
THE CHAT.
BASICALLY THESE ARE IT IS A VERY
SIMILAR INITIATIVE COMPARED TO
THE ONE PRESENTED BY DR. GANDHI
APPROVED BY NIAID.
HERE WE HAVE THREE OTHER
INSTITUTES DOING EXACTLY THE
SAME.
NEXT SLIDE.
FINALLY I WILL CLOSE BY
REMINDING EVERYBODY ON THIS
CHALLENGE BY THE OFFICE OF DATA
SCIENCE STRATEGY IN
COLLABORATION WITH FASEB
HIGHLIGHTING THE -- OUR UPDATE
SHARING AND ER USE IN BIOLOGICAL
BIOMEDICAL SCIENCE.
THAT IS ALL I HAVE.
THANK YOU VERY MUCH.
>> THANK YOU, DR. ALBERTI.
SO WE HAVE SOME TIME FOR SOME
QUESTIONS.
HEARING NONE WE WILL MOVE ON.
AGAIN I WOULD LIKE TO THANK ALL
THE PRESENTERS IN THIS LAST
SESSION.
AS WE BEGIN TO CLOSE JUST WANT
TO REMIND EVERYONE THAT WE HAVE
ALLOTTED TIME FOR PUBLIC
COMMENTS.
DR. GLENSHAW HAVE YOU RECEIVED
COMMENTS FOR TODAY?
>> NOT FOR TODAY.
I WILL THOUGH PUT THE SURVEY IN
THE CHAT AGAIN FOR THOSE THAT
HAVEN'T HAD A CHANCE TO FILL IN
JUST PREFERENCES FOR THE FORMAT
FOR THE OCTOBER.
>> THANK YOU.
WE WILL PASS IT BACK OVER TO DR.
GOODENOW FOR CLOSING REMARKS.
>> THANK YOU SO MUCH.
HUGE THANK YOU TO EVERYONE THAT
PARTICIPATED IN THIS MEETING
TODAY.
THE PRESENTATIONS ARE REALLY
OOZE WE THINK ABOUT THIS GOING
FORWARD HOW TO CONTINUE TO
SYNERGIZE AND LOOK AT THE IMPACT
EACH SEPARATELY WHEN WE COMBINE
IN WAYS TALK ABOUT TODAY WITHIN
THE NIH AND ACROSS THE AGENCIES.
AND ACROSS THE DEPARTMENTS.
I WANT TO ADD ONE OTHER PIECE OF
INFORMATION ANNOUNCED TODAY WHEN
I TALKED EARLIER SHOWED YOU THE
ORGANIZATION NIH AND HOW THE
OFFICE OAR AND OTHERS ARE
EMBEDDED IN OFFICE OF THE NIH
DIRECTOR.
I DIDN'T FOCUS ON THE FACT THAT
THE ORGANIZATION OF THE OFFICES
IS IN THE DIVISION THAT IS
CALLED DIVISION OF PROGRAM
COORDINATION PLANNING AND
STRATEGIC INITIATIVES OR DPKPSI.
THE PERSON HEADING DPKPSI IN THE
ROLE AS DIRECTOR OF THE DIVISION
BUT DEPUTY DIRECTORS OF THE NIH,
REPORTING TO PRINCIPLE DEPUTY
NIH DIRECTOR IS DR. JAMES
ANDERSON.
AND TODAY WE BEFORE THIS MEETING
JIN HAD A MEETING WITH OFFICE
DIRECTORS TO ANNOUNCE THAT HE IS
RETIRING.
HE IS SERVING AS DPKPSI DIVISION
DIRECTOR FOR 12 YEARS AND I WANT
TO GIVE BACKGROUND IN THE COUPLE
OF COMMENTS IF YOU CAN INDULGE
BEFORE WE FINISH UP.
AS A NON-ACTING DIRECTOR OF
DPKPSI JIN FORMED DIVISION
OFFICES TO BECOME CENTRAL NIH
COORDINATORS FROM THEMATIC AREAS
INCLUDING LARGE NUMBER OF IMPACT
NIH COMMON FUND PROGRAMS.
IT WAS UNDER JIM'S LEADERSHIP
THE NUMBER OF OFFICES WITHIN
DPKPSI GREW FROM 7 TO 14 AND IT
WAS NOT BY CHOICE JIM'S TRYING
TO ESTABLISH LARGE EMPIRE BUT IN
FACT CONGRESS PASSING
LEGISLATION THESE OFFICES ARE
FORMED WITHIN THE NIH AND JIM
CARRY OUT THOSE MANDATES.
HE HAS BEEN INSTRUMENTAL IN
DEVELOPMENT OF FORT COMING NIH
WIDE STRATEGIC PLAN FOR
DIVERSITY EQUITY INCLUSION AND
ACCESSIBILITY.
AND IN THE CREATION OF
INNOVATIVE PROGRAMS THAT ADVANCE
TRAINING AND FACULTY RECRUITMENT
RETENTION AND INSTITUTIONAL
CULTURAL CHANGE.
JIM RECRUITED ME.
TO THE NIH AND HAS BEEN AMAZING
MENTOR AND ADVISOR OVER SIX
YEARS.
IT WILL BE A BIG CHANGE FOR ALL
OF US TO MOVE DIFFERENT
DIRECTION.
GOOD NEWS IS WHILE THERE IS A
SEARCH FOR DPKPSI DIRECTOR
ACTING DIRECTOR IS BOB ISINGER
MANY OF YOU KNOW AS MEMBER OF
THE OAR A LONG TIME AND IS --
WAS ACTING OAR DIRECTOR DURING
THE INJURY BETWEEN JACK WHAT
IT'S CAR PREVIOUS DIRECT TORE
AND MY RECRUITMENT INTO THE
POSITION.
SO WE ARE VERY EXCITED BOB IS
STACK, MAY NOT HAVE KNOWN ME HE
LEFT THE NIH EARLIER THIS YEAR
TO TAKE A POSITION AT THE MILKEN
FOUNDATION.
BUT HE HAS AGREED TO COME BACK
AND HE IS KEEPING THINGS IN
ORDER UNTIL WE HAVE A NEW
DIRECTOR SO WE ARE VERY -- SINCE
MANY OF YOU KNOW THESE DIFFERENT
FOLKS I WANT TO GET THAT -- LET
YOU KNOW WHAT WAS GOING ON AS
HOT OFF THE PRESS TODAY.
WITH THAT BEING SAID, THANK YOU
AGAIN.
I'M ANXIOUS TO SEE THE RESULTS
OF THE POLL TO DETERMINE WHAT WE
ARE GOING TO DO IN OCTOBER.
IT WOULD BE LOVERLY TO SEE MANY
OF YOU -- LOVELY TO SEE MANY OF
YOU.
SO FINGERS CROSSED THAT WE CAN
AT LEAST DO SOME HYBRID MEETING.
BUT THANK YOU AGAIN.
I DON'T HAVE TO SAY SAFE TRAVELS
THIS TIME BECAUSE YOU ARE ALL
WHERE YOU SHOULD BE.
THANKS A LOT.
AND TO THE OAR STAFF, TO THE
NIH, AND TO ALL OF YOU WHO ARE
ACROSS THE GOVERNMENT AND ALL
THE OTHER AREAS YOU SO WELL
REPRESENT TO US DURING THE THESE
SESSIONS.
THANK YOU.
HAVE A GREAT SUMMER.
>> THANK YOU, DR. GOODENOW.
JUST AS REMINDER TO EVERYONE
BEFORE WE LEAVE THE NEXT OARAC
MEETING IS THURSDAY OCTOBER 27,
2022, HOPE THAT COULD BE A
HYBRID MEETING FOR US.
BUT NEVERTHELESS TODAY'S MEETING
IS ADJOURNED.
THANK YOU, EVERYONE.
THANKS.